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ABSTRACT 
Pharmaceuticals are biologically active compounds that may be consumed in hundreds 
of tonnes per year, and which are excreted into municipal sewerage systems.  Many 
pharmaceuticals persist during sewage treatment, and significant environmental risk has 
been linked to incomplete removal of pharmaceuticals.  Evaluation of this risk is 
important and should be as representative as possible, taking into consideration all 
significant exposure routes and removal processes.  Sludge treatment processes are of 
particular interest because they offer a final opportunity for the removal of persistent 
compounds before the disposal of treated biosolids.  During environmental risk 
assessment, it is currently assumed that anaerobic sludge treatment results in 
insignificant removal of persistent and adsorptive compounds from sewage sludge.  
This project was undertaken to address whether this assumption is valid.  This thesis 
describes research into the behaviour and fate of pharmaceuticals in anaerobic digester 
sludge, and examines how redox conditions influence removal efficiency.  Nine 
commonly used pharmaceuticals (caffeine, cimetidine, fluoxetine, ibuprofen, 
metformin, naproxen, paroxetine, propranolol and salicylic acid) were selected for use 
based upon detection levels within sewage sludge and predicted anaerobic 
biodegradability.  Initial experiments were conducted to identify toxicity to anaerobic 
microorganisms and anaerobic biodegradability.  No toxicity to the microorganisms in 
anaerobic sludge was identified at ≤ 50 mg C L-1for any of the selected pharmaceuticals.  
The extent of removal in anaerobic sludge and the principal removal mechanism was 
found to vary between the selected pharmaceuticals.  Metformin and salicylic acid were 
removed by 82 and 93% through mineralisation, respectively; naproxen was completely 
removed through primary biodegradation; fluoxetine, paroxetine and propranolol were 
removed by 92 and 96 and 55% due to adsorption, respectively.  It was hypothesised 
that the removal of pharmaceuticals in anaerobic sludge through biodegradation and 
adsorption would be observed at varying rates under differing redox conditions.  Test 
systems using headspace gas flushing and chemical amendment were evaluated for the 
control of redox conditions, with Eh measurements and DOC removal being used to 
indicate the stability of the system and its capacity for biodegradation.  The addition of 
nitrate, sulfate and carbonate resulted in poised Eh values in the region of +200, -200 
and -200 mV, respectively and 81, 78 and 74% removal of DOC, respectively.  This 
methodology was subsequently used to evaluate the removal of naproxen, propranolol 
and fluoxetine under carbonate-, nitrate- and sulfate-amended conditions.  Significant 
differences (p = 0.001) in the removal of naproxen through primary biodegradation 
were found to exist between different redox conditions.  Naproxen was completely 
removed under control conditions, while 26, 98 and 61% removal was observed under 
nitrate- sulfate- and carbonate amended conditions, respectively.  Some differences 
were observed in Kd values, however, redox amendment was found to have little 
influence upon the elimination of propranolol and fluoxetine through adsorption.  It was 
identified from this work that pharmaceuticals within the aqueous phase degraded under 
anaerobic conditions as predicted, while pharmaceuticals associated with the biosolids 
were removed through adsorption and present a potential threat to the environment on 
the disposal of treated biosolids.  This work supports the current industry assumption 
that anaerobic treatment of biosolids offers limited opportunity for the removal of 
adsorptive pharmaceuticals, and also found no evidence for their enhanced removal 
under redox-controlled conditions.  While research described within this thesis increases 
knowledge of the behaviour of pharmaceuticals in sewage sludge under anaerobic 
conditions, data is presented for a limited range of test substances only, and further 
investigation into the behaviour of additional compound classes is recommended.
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Kow Octanol-water partition coefficient 
L Litre 
Log Kow Logarithm of octanol-water partition coefficient 
mg C L
-1
 Milligram as carbon per litre 
mg kg
-1
 Milligram per kilogram 
pKa Acid dissociation constant 
rpm Revolution per min 
v/v Volume to volume 
W Watt 
w/w Weight to weight 
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CHAPTER 1  
 
LITERATURE REVIEW AND RESEARCH STRATEGY 
 
1.1 Fate and effects of pharmaceuticals in the environment 
1.1.1 Introduction 
Pharmaceuticals are biologically-active compounds used in the treatment of disease, 
that are diverse in their physicochemical characteristics and in their specific modes of 
action.  There are currently over 3000 different pharmaceutical ingredients licensed for 
use within the EU, many consumed in hundreds of tonnes per year (Fent et al., 2006; 
Jones et al., 2002).  A significant fraction of pharmaceuticals are excreted 
unmetabolised into municipal sewerage systems, where they undergo a series of 
chemical and biological sewage treatment processes.  Effective removal of many 
pharmaceuticals is achieved during sewage treatment, however, many others resist 
treatment processes.  Depending on physicochemical properties, the residual portion 
may be found in the recycled water or in the sludge fraction known as the biosolids 
(Carballa et al., 2004; Daughton & Ternes, 1999; Halling-Sørensen et al., 1998; Wick et 
al., 2009).   
 
It has been shown that persistent pharmaceuticals can adversely affect wildlife within 
the aquatic and terrestrial environments through practices such as the release of polluted 
effluent into surfacewater or through the spreading of contaminated biosolids onto 
agricultural land (Schultz et al., 2011; Lajeunesse et al., 2012).  Awareness of the 
environmental impact of pharmaceuticals has grown in recent years, and the 
pharmaceutical industry has invested in research into the environmental fate and effects 
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of pharmaceuticals.  There is also a legal requirement for pharmaceutical companies to 
generate environmental fate and effects data when preparing environmental risk 
assessments for new drugs or new formulations of existing drugs.  Environmental risk 
assessment is required before a product can be licensed, and in Europe is performed 
following the Guideline on the Environmental Risk Assessment of Medicinal Products 
for Human Use (EMEA, 2006), using standardised protocols such as those issued by the 
Organisation for Economic Cooperation and Development (OECD).   
 
The testing strategy is based upon generating initial data to predict the level of exposure 
likely within the aquatic environment using physicochemical and consumption data.  A 
second tier of testing including aquatic ecotoxicology, ready biodegradability, microbial 
inhibition and adsorption-desorption is then performed.  Compounds which do not 
readily biodegrade using a diluted activated sludge inoculum during this tier of testing 
and which adsorb significantly to sludge require an additional tier of testing to evaluate 
potential effects within the terrestrial environment. 
 
There may, however, be the potential for such compounds to be effectively removed 
during anaerobic treatment processes commonly used for the stabilisation of sewage 
sludge, eliminating the need for the need for complex and unnecessary terrestrial 
ecotoxicity, and soil transformation tests.  This Chapter will evaluate the fate and effects 
of pharmaceuticals within the environment, before investigating the biochemical 
processes that occur during anaerobic digestion and the methodologies used to study 
biodegradability under anaerobic conditions.  Table 1.1 shows a selection of frequently 
dispensed pharmaceutical compounds across a number of therapeutic areas, and 
indicates sales figures within the UK for the previous three years.      
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Table 1.1 Amount of frequently dispensed pharmaceuticals sold in the UK (IMS 
data)  
Therapeutic Area, 
Compound and Class 
2009 (kg) 2010 (kg) 2011 (kg) 
Lipid regulating 
Atorvastatin 
Simvastatin 
 
18,883 
50,071 
 
16,859 
51,568 
 
17,633 
53,752 
Gastrointestinal 
Proton pump inhibitor 
Omeprazole 
 
 
17,074 
 
 
18,822 
 
 
21,457 
Antidiabetes 
Biguanide 
Metformin 
 
 
848,675 
 
 
918,990 
 
 
966,687 
Cardiovascular 
β-blocker 
Atenolol 
Propranolol 
 
 
32,944 
10,268 
 
 
30,528 
10,592 
 
 
28,002 
11,114 
Central nervous system 
Anti-epileptic 
Carbamazepine 
SSRI antidepressant 
Citalopram 
 
 
160,167 
 
10,596 
 
 
142,484 
 
12,192 
 
 
129,510 
 
13,103 
Antimicrobial 
β-lactam 
Amoxicillin 
Sulfonamide 
Sulfamethoxazole 
 
 
184,059 
 
3,725 
 
 
194,033 
 
3,870 
 
 
198,884 
 
4,075 
1.1.2 Physicochemical properties of pharmaceutical compounds  
For a molecule to be a successful drug candidate it must possess fundamental ‘drug-
like’ characteristics such as high aqueous solubility and oral bioavailability (Lipinski et 
al., 1997).  Both structural and physicochemical properties influence further interactions 
between a compound and the biological environment within the target organism, and 
researchers working within the area of drug discovery aim to correlate structural 
characteristics of successful compounds with desirable physicochemical and 
biochemical characteristics when synthesising new molecules (Kerns & Di, 2008; 
Lipinski et al., 1997).  Structural characteristics describe the physical nature of the 
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molecule and include: molecular weight; number of H-bonds; lipophilicity; pKa; and 
reactivity of the molecule.  Physicochemical characteristics describe the interactions 
that occur between a compound and its physical environment, and include properties 
such as aqueous solubility and chemical stability (Kerns & Di, 2008).  Structurally 
similar compounds often have similar modes of action and belong to the same chemical 
class (Kümmerer, 2008).  Pharmaceuticals are classified according to anatomical, 
therapeutic, and chemical (ATC) groups; target anatomical system; therapeutic 
properties of the drug; or chemical characteristics of the molecule (Wennmalm, 2011). 
 
The structural and physicochemical properties that influence the behaviour of a 
compound within the target organism also influence the behaviour of a compound 
within the environment including the extent of microbial degradation, and also how a 
compound partitions between the aqueous phase and the solid phase.  Pharmaceuticals 
often contain basic or acidic moieties such as amino or carboxyl groups, and may be 
basic, acidic, neutral or zwitterionic under environmental conditions (Kümmerer, 2008).  
These differences in structural and physicochemical properties make the study of 
pharmaceuticals within the environment very complex, and scientists often evaluate 
how compounds behave across a range of structural properties in order to gain a 
mechanistic understanding of biotic and abiotic removal processes. 
 
1.1.3 Metabolism of pharmaceuticals within the human body 
Some pharmaceuticals may be extensively metabolised while others may only be 
partially metabolised or excreted completely intact.  Metabolites that result from 
structural changes within the human body may be of less, equal, or greater significance 
within the environment than parent compounds (Kümmerer, 2008).  Table 1.2 shows the 
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extent of metabolism of a number of frequently dispensed pharmaceuticals, and lists the 
major human metabolites.  
 
Table 1.2 Human metabolism of frequently dispensed pharmaceuticals 
Therapeutic area, 
compound and class 
% Excretion 
of parent 
Metabolites excreted in urine and faeces 
Lipid regulating 
Atorvastatin 
 
Simvastatin 
 
1% 
 
73% 
 
Atorvastatin acid, 2-hydroxyatorvastatin acid, 4-
hydroxyatorvastatin
a)
  
β-hydroxyacid & β-hydroxyacid of 6’-hydroxy, 6’-
hydroxymethyl & 6’-ethoxymethylene derivativesb) 
Gastrointestinal 
Proton pump inhibitor 
Omeprazole 
 
 
79% 
 
 
Hydroxyomeprazole, omeprazole acid
c)
 
Antidiabetes 
Biguanide 
Metformin 
 
 
100% 
 
 
N/A 
d)
 
Cardiovascular 
β-blocker 
Atenolol 
Propranolol 
 
 
95% 
0.5% 
 
 
Hydroxyatenolol
e) 
Naphthoxylactic acid, 4-hydroxypropranolol sulfate 
propranolol glucoronide
f)
 
CNS 
Anti-epileptic 
Carbamazepine 
SSRI antidepressant 
Citalopram 
 
 
2% 
 
10% 
 
 
10,11-epoxycarbamazepine
g)
 
 
Demethylcitalopram, didemethylcitalopram, 
citalopram-N-oxide
h)
 
Antimicrobial 
β-lactam  
Amoxicillin 
 
Sulfonamide 
Sulfamethoxazole 
 
 
60% 
 
 
54% 
 
 
Amoxicilloic acid, amoxicillin diketopiperazine-
2´,5´-dione
i)
 
 
 N4-acetyl-sulfamethoxazole, sulfamethoxazole-N1-
glucoronide
j)
 
References: 
a)
Lennernäs, 2003;
 b)
Merck & Co., 1999; 
c)
Renberg et al., 1989; 
d)
Campbell et al., 
1996; 
e)
Reeves et al., 1978; 
f)
Walle et al., 1985; 
g)
Houeto et al., 2012; 
h)
Forest, 2004; 
i)
Fernandez-Torres et al., 2010; 
j)
Radke et al., 2009. 
  
Phase I reactions convert the drug to a more polar metabolite through the action of non-
specific esterases present in the liver, plasma or gastrointestinal tract during oxidation, 
reduction or hydrolysis reactions (Halling-Sørensen et al., 1998).  Phase II reactions 
involve conjugation of Phase I metabolites with, e.g., glucose, which normally results in 
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inactive compounds rapidly excreted in the urine.  This transformation has been shown 
to be reversible, as Phase II metabolites of antibiotics and lipid regulators have been 
shown to transform back into either the parent compound or the Phase I metabolite 
during sewage treatment (Göbel et al., 2007; Halling-Sørensen et al., 1998; Khan & 
Ongerth, 2002; Ternes, 1998; Wick et al., 2009).   
 
1.1.4 Processes for the treatment of municipal wastewater 
Sewage treatment plants (STPs) provide an interface between the sewerage system and 
the environment, and use a number of treatments to remove both pathogens and 
nutrients.  While configurations vary between plants, all STPs use a combination of 
physical, chemical and biological treatment processes before recycling processed water 
and disposing of treated biosolids.  
 
1.1.4.1 Primary sewage treatment processes 
When influent enters an STP, the raw sewage first undergoes primary treatment to 
remove large particulates using a screen and an aerated grit removal tank.  Following 
primary treatment processes sewage is settled in a primary clarification tank after which 
it is separated into primary sludge and effluent.  Coagulation-flocculation and flotation 
are used for the removal of suspended solids and colloids (Suarez et al., 2009).  
Flotation involves separating finely suspended particles using rising bubbles, while 
coagulation-flocculation involves the addition of metal salts such as aluminium sulfate, 
Al2(SO4)3, and ferrous sulfate, FeSO4 to adjust the pH of the sewage and produce an 
insoluble precipitate which can then be removed by filtration (Bolton & Klein, 1971). 
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1.1.5 Biological sewage treatment processes  
Primary effluent undergoes stabilisation to remove nutrients such as phosphorus and 
nitrogen, and also to transform biodegradable compounds, including pharmaceuticals in 
a biologically oxidative environment (Ternes et al., 2004).  A considerable amount of 
investigation into the biodegradation of pharmaceuticals during biological sewage 
treatment has been performed.  Table 1.3 summarises the removal of a range of 
frequently dispensed pharmaceuticals during aerobic sewage treatment processes.  
   
Table 1.3 Removal of frequently dispensed pharmaceuticals during biological 
sewage treatment 
Therapeutic Area, 
Compound and Class 
Removal (%) System Type 
Lipid regulating 
Atorvastatin 
Simvastatin 86 
93 
Conventional activated sludge
a) 
Conventional activated sludge
a) 
Gastrointestinal 
Proton pump inhibitor 
Omeprazole 9 Conventional activated sludgeb) 
Antidiabetes 
Biguanide 
Metformin 90 Conventional activated sludgec) 
Cardiovascular 
β-blocker 
Atenolol 
Propranolol 
 
 
76 
52-59 
78 
Conventional activated sludge
d) 
Conventional activated sludge
d,e) 
Membrane bioreactor
d) 
CNS 
Anti-epileptic 
Carbamazepine 
SSRI antidepressant 
Citalopram 
-3, -4 
 
30 
Conventional activated sludge
f,g) 
 
Biological nutrient removal
h) 
Antimicrobial 
β-lactam  
Amoxicillin 
Sulfonamide 
Sulfamethoxazole 
96 
 
81 
Conventional activated sludge
i) 
 
Sequencing batch reactor
j) 
References: 
a)
Ottmar et al., 2012; 
b)
Rosal et al., 2010; 
c)
Scheurer et al., 2012; 
d)
Maurer et al., 
2007; 
e)
Lahti & Oikari, 2011; 
f)
Santos et al., 2007; 
g)
Clara et al., 2005b; 
h)
Lajeunesse et al., 
2012; 
i)
Watkinson et al., 2007; 
j)
Yang et al., 2012.  
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Biological treatment processes may include aerobic, anoxic or anaerobic phases, and 
can be either suspended growth or attached growth (biofilm) processes.  The most 
common suspended growth system for the treatment of domestic wastewater is the 
conventional activated sludge process (CAS), which stabilises waste during contact time 
with fast-growing and floc-forming microorganisms in an aeration tank (Radjenovic et 
al., 2007; Wennmalm, 2011).  More advanced technologies used for biological 
treatment include nitrification/denitrification units for enhanced removal of nitrogen, 
membrane bioreactors (MBR), which combine a membrane process with contact time in 
a bioreactor containing dispersed bacteria (Clara et al., 2005a; Radjenovic et al., 2007). 
 
1.1.6 Sewage sludge treatment processes 
Although non-treated sewage sludge may legally be spread onto agricultural land, 
sewage sludge processing is performed to help reduce pathogens, eliminate offensive 
odours and prevent putrefaction of dewatered primary and treated sludge.  The major 
proportion of feed sludge consists of primary sludge formed as a result of settling fine 
solids, and is composed of faecal solids, grit, grease, oil and a range of microorganisms.  
The minor proportion of feed sludge consists of secondary sludge formed as a result of 
settlement in activated sludge treatment, and is composed mainly of microbial flocs 
(Orive Melero, 2009).  Stabilisation of sewage sludge can be achieved through a 
number of means including alkaline stabilisation and biological treatment that may be 
either aerobic or anaerobic.  Anaerobic digestion has, however, become the most widely 
adopted process within the UK and Europe for the treatment of sewage sludge (Carballa 
et al., 2007).  It significantly reduces the amount of final sludge solids for disposal, and 
there is also potential to generate electricity through combustion of the biogas generated 
as shown in Figure 1.1.   
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Figure 1.1 Sewage treatment processes (from www.water.org.uk). 
 
Biogas consists of approximately 60% methane, 40% carbon dioxide in addition to trace 
levels of other contaminant gases (Mata-Alvarez et al., 2000).  Anaerobic digestion is 
used for the treatment of 66% of municipal sewage sludge within the UK, however 
many other sources of biomass are also used as feedstocks including food waste, crops 
and slurry.  There are currently 146 facilities within the UK that generate electricity 
from the anaerobic digestion of sewage sludge (Defra, 2011). 
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In its most basic form anaerobic digestion is performed with a 30-60 day solids 
retention time (SRT) in an unheated static tank (Bolton & Klein, 1971).  However, 
digestion is now commonly performed in mixed, heated units at 35°C (mesophilic) or 
55°C (thermophilic) temperature which increases the overall rate of the process (Appels 
et al., 2008).  Other practices employed to enhance operational efficiency include the 
use of pretreatments such as mechanical disruption, and the separation of the hydrolytic 
and methanogenic steps in a two-stage digestion process (Barret et al., 2010b; Carballa 
et al., 2006; Carballa et al., 2007; Jelic et al., 2012; Musson et al., 2010). 
 
1.1.7 Physical characteristics of sewage sludge 
Sewage sludge is formed following settlement of screened sewage and excess mixed 
liquor within activated sludge tanks.  The biomass present within sewage sludge is 
composed mainly of heterotrophic bacteria that obtain nutrition from the digestion of 
organic compounds, but also contains protozoa and a range of filter feeders.  This 
biomass is supported by a complex medium rich in organic material; macronutrients 
including nitrogen, phosphorus, calcium, magnesium, and sulphur; and a number of 
other essential microelements.  The carbon species that exist in sewage sludge range in 
the extent of biodegradability, and change in nature throughout the sewage treatment 
process (Kosobucki & Buszewski, 2011). 
 
The flocs present within mixed liquor are held together through electrostatic interactions 
and van der Waals forces between the extracellular polymers of the biomass and 
inorganic ions present within the sewage (Steiner et al., 1976).  Precipitation of 
dissolved molecules during sedimentation and redox reactions that take place during 
sewage treatment result in the formation of gelatinous colloidal matter (Bolton & Klein, 
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1971).  Interactions between particles may be affected due to changes in ion 
concentration and redox conditions, or changes within the properties of the extracellular 
polymers as the sludge ages (Jjemba, 2002).  It has also been demonstrated that 
alterations in these conditions influence sorption of organic molecules, which may have 
a significant impact on the removal of micropollutants such as pharmaceuticals during 
sewage treatment (Finlayson, 1998).  
   
1.1.8 Sorption of pharmaceuticals 
The most common physicochemical property of a compound used to describe its 
affinity for organic matter is octanol-water partition coefficient (log Kow) which defines 
the partitioning of a neutral compound between an aqueous and immiscible solvent. 
Adsorption is generally considered to be a significant removal mechanism for neutral 
compounds when log Kow > 4.0 (Jones-Lepp & Stevens, 2007). 
 
Due to the presence of minerals and organic carbon from a number of sources, Kd is 
recognised as being more appropriate to describe partitioning between ionic molecules 
and sewage sludge.  This value takes into account hydrophobic absorption as 
characterised by Kow and electrostatic adsorption as characterised by pKa (Carballa et al., 
2005, Fent et al., 2006, Ternes et al., 2004).  The Kd is defined as the ratio of the 
concentrations of a substance in the solid and in the aqueous phases at equilibrium, and 
is determined by the equation (Carballa et al., 2005): 
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where Kd is the solid water distribution coefficient (L kg
-1
); 
X is the concentration in the solid phase (mg kg
-1
); 
S is the concentration in the aqueous phase (mg L
-1
). 
 
The determination of Kd is particularly important when evaluating the potential for 
pharmaceuticals to accumulate within the environment.  Adsorption is generally 
considered to be a significant removal mechanism when the Kd value is > 1,000 L kg 
-1 
(Clara et al., 2005b; Ternes et al., 2007).  Methods employed for the determination of 
Kd include batch sorption experiments, which are used to construct sorption isotherms 
to describe the dependence of Kd on concentration (Cs) (Tolls, 2001).  The dependence 
of Kd on Cs can then be determined from sorption isotherms.  For non-polar compounds, 
the Kd may be normalised to the measured organic carbon concentration of the solid 
phase.  This organic carbon partition coefficient (Koc) describes the mass of a compound 
in the soil per mass of organic carbon present and facilitates extrapolation from one 
solid matrix to another e.g. soil (Ahanger, 2011; Kümmerer, 2008).  However, for ionic 
compounds this method is not appropriate (Tolls, 2001). 
 
1.1.9 How pharmaceuticals enter the environment 
Pharmaceuticals may enter the terrestrial environment through the spreading of 
persistent compounds that remain within treated biosolids, through the landfill of 
disposed pharmaceuticals, or through the disposal of raw sewage or effluents released 
from STPs (Wu et al., 2009).  As shown in Figure 1.2, the most significant transfer of 
pharmaceuticals to the aquatic environment is likely to occur through the discharge of 
recycled water, or association with land applied biosolids.  The disposal of biosolids 
into the sea has been banned within the EU since 1998 under the Urban Waste Water 
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Treatment Directive, and application of biosolids onto agricultural land is now a 
common practice due to the nutrients and trace elements that are present (Redshaw et 
al., 2008).  While these nutrients and trace elements are beneficial in controlled 
quantities, they may be harmful in excessive amounts, therefore the application of 
biosolids is managed to prevent eutrophication and heavy metal toxicity (South West 
Water, 2005).  In addition to these potentially toxic elements, biosolids contain an array 
of micropollutants such as pharmaceuticals that remain following sludge treatment 
processes.  When applied to the soil these micropollutants may be mobilised and 
subsequently leach into ground water, or enter surface water through runoff (Fent et al., 
2006, Göbel et al., 2007, Jjemba, 2002, Ternes, 1998, Wick et al., 2009; Xia et al., 
2005).  These entry paths are shown in Figure 1.2. 
 
Figure 1.2 Entry paths into the environment for medicinal products (EMEA, 
2006). 
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1.1.10 Effects of pharmaceuticals within the environment 
During recent years there has been increasing scientific concern regarding the effects of 
chemical pollutants upon various trophic levels within the environment.  Particular 
causes for concern include the transfer of resistance genes between microorganisms in 
response to high levels of antibiotics within the environment, and the impact of 
endocrine-disrupting chemicals (EDCs), such as synthetic steroid hormones, upon 
reproduction and development in a number of wildlife species. 
 
1.1.11 Antibiotic resistance within the environment 
Antibiotics are a diverse range of molecules used for the prevention or treatment of 
microbial infections in human and veterinary medicine.  However, prophylactic use of 
antibiotics is also widespread in food production systems in many parts of the world 
(Kümmerer, 2009b).  A large proportion of antibiotics consumed are excreted 
unchanged and are largely resistant to biodegradation, resulting in significant 
concentrations within both the aquatic and particularly the terrestrial environment 
(Thiele-Bruhn, 2003).  The bacteria that inhabit these environments have the capacity to 
adapt themselves to the presence of these antibiotics through the development of 
mutations within their DNA which are transferred to subsequent generations.  This 
change renders the agent ineffective against the organism which is referred to as 
resistant.  A significant amount of research has been performed within the area of 
resistant bacteria because they may be acquired by humans from a range of sources, but 
there may also be significant impacts for ecosystem functions and also for sewage 
treatment plants which are as yet unknown (Kümmerer, 2009a).  To date, the most 
medically significant example of a resistant strain of bacteria is methicillin-resistant 
Staphylococcus aureus (MRSA), which is often associated with hospitals and poses a 
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threat through secondary infection to the elderly and immune compromised following 
surgery.  In order to limit the further development of resistant strains it is important to 
limit the duration of drug administration in medicine and to eliminate continuous use 
within livestock production systems.  
 
1.1.12 Endocrine disruption within the environment 
17α-ethinylestradiol (EE2) is a lipophilic synthetic oestrogen which is present in the 
contraceptive pill and has become ubiquitous within the environment at biologically 
active concentrations due to incomplete removal during sewage treatment (Nikolaou et 
al., 2007).  Numerous reports of feminisation within wild fish populations in rivers 
downstream of sewage treatment works have stimulated a significant amount of 
research to better understand the mechanisms that cause endocrine disruption (Liney et 
al., 2006; Maunder et al., 2007).  EE2 and other EDCs have been shown to result in a 
variety of responses including reduced dominance behaviour, reduced 11-
ketotestosterone and testosterone concentrations, induction of egg yolk precursor 
protein vitellogenin, and underdeveloped gonads with poor gamete quality (Maunder et 
al., 2007; Salierno & Kane, 2009).  Through the study of a number of freshwater fish 
species it has been demonstrated that these effects may be induced through exposure to 
concentrations as low as 10 ng L
-1
.  These effects have been confirmed in 
multigenerational laboratory studies to influence reproductive performance resulting in 
population impacts, and potential ecosystem effects (Nash et al., 2004).  To minimise 
the risk to the environment it is important that removal during sewage treatment 
processes is optimised.  Removal through adsorption to sludge has been identified as an 
important elimination pathway for EDCs from wastewater (Clara et al., 2004).  
However uptake of EE2 by plants via root systems has been demonstrated, therefore 
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further research is likely to focus upon the removal of EDCs from sludge in order to 
minimise entry into the food chain (Martín et al., 2012). 
 
1.1.13 Indirect effects of pharmaceuticals within the environment 
Often the effects of pharmaceuticals within the environment are through direct exposure 
to biologically active compounds, such as the effects of endocrine disrupting chemicals 
in fish (Kümmerer, 2009b).  However, there have also been incidences of acute effects 
of pharmaceuticals when consumed through the food chain, with devastating 
consequences.  A 95% decrease in the Oriental white-backed vulture population through 
renal failure was observed between 2000 and 2003 due to the influence of the anti-
inflammatory drug diclofenac which is also used as a veterinary medication.  Diclofenac 
was not ingested through direct administration, but through the scavenging of 
diclofenac-treated livestock carcases (Oaks et al., 2004).  Since this population crisis, 
the Oriental white-backed vulture has been listed as critically endangered.  This crisis 
demonstrates the indirect effects of pharmaceuticals within the environment, when 
compounds are transferred between trophic levels.  
 
1.2 Environmental risk assessment and removal of 
pharmaceuticals during wastewater and sludge treatment processes 
As the previous section demonstrates many pharmaceutical compounds remain highly 
biologically potent following excretion into the environment.  However, many of the 
risks such as the effects that may occur between trophic levels and the effects of 
mixtures within the environment remain poorly understood.  Since the realisation of the 
harm that can be caused through the presence of pharmaceuticals within the 
environment, measures have been put in place wherever possible to manage this risk 
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and to reduce exposure through strategies such as the controlled use of drugs wherever 
possible, through the use of enhanced treatment processes, and also through the 
development of ‘greener’ pharmaceuticals that are fast and easily degradable after use 
(Kümmerer, 2009b). 
 
Since 1995 the completion of an environmental risk assessment (ERA) has been 
necessary for all new pharmaceutical products prior to the authorisation of marketing, 
although this is not required for pharmaceuticals registered prior to this period.  In 
Europe, pharmaceuticals are regulated separately from other categories of chemicals by 
the European Medicines Agency (EMA), which prior to 2009 was known as the 
European Medicines Evaluation Agency (EMEA).  ERA is performed following the 
Guideline on the Environmental risk assessment of Medicinal products for Human Use 
(EMEA, 2006).  Several variables including level of consumption, excretion efficiency 
from the body, sorption properties, and metabolic decomposition during sewage 
treatment are considered when estimating the fate of a pharmaceutical within the 
environment (Díaz-Cruz et al., 2003).  The current environmental risk assessment 
guideline addresses these factors in a stepwise approach. 
 
1.2.1   Environmental risk assessment process within the EU 
During Phase I of the environmental risk assessment, an estimation of exposure is 
performed and log Kow determined.  An initial predicted environmental concentration 
(PEC) within surface water is then calculated and used to determine which types of 
further tests may be required.  If the PECSW exceeds the environmental threshold of 
10 ng L
-1
, Phase II testing is required to generate experimental data on the fate and 
effects of the active pharmaceutical ingredient (API) in the environment.  For all APIs 
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with a log Kow > 4.5, screening should include an assessment for persistence, 
bioaccumulation and toxicity (Oakes et al., 2010).  
 
During Phase II a ratio is calculated between the predicted environmental concentration 
and the predicted no effect concentration (PEC/PNEC).  Phase II testing is two-tiered, 
with Tier A being conducted to identify if an API presents a risk to the environment.  
Tests included within this tier of assessment include aquatic toxicity tests, microbial 
inhibition, adsorption-desorption, ready biodegradability, and transformation within 
aquatic sediments.  For substances that are shown to have a high affinity to sludge and 
to be non readily-biodegradable, Tier B tests are conducted to further evaluate these 
effects within the environment.  Tests included within this tier of assessment include 
toxicity to terrestrial organisms, plant growth tests, and transformation within soil 
(EMEA, 2006).  
 
1.2.2  Estimation of pharmaceutical consumption 
The consumption of many commonly used pharmaceuticals is substantial, and may vary 
according to season, age demographic, and other social factors.  Examples of this 
include the consumption of drugs such as antibiotics and anti-inflammatory drugs in 
greater quantities during winter months, or higher level consumption of drugs such as 
nitrates, calcium channel blockers and β-blockers in areas where a large proportion of 
the population are elderly (Heberer, 2002).  Data for prescribed drug use in the UK are 
kept by the Department of Health (DOH).  However, it can often be difficult to make 
accurate assessments because of internet sales, and over-the-counter drug use is also 
very difficult to estimate (Jones et al., 2002).  Records of pharmaceutical sales in kg 
across the globe are maintained annually, and are used by the pharmaceutical industry to 
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track trends.  This information provides more accurate consumption data than using 
DOH information combined with defined daily dose (DDD) information.  Between 
2009 and 2011 the compounds which were most frequently prescribed within the UK 
included lipid regulators, antisecretory drugs, antihypertensives, analgesics, 
antidepressants, antidiabetic drugs and antibiotics.   
 
1.2.3  Removal due to biodegradation 
Biodegradability indicates the property of a substance to undergo a biologically 
mediated degradation (Angelidaki & Sanders, 2004).  Following disposal in wastewater, 
pharmaceutical compounds have the potential to encounter aerobic, anoxic and 
anaerobic conditions.  Therefore, it is important to assess their fate under all conditions 
(Musson et al., 2010).  Although the use of anaerobic treatments for the stabilisation of 
sludge is a widespread practice, the study of the biodegradation of xenobiotic 
compounds such as pharmaceuticals under anaerobic conditions is a relatively new area 
of research. 
 
When a test substance is converted into inorganic compounds and other products that 
cannot be further biologically degraded, biodegradation is described as ultimate, while 
biodegradation is said to be primary if the chemical structure is altered to form products 
that may biodegrade further (Angelidaki & Sanders, 2004; Batstone et al., 2002; Rozzi 
& Remigi, 2004).  An organic substance can also be referred to as inherently 
biodegradable if it has the potential to biodegrade following specific treatment such as 
pre-exposure of the inoculum to the substrate, increased test duration, or higher biomass 
concentration (OECD, 2005). 
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1.2.4  Removal due to sorption 
The removal of chemical substances by sorption processes during sewage treatment 
involves the transfer of the substance from the aqueous phase to the biosolids without 
chemically changing it.  This occurs during physicochemical treatment processes such 
as flotation and coagulation-flocculation, but may also take place during biological and 
sludge treatment processes. 
 
There are three consecutive steps in the adsorption of materials from solution by porous 
adsorbents: diffusion across a boundary layer, internal diffusion within the pores of the 
adsorbent, and adsorption to the interior surface (Joss et al., 2004).  Bonding 
mechanisms vary, depending on molecule type, with hydrophobic interaction being the 
principal bonding mechanism between neutral molecules and the surface of the sludge, 
and cation exchange being the principal bonding mechanism between ionic molecules 
and the surface of the sludge (Schaffer et al., 2012; Tolls, 2001). 
 
1.2.5  Extraction and analysis of pharmaceuticals within the biosolids 
Advances within the area of environmental analysis have provided the tools with which 
to study many areas of environmental concern (   a -Cruz et al., 2003).  Recently there 
have been particular advances in extraction methodologies that allow us to quantify 
organic compounds within solid matrices such as soils, sediments and sludges.  This 
allows us to fully assess the removal processes of pharmaceutical compounds during 
wastewater and sludge processing treatments, and gives a much greater insight into the 
fate of these substances within the environment.  
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1.2.6 Extraction of pharmaceuticals in the biosolids  
Traditionally, extraction of analytes from solid matrices has been performed by 
extraction of oven dried samples with polar organic solvents using techniques such as 
Soxhlet extraction, mechanical shaking, or extraction performed in an ultrasonic bath 
because of the high extraction efficiencies offered (   a -Cruz et al., 2003).  However, 
more recent publications have reported increasing use of microwave-assisted solvent 
extraction (MASE) and accelerated solvent extraction (ASE) (Barron et al., 2008).  Both 
ASE and MASE have been used by the U.S. EPA as standard methods for the extraction 
of non-volatile compounds from solid samples since 1996 and 2000, respectively.  ASE 
has been particularly well documented in the literature and involves placing the sample 
in a stainless steel extraction cell which is filled automatically with suitable solvents 
under high temperature (100-180°C) and pressure (100-200 bar).  At high temperature 
and pressure, the solvent viscosity is low which allows the solvent to penetrate deep into 
the sample matrix and extract analyte trapped in the matrix pores, thus allowing high 
extraction efficiency with short extraction times and low solvent consumption (Kou & 
Mitra, 2003).  Other less well-documented techniques include focussed ultrasound 
solid-liquid extraction using ultrasonic probes, and supercritical fluid extraction where 
carbon dioxide is commonly used as a fluid through the modification of temperature and 
pressure (Kou & Mitra, 2003). 
 
Most of the methods used for the extraction of organic compounds from the biosolids 
are not selective, and sample clean-up is required prior to analysis.  A summary of 
methods commonly used for the extraction, clean-up and analysis of pharmaceuticals 
from solid environmental matrices is shown in Table 1.4.  A more detailed review of 
similar methodology can be found within the literature (Zuloaga et al., 2012).   
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Table 1.4 Methodology used for the extraction and analysis of pharmaceuticals in the biosolids 
Extraction 
Technique 
Extraction Solvent SPE 
Phase 
Analytical 
Phase 
Mobile Phase Detection 
Method 
Reference 
PLE MeOH/H2O Oasis 
MCX 
C18 Aq. CH3COOH/MeOH 
CH3COOH 
LC-MS/MS Baker & 
Kasprzyk-
Hordern, 2011 
PLE MeOH/H2O Oasis 
HLB 
C18 Aq. NH4AC/ACN LC-MS/MS Barron et al., 
2008 
PLE ACN/H2O C18/ 
PLRP-s 
C18 Aq.NH4HCO2.HCOOH/ACN LC-MS/MS Kinney et al., 
2006 
PLE MeOH/H2O Oasis 
HLB 
C18 Aq.HCOOH/ACN LC-MS/MS Jelić et al., 2009 
PLE H3PO4/MeOH 0.45 μm 
filter 
C18 Aq.H3PO4/ACN LC-MS/MS Nieto et al., 2007 
PLE MeOH/H2O.CH3COOH Oasis 
MCX 
C18 Aq. NH4AC/ACN LC-MS/MS Scheurer et al., 
2010 
USE Aq.H3PO4/ACN Oasis 
HLB 
C18 
HILIC 
Aq.HCOOH/ACN/MeOH 
Aq. NH4AC.CH3COOH/MeOH 
LC-MS/MS U.S. EPA, 2009 
USE Acetone/CH3COOH, Ethyl 
acetate 
Oasis 
MCX 
C18 Aq.CH3COOH/ACN LC-MS/MS Löffler & Ternes, 
2003 
USE MeOH, Acetone Oasis 
HLB 
C18 Aq.KH2PO4/ACN LC-DAD-Flo Martín et al., 
2010 
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1.2.7  Clean-up of samples extracted from the biosolids  
Sample clean-up is important for chromatographic separation such as gas 
chromatography (GC) and high performance liquid chromatography (HPLC), since 
solid samples can contain many compounds which can make identification of the 
analyte of interest difficult particularly at low concentrations due to chromatographic 
interferences or ion suppression in MS detection (   a -Cruz et al., 2003; Mitra & 
Brukh, 2003).  The most commonly used method for the clean-up of extracts prior to 
analysis is solid-phase extraction (SPE) since there are a large range of sorbents 
available which can be selected for the analytes of interest (Fontanals et al., 2010).  SPE 
is also a popular choice because it can be automated off-line or performed on-line prior 
to analysis, making the process much more rapid and efficient. 
 
Reverse phase sorbents have been available for many years, but due to poor selectivity 
they are unsuitable for use with many polar compounds, which are commonly found 
within the environment.  In order to overcome this problem, a number of cationic or 
anionic mixed-mode sorbents have been developed to extract analytes with particular 
chemical properties (Fontanals et al., 2010).  Selectivity for analytes is high and 
interferences are effectively removed during washing and elution steps, therefore 
mixed-mode phases such as Oasis MCX (Waters) and Strata X-C (Phenomenex) are 
now routinely used for the cleanup of extracts from environmental matrices. 
 
1.2.8  Analysis of pharmaceuticals extracted from the biosolids  
Analysis of prepared samples can be performed using a variety of instruments.  While 
gas chromatography-mass spectrometry (GC-MS) is the most widely used technique for 
the analysis of non-polar compounds, e.g., pesticides, petroleum hydrocarbons and 
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polycyclic aromatic hydrocarbons (PAHs), the analysis of pharmaceuticals in 
environmental samples is usually carried out by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) using reverse phase C18 columns with different mobile 
phases (Barceló & Petrovic, 2007).  Detection by UV and fluorescence is also widely 
used, however, MS is now routinely used within most environmental laboratories due to 
the low detection levels that can be achieved, which may be below 0.1 pg (   a -Cruz et 
al., 2003).  Triple quadrupole mass spectrometers (QqQ) are the most widely used 
instruments for the quantification of analytes within environmental samples due to the 
high sensitivity they provide (Barceló & Petrovic, 2007).  LC-MS/MS is also a widely 
used tool in for the identification of transformation products formed in different 
environmental matrices through the comparison of fragmentation patterns.  Hybrid-MS 
instruments including the linear ion trap (Qq-LIT), Orbitrap and quadrupole-time of 
flight (Qq-TOF) are the most widely used instruments for identification and 
confirmation of metabolites within environmental samples due to the high accuracy that 
they provide which can be within a few ppm of the exact m/z (Barceló & Petrovic, 
2007).  A number of monitoring campaigns have been performed measuring 
pharmaceuticals within the biosolids and related matrices.  Measured concentrations 
have been summarised and grouped into therapeutic area, compound and class in Tables 
1.5, 1.6 and 1.7. 
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Table 1.5 Antimicrobial compounds detected within biosolids 
Therapeutic Area, 
Compound and Class 
Measured Concentration 
(μg kg-1) 
Sample Matrix 
Antimicrobial  
Fluoroquinolone 
Ciprofloxacin 
 
 
Enrofloxacin 
Lomefloxacin 
Norfloxacin 
 
Ofloxacin 
Oxolinic acid 
Sarafloxacin 
 
 
74.5-47,500
a)
 
22.64-46.36
b) 
3,100
c)
 
12.1-66
a)
 
33.3-39.8
a)
 
99.3-1,290
a)
 
2,900
c)
 
73.9-58,100
a) 
39.4
a)
 
179-1,980
a)
 
 
 
Composted sludge 
Biosolids 
Digested Sludge 
Composted sludge 
Composted sludge 
Composted sludge 
Digested Sludge 
Composted sludge 
Composted sludge 
Composted sludge 
Lincosamide 
Clindamycin 
Lincomycin 
 
3.72-15.42
b)
 
13.9-33.4
a)
 
 
Biosolids 
Composted sludge 
Macrolide 
Azithromycin 
Clarithromycin 
Erythromycin 
 
Ormetoprim 
Roxithromycin 
Virginiamycin 
 
10.2-6,530
a)
 
1.57-30.24
b)
 
3.1-180
a)
 
8.0-41
d)
 
5.91
a)
 
14.3-22.8
a)
 
43.5-469
a)
 
 
Composted sludge 
Biosolids 
Composted sludge 
Biosolids 
Composted sludge 
Composted sludge 
Composted sludge 
Pyrimidine 
Trimethoprim 
 
 
12.4-204
a)
 
2.0-22
d)
 
 
Composted sludge 
Biosolids 
Sulfonamide 
Sulfamethazine 
Sulfamethoxazole 
Sulfanilamide 
 
Sulfisoxazole 
 
22.9-140
a)
 
21.5-23.2
a)
 
11.00-26.66
b)
 
3.91-651
a)
 
150-160
d)
 
191-15, 600
a)
 
9.14-21.92
b)
 
 
Composted sludge 
Composted sludge 
Biosolids 
Composted sludge 
Biosolids 
Composted sludge 
Biosolids 
Tetracycline 
Chlortetracyline 
 
Demeclocycline 
Doxycycline 
Minocycline 
Oxytetracycline 
Tetracycline 
 
Antifungal 
Miconazole 
 
Thiabendazole 
 
 
1,010
a)
 
12.79-14.75
b)
 
96-200
a)
 
50.8-5,090
a)
 
351-8,650
a)
 
18.6-467
a)
 
38.3-5,270
a)
 
15.76
b)
 
 
 14.2-9,210
a)
 
14-460
d)
 
8.42-239
a)
 
2.0-5,000
d)
 
 
Composted sludge 
Biosolids 
Composted sludge 
Composted sludge 
Composted sludge 
Composted sludge 
Composted sludge 
Biosolids 
 
Composted sludge 
Biosolids 
Composted sludge 
Biosolids 
 43 
 
Table 1.5 (continued) 
Disinfectant 
Triclocarban 
Triclosan 
 
187-441,000
a)
 
430-133,000
a)
 
 
Composted sludge 
Composted sludge 
References: 
a)
U.S. EPA, 2009, 
b)
Spongberg et al., 2008, 
c)
Golet et al., 2003, 
d)
Kinney et al., 
2006.  
 
Table 1.6 Psychoactive compounds and stimulants detected within biosolids 
Therapeutic Area, 
Compound and Class 
Measured Concentration 
(μg kg-1) 
Sample Matrix 
Analgesic 
Acetaminophen 
 
 
Codeine 
 
1,120-1,300
a)
 
4,535
b)
 
23-1,400
d)
 
9.59-328
a)
 
3.0-22
d)
 
 
Composted sludge 
Primary sludge 
Biosolids 
Composted sludge 
Biosolids 
NSAID 
Diclofenac 
 
 
Ibuprofen 
 
 
Ketoprofen 
Mefenamic Acid 
Naproxen 
 
 
Salicylic acid 
 
 
209
c)
 
32-183
e)
 
10.45-23.10
f)
 
99.5-11,900
a)
 
3,988
b)
 
70-99
e)
 
211
c)
 
3.5
c)
 
20.9-1,020
a)
 
1,022
b)
 
59-242
e)
 
13,748
b)
 
96.30-252.87
f)
 
 
Primary sludge 
Pretreated sludge 
Biosolids 
Composted sludge 
Primary sludge 
Pretreated sludge 
Primary sludge 
Primary sludge 
Composted sludge 
Primary sludge 
Pretreated sludge 
Primary sludge 
Biosolids 
Antiepileptic 
Carbamazepine 
 
 
8.74-6,030
a)
 
1,731
e)
 
80
f)
 
48-215
b)
 
4.76-12.86
c)
 
8.0-390
d)
 
 
Composted sludge 
Primary sludge 
Primary sludge 
Pretreated sludge 
Biosolids 
Biosolids 
Stimulant 
Caffeine 
 
 
65.1-1,110
a)
 
57-65
b)
 
4.52-5.21
c)
 
 
Composted sludge 
Pretreated sludge 
Biosolids 
SSRI Antidepressant 
Fluoxetine 
 
Paroxetine  
 
12.4-3,130
a)
 
72
f)
 
2.0-1,500
d)
 
52
f) 
 
Composted sludge 
Primary sludge 
Biosolids 
Primary sludge 
References: 
a) 
U.S. EPA, 2009, 
b)
 Nieto et al., 2007, 
c) 
Spongberg et al., 2008, 
d) 
Kinney et al., 
2006, 
e) 
Khan and Ongerth, 2002, 
f) 
Radjenovic et al., 2009.
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Table 1.7 Additional compounds detected within biosolids 
Therapeutic Area, 
Compound and Class 
Measured Conc. 
(μg kg-1) 
Sample Matrix 
Gastrointestinal 
H2 Antagonist 
Cimetidine 
 
Famotidine 
Ranitidine 
 
 
7.59-9,780
a)
 
13-71
d)
 
11
c)
 
3.83-2,250
a)
 
 
 
Composted sludge 
Biosolids 
Primary sludge 
Composted sludge 
Antidiabetes 
Biguanide 
Metformin 
 
 
550-1,160
a)
 
 
 
Composted sludge 
Respiratory tract 
β2 Agonist 
Albuterol 
 
 
23.2
a)
 
8.0-380
d)
 
 
 
Composted sludge 
Biosolids 
Allergic disorders 
H1Antagonist 
Diphenhydramine 
 
Loratidine 
 
 
36.7-5,730
a)
 
15-7,000
d)
 
53
c)
 
 
 
Composted sludge 
Biosolids 
Primary sludge 
References: 
a)
U.S. EPA, 2009, 
b)
Khan and Ongerth, 2002, 
c) 
Radjenovic et al., 2009, 
d)
Kinney et 
al., 2006. 
 
1.2.9  Removal of pharmaceuticals during sewage treatment processes 
It is important to understand the removal efficiency of treatment processes used for the 
stabilisation of wastewater and biosolids in order to evaluate the potential risk that 
consumed pharmaceuticals pose to the environment.  Municipal STPs are designed 
primarily for the reduction of biological organic material and nutrients within 
wastewater, and fail to effectively eliminate organic contaminants, such as 
pharmaceuticals and personal care products (PPCPs) (Heberer, 2002; Ternes, 1998).  
Some STP processes efficiently remove some chemicals, but are ineffective at treating 
others, and it is important to know how much of which substances are removed during 
which process and the mechanism of their removal.  This knowledge is important in 
order to perform accurate environmental risk assessments and to make 
recommendations about how STP processes can be improved and optimised. 
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1.2.10  Removal of pharmaceuticals during primary sewage treatment   
Removal during coagulation-flocculation and flotation treatment processes is due to the 
physicochemical processes of adsorption and absorption.  Coagulation-flocculation and 
flotation are useful tools for the removal of fats and suspended solids, and recent studies 
have also shown this treatment to be successful for the removal of several 
pharmaceuticals and personal care products.   
 
Coagulation-flocculation has been shown to be an effective removal mechanism for 
ionisable compounds through enhanced electrostatic bonding of positively-charged 
groups with the negatively-charged surfaces of the biosolids (Carballa et al., 2005; 
Golet et al., 2003; Vieno et al., 2006).  The influence of coagulation-flotation treatment 
diminishes with lowering Kd value.  This has been demonstrated by several researchers 
in laboratory experiments using NSAID compounds.  Up to 70% removal of diclofenac 
has been achieved, while 20-25% removal of naproxen and no removal of ibuprofen 
have been observed (Carballa et al., 2005; Suarez et al., 2009; Vieno et al., 2006).  
Flotation has been shown to be an effective removal treatment process for the removal 
of lipophilic compounds through hydrophobic interactions.  Efficient removal of several 
compounds has been observed including the synthetic musk compounds galaxolide 
(log Kow 6.3) and tonalide (log Kow 6.4), and the steroid oestrogen 17β-oestradiol 
(log Kow 3.9) (Carballa et al., 2004; Carballa et al., 2005; Suarez et al., 2009). 
 
Both physicochemical treatment processes have been demonstrated to transfer 
substances with particular physicochemical properties from wastewater to the biosolids, 
thus reducing concentrations present within the effluent.  However, adsorbed substances 
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remain within the biosolids following settling and will be transferred to the terrestrial 
environment on disposal unless destroyed during sludge treatment processes. 
 
1.2.11  Removal of pharmaceuticals during biological sewage treatment 
The removal efficiencies of many PPCPs and endocrine-disrupting hormones have been 
evaluated during biological sewage treatment.  A comprehensive review of PPCPs 
removal in treatment systems can be found in Onesios et al. (2009). 
 
 Elimination of commonly-used pharmaceutical compounds during biological sewage 
treatment has been investigated in both laboratory simulations and under full scale STP 
conditions.  Non-polar drugs such as benzodiazepine sedatives, and carbamazepine, a 
tricyclic compound commonly prescribed for the treatment of epilepsy, are resistant to 
biological sewage treatment processes, while polar compounds such as many analgesic 
and anti-inflammatory drugs which exhibit low partition coefficients are efficiently 
removed (Calisto & Esteves, 2009; Kasprzyk-Hordern et al., 2009).  The removal of and 
the metabolism of pharmaceuticals during sewage treatment often involves complex 
transformations from parent compound to metabolites, therefore no distinct pattern of 
removal has been identified in relation to chemical structure or therapeutic group (Jelic 
et al., 2012).  An example of irregular behaviour within a compound class has been 
demonstrated by several researchers through the study of non-steroidal anti-
inflammatory drugs (NSAIDs) , where it has been demonstrated that ibuprofen, 
naproxen and ketoprofen are all effectively degraded during aerobic sewage treatment 
processes, while diclofenac is recalcitrant and remains within the sludge (Joss et al., 
2005; Kimura et al., 2007; Quintana et al., 2005). 
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During secondary sedimentation, the compounds that will accumulate onto the surface 
of the waste sludge will be sorptive compounds that are non-biodegradable during 
sewage treatment processes.  Compounds that remain within the sludge undergo further 
processing during sludge stabilisation to reduce the impact that they may have on the 
environment upon reuse.  
 
1.2.12  Removal of pharmaceuticals during anaerobic sludge treatment 
The behaviour of organic compounds during anaerobic sludge treatment processes is a 
relatively new area of research, but one which is of particular interest for adsorptive 
compounds as it offers a final opportunity for removal before the disposal of biosolids.  
However, the behaviour of linear alkylbenzene sulfonates (LASs) and quaternary 
ammonium compounds (QACs) under anaerobic conditions has received particular 
attention (Stasinakis, 2012).  Both are widely used as surfactants in household and 
industrial products, and both are persistent groups of compounds that have been 
reported in the terrestrial environment (Sablayrolles et al., 2009).  While both LASs and 
QACs have been demonstrated to be recalcitrant, anaerobic treatment processes have 
been demonstrated to offer some potential for their removal (García et al., 2000; 
Morgensen et al., 2003). 
 
The study of pharmaceuticals under anaerobic conditions is, a much less studied field of 
research, possibly owing to the lower concentrations found within the environment.  
Most studies investigating the removal of pharmaceuticals under anaerobic conditions 
have been performed in batch tests or laboratory-scale bioreactors, however, more 
recent data has included the removal of pharmaceuticals during anaerobic digestion at a 
municipal plant (Jelic et al., 2012).  Data from across a range of therapeutic groups 
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suggests that as with biological sewage treatment processes, the efficiencies of removal 
vary considerably during anaerobic digestion of sewage sludge.  Compounds such as 
benzodiazepine sedatives and carbamazepine have demonstrated resistance to sludge 
treatment processes, while NSAID drugs have shown good rates of removal (Jelic et al., 
2012).  Biotransformation has been identified as the principal mechanism in the removal 
of pharmaceuticals during anaerobic digestion of sewage sludge, making it difficult to 
identify a pattern of removal.  Attempts have been made to compare the extent of 
biodegradation to compound sorption characteristics, however, a relationship between 
the two has not been demonstrated (Jelic et al., 2012).   
 
Compounds that are resistant to sludge treatment processes have the potential to be 
transferred to the environment upon disposal, usually through spreading onto farmland 
for the recycling of macronutrients (Eriksson et al., 2008).  From here, adsorbed organic 
compounds may become mobile and have the potential for uptake by crops, which may 
impact upon humans or livestock.  It is therefore important to understand the extent of 
removal during sludge stabilisation in order to make an accurate assessment of the 
potential risks to humans and the environment. 
 
1.3 Reactions within the anaerobic digestion process and methods 
used to assess anaerobic biodegradability 
1.3.1  Biochemical reactions within the anaerobic digestion process  
Anaerobic digestion consists of several serial and parallel reactions and processes, and 
requires a complex community of symbiotic microorganisms (Batstone et al., 2002).  
Due to its potential to yield renewable energy, significant efforts have been made to 
optimise the process.  A model (ADM1) to support the global use of anaerobic digestion 
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as a waste treatment technology and renewable energy source has been developed by 
the International Water Association (IWA) Anaerobic Digestion Modelling Task Group 
(Batstone et al., 2002).  The three steps of acidogenesis, acetogenesis and 
methanogenesis take place during the anaerobic digestion process following enzymatic 
hydrolysis of complex organic matter.   Glucose and amino acids formed during 
hydrolysis are used to form hydrogen and acetate which are used during the terminal 
step to produce CO2 and CH4 as shown in Figure 1.3 (Zinder et al., 1984). 
 
Figure 1.3 Degradation of organic matter during anaerobic digestion (Batstone et 
al., 2002). 
 
The microbial community within an anaerobic digester is comprised of microorganisms 
from domains Archaea and Bacteria.  The trophic groups that are generally considered 
relevant for anaerobic processes are hydrolysing bacteria, acidogenic bacteria, 
acetogenic bacteria, acetotrophic and hydrogenotrophic methanogens (Rozzi & Remigi, 
2004).  The dominant Archaea present within anaerobic digester sludge from 
wastewater origin are the Methanomicrobiales and the Methanosarcinales which utilise 
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acetate and hydrogen, while those within the domain Bacteria are much more diverse 
and may utilise a number of substrates including acetate, propionate, butyrate and even 
glucose (Ariesyady et al., 2007).   
 
1.3.2  Electrochemical conditions within the anaerobic digestion process 
Redox potential (Eh) is comprised of two half reactions: the oxidation potential, and the 
reduction potential.  If the Eh is high, there is a strong tendency for a solution to accept 
protons, and the solution is oxidising.  If the Eh is low, there is a strong tendency of a 
solution to donate protons, and the solution is reducing.  The environment within an 
anaerobic digester contains of inorganic compounds from a range of sources which 
influence the redox status of the sludge (Yu & Rinklebe, 2011).  The potential measured 
with an inert electrode (Eh) is a commonly measured parameter to indicate performance 
during anaerobic digestion (Lee, 2008).   Organic compounds may be reduced through 
the processes of fermentation below -100 mV, however the formation of methane does 
not occur unless redox conditions fall below -300 mV (Lee, 2008).    
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Figure 1.4 (a) Eh ranges for microbial utilization of electron acceptors (Atlas & 
Bartha, 1993), and (b) environmentally relevant redox couples (Borch et al., 2010). 
 
Typically redox potential can vary from +700 mV to -300 mV (Yu & Rinklebe, 2011).  
Once all available oxygen within a system has been consumed by obligately aerobic 
microorganisms (+300 to  +350 mV) the following electron acceptors are utilised in 
sequential order by facultative anaerobes as shown in Figure 1.4b ; O2 (+350 mV) > 
NO3
-
(+100 to +300 mV) > Mn(IV) (+50 to +250 mV) > Fe(III) (+100 to -100 mV) > 
SO4
2- 
(-100 to -200 mV) > CO2 (< 200 mV) (Brezonik & Arnold, 2011; Graetz et al., 
1973; McMahon & Chapelle, 2008).  Some degree of overlap between electron 
acceptors is likely to occur as shown in Figure 1.4a.  For example, sulphate reducing 
bacteria occupy a similar zone within the redox scale to methanogens, and compete for 
acetate and H2 to form H2S (Lee, 2008).  In anaerobic digestion this type of competition 
between microbial groups is generally undesirable, as it lowers the efficiency of the 
digestion process through reduced biogas yield.  It is known to be a particular problem 
in industrial wastewater containing high sulphate levels (Zhang et al., 2013).      
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While changes in redox potential and electron acceptor availability may have a negative 
impact upon biogas yield, it is understood that the mobilisation or degradation of 
contaminants within the environment may be positively influenced through the 
manipulation of microbial activity following redox amendment (Hunter et al., 1998).  
The influence of redox processes has been investigated with respect to a number of 
contaminants including petroleum hydrocarbons, pesticides, chlorinated solvents, 
explosives, and more recently in relation to emerging contaminants including 
pharmaceuticals (Barbieri et al., 2011; Borch et al., 2010; Ivanov et al., 2010).  It is 
considered that if different compounds are degraded under different redox conditions, 
the artificial promotion of a series of redox states within an environment should result in 
the elimination of most of the contaminants present (Barbieri et al., 2011).  This has 
been investigated within the laboratory in both wastewater matrices and culture media 
containing specific terminal electron acceptors including nitrate, iron, manganese, and 
sulfate (Barbieri et al., 2011; Crawford et al., 2000; Ivanov et al; 2010; Quintana et al., 
2005).     
 
1.3.3  Biodegradation of organic compounds under anaerobic conditions 
Biodegradation is one of the most important processes involved in the removal of 
micropollutants within the environment.  Oxidation, reduction, hydrolysis and 
conjugation are the main reaction types involved in biodegradation (Samiullah, 1990).  
The physicochemical properties of a substance are important determinants of 
biodegradability, and affect the bioavailability of micropollutants and biodegradable 
carbon to microorganisms (Barret et al., 2010a).  Although this does not always hold 
true, it is generally considered that large polycyclic hydrocarbons such as oestrogens are 
less degradable than cyclic compounds, and cyclic compounds are less degradable than 
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aliphatic compounds.  The presence of halogen substituents for example has been 
shown to increase the electrophilicity and oxidation state of a compound, making it less 
susceptible to substitution and oxidation (Samiullah, 1990).   In order to understand 
pathways of biodegradation, knowledge of organic functional groups is required in 
order to match a new chemical structure to one whose metabolism is already known 
(Wackett & Ellis, 1999).     
 
The degradation of substituted monoaromatic compounds such as toluene is well-
studied, and is relevant to pharmaceuticals such as acetylsalicylic acid.  The anaerobic 
degradation pathway follows initial reduction of constituents such as COOH and OH, 
followed by ring cleavage which results in complete mineralisation (Foght, 2008; 
Wackett & Ellis, 1999).  In anaerobic batch studies, 99% biodegradability was 
demonstrated for acetylsalicylic acid, demonstrating its effective removal from the 
biosolids (Musson et al., 2010; Quintana et al., 2005). 
 
Anaerobic degradation of polycyclic aromatic compounds and substituted polycyclic 
aromatic compounds with nitrate, sulfate or iron as terminal electron acceptor have also 
been demonstrated (Foght, 2008).  Numerous pathways have been proposed for the 
degradation of naphthalene and methylnaphthalene including carboxylation through 
incorporation of bicarbonate, and methylation through incorporation of a methyl group 
(Meckenstock et al., 2000; Safinowski et al., 2006).  The degradation pathways and 
transformation products of a number of NSAIDs from the group of naphthalene or 
benzene acid derivatives such as naproxen and diclofenac have been studied during 
aerobic and anaerobic sewage treatment.  No transformation was observed for 
diclofenac under either aerobic or anaerobic conditions, while ether cleavage of 
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naproxen was observed to form the stable metabolite O-desmethylnaproxen under both 
aerobic and anaerobic conditions (Lahti & Oikari, 2011; Quintana et al., 2005).   
          
1.3.4  Determination of anaerobic biodegradability 
Interest in the environmental fate of chemicals is growing amongst industries and 
government regulators in order to prevent negative impact upon ecosystems (Wackett & 
Ellis, 1999).  The most realistic method of evaluating test substance removal during 
sewage treatment is to dose the analyte of interest into a STP and measure 
concentrations entering and leaving each treatment process.  However, this is not 
practical for a number of reasons and the process must therefore be simulated under 
controlled laboratory conditions.  A number of alternative approaches with varying 
degrees of complexity have therefore been proposed.  
 
1.3.5  Quantitative structure activity relationships 
QSAR models consist of molecular descriptors of a training set of compounds, which 
are used to predict the behaviour of new chemicals.  As a first-line approach the use of 
predictive software such as BIOWIN7 (Boethling et al., 2004) or the University of 
Minnesota Biocatalysis/Biodegradation Database (Gao et al., 2012) can be highly 
effective, particularly to assess large numbers of chemicals.  Software programmes such 
as these are valuable reference tools containing biotransformation rules compiled from 
reactions published in available scientific literature.  Most organic compounds are 
composed of different arrangements of the most common 40 functional groups (Wackett 
& Ellis, 1999).  These rules can be applied to predict how susceptible different 
configurations of these functional groups will be to different forms of attack (Gao et al., 
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2012). Comparative studies have demonstrated that some discrepancies exist between 
predicted data and experimental values (Andersen et al., 2003).  However, this type of 
approach when screening chemicals has been shown to significantly reduce false 
positive results during further tests (Boethling et al., 2004; Yu et al., 2006).   
 
1.3.6 Determination of anaerobic biodegradability through the use of 
manometric techniques 
Measurement of biological activity through gas production may be determined in a 
number of ways including pressure measurement, liquid displacement, and through the 
analysis of gas composition (Gartiser et al., 2007; Rozzi & Remiggi, 2004).  
Respirometric methods are simple to perform, have been well validated, and give an 
indication of the potential for anaerobic biodegradation (Battersby & Wilson, 1988; 
Birch et al., 1989).  Standard protocols for the evaluation of biodegradability in 
anaerobic digester sludge that employ both volumetric and respirometric methods have 
been in common use worldwide for over thirty years (ISO, 1995; OPPTS, 1998; OECD, 
2006).  However, it is important to ensure that the high test substance concentrations 
required to perform respirometric tests (≥ 20 mg C L-1) are not toxic or inhibitory to the 
microbial population (Shelton & Tiedje, 1984).  The presence of any xenobiotic 
compound within anaerobic sludge has the potential to result in a disturbance due to 
microbial inhibition, which may be determined respirometrically (Gartiser et al., 2007).  
Anaerobic inhibition is expressed as a percentage reduction of activity in response to a 
test substance when compared with baseline activity under optimal conditions (OECD, 
2007). 
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Determination of chemical removal under anaerobic conditions using respirometric 
methods is often used within industry, however published data are scarce.  Information 
is available detailing the biodegradation of only a limited number of pharmaceutical 
compounds.  The behaviour of antibiotics under anaerobic conditions is of particular 
concern due to the potential for entry into the environment following incomplete 
removal.  Inhibitory activity upon methanogens has been demonstrated from 
tetracycline, aminoglycoside, fluoroquinolone and macrolide antibiotics, with moderate 
biodegradation of only the β-lactam antibiotic benzylpenicillin being shown (Gartiser et 
al., 2007). 
 
Gas production is a recognised parameter for the evaluation of sludge activity 
particularly when analysis of the test material is complex and difficult to measure 
accurately.  The composition of the gas phase may be determined using GC with flame 
ionisation detection (FID) following headspace injection, or through the use of a hand 
held gas analyser with an infrared sensor.  Respirometric experiments can be a useful 
screening tool for evaluating multiple compounds under a variety of conditions.  
However, more detailed information may be preferred in order to gain a fuller 
understanding of the mechanisms of removal.  In these cases the use of specific analysis 
for the determination of the parent compound and any potential transformation products 
should be employed. 
         
1.3.7 Determination of anaerobic biodegradation through the use of specific 
analysis  
Additional analyses can be performed in order to give more detailed information about 
the environmental fate of a compound by measuring the total removal due to 
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mineralisation, the formation of transformation products, and removal due to abiotic 
factors such as adsorption (Gartiser et al., 2007).  This can be achieved through the 
removal of samples from a batch experiment such as the respirometric test previously 
described, or through the use of a test system such as the OEC  314 C ‘Minerali ation 
and Transformation in Anaerobic  igester Sludge’ (OECD, 2008), where the test 
substance is dosed into a laboratory bioreactor with a volume of several litres.  To 
determine partitioning of non-labelled test substances, samples are centrifuged before 
the supernatant is analysed and the sludge fraction is freeze-dried, extracted, cleaned-up 
and then analysed.  Analyte recovery during extraction and clean-up steps is normally 
verified through the use of spiked matrix blanks and/or internal standards.   
 
The removal of multiple compound types has been evaluated within laboratory scale 
bioreactor experiments.  Effective removal of steroid oestrogens, sulphonamide 
antibiotics and NSAID compounds has been demonstrated (Carballa et al., 2007; 
Paterakis et al., 2012).  Benzodiazepine sedatives and the tricyclic compound 
carbamazepine and its main metabolite epoxy-carbamazepine have shown low levels of 
removal, which is in agreement with full scale STP data (Carballa et al., 2007; Jelic et 
al., 2012).    
 
A continuous experiment where the reactor is fed daily or weekly with primary sludge 
while an equal volume of digested material is removed regularly from the vessel is more 
representative of full-scale conditions (Carballa et al., 2007).  It is recommended that 
tests such as the OEC  314 C are performed at an ‘environmentally relevant’ 
concentration usually < 1.0 mg L
-1
.  For test substances being evaluated using this 
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system, extraction from the sludge phase followed by cleanup steps using methods such 
as SPE and analysis by LC-MS/MS is often required. 
 
1.3.8 Determination of anaerobic biodegradation through the use of 14C 
radioisotopes 
An alternative approach that may be used to evaluate the environmental fate 
(biodegradation and partitioning) of a substance within a bioreactor at environmentally 
relevant concentrations is the use of radiolabelled compounds (Cirja et al., 2006).  The 
level of radioactivity being dosed into the reactor is determined using liquid scintillation 
counting (LSC), and further LSC counts to determine mass balance are made by 
measuring the amount of radioactivity in the waste sludge and in any evolved trapped 
gases and volatile organic compounds (Junker et al., 2006).  To determine partitioning 
of the radioactivity, samples are first centrifuged before the supernatant is scintillation 
counted, the sludge fraction dried, and non-extractable radioactivity measured by 
combustion (Cirja et al., 2006).  Radiolabelling may be further used to perform HPLC 
analysis of extracted samples and identify if the radiolabelled trace can be assigned to 
any known transformation products.  Through analysis of the fragmentation pattern 
using LC-MS/MS coupled with radio-detection transformation products may then be 
identified (Cirja et al., 2006).  While the cost of radioisotopes may, in some cases, be 
prohibitive and a great deal of technical care must be taken with their use, they can 
assist greatly with the identification of transformation products.  They can also give 
realistic descriptions of mineralisation kinetics and can also determine partitioning 
within the biosolids without the complex extraction, cleanup and quantification required 
when using non-labelled substances (Nuck & Federle, 1996).  
 
 59 
 
1.3.9 Molecular biology tools for evaluating the anaerobic biodegradation of 
pharmaceuticals 
Measuring the degradation of chemical compounds within the environment and in 
laboratory experiments through specific analysis and the measurement of transformation 
products provides information about removal mechanisms and reaction kinetics. 
However, the use of molecular biology tools provides insight into the interactions and 
metabolic functions of the degrading microorganisms that facilitate the biochemical 
reactions taking place (Talbot et al., 2008).  An overview of microbial changes at the 
community level can be obtained through the use of PCR-based molecular 
fingerprinting techniques such as denaturing gradient gel electrophoresis (DGGE) and 
terminal restriction fragment-length polymorphism (T-RFLP).  While more detailed 
information such as identification and the abundance of target organisms may be 
obtained through the use of more direct methods such as 16S rRNA clone libraries and 
real-time PCR techniques that use fluorogenic probes (Muyzer & Smalla, 1998; Ward et 
al., 1990; Yu et al., 2005).   
 
One of the ultimate goals of biodegradation experiments is the identification of 
metabolically active cells.  This may be achieved through the use of techniques such as 
stable isotope probing (SIP) or microautoradiography-fluorescence in-situ hybridisation 
(MAR-FISH).  Both techniques facilitate the evaluation of substrate assimilation by 
major phylogenetic groups through incubation of an environmental sample with an 
isotopically labelled substrate (Nielsen & Nielsen, 2012; Madsen, 2006; Talbot et al., 
2008; Zang et al., 2008).  SIP involves identification of metabolically active 
microorganisms through cloning/sequencing of ‘heavy’ cells following density gradient 
ultracentrifugation, while the MAR-FISH technique enables relative abundances of 
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metabolically active groups to be measured through visualisation of fluorogenic probe-
defined microorganisms using bright field or laser-scanning microscopy (Radajewski et 
al., 2000). 
 
Through the use of the methods described it is possible to obtain a wealth of 
information about community structure and metabolism of the microorganisms 
responsible for the biodegradation of environmental pollutants.  This information in 
combination with removal data obtained through chemical analysis provides a more 
detailed picture of biodegradation mechanisms within the environment.  Further 
information about the ecology, physiology, biochemistry and gene regulation of the 
microorganisms that perform pollutant elimination is required to provide a more full 
understanding of these mechanisms, and it is likely that these areas will form the basis 
of future research (Madsen, 2006). 
 
1.3.10 Anaerobic biodegradability of pharmaceuticals - current knowledge and 
research needs  
From the literature it can be seen that a vast range of pharmaceuticals exist and that they 
are chemically diverse in nature due to the range of therapeutic areas that they are used 
to treat.  As a by-product of their function, pharmaceuticals are often found to persist 
within the environment long after they have been excreted from the body, which has 
been linked with negative effects within both aquatic and terrestrial organisms.  It is 
important that we understand the risk that pharmaceuticals present to the environment 
through environmental monitoring and thorough testing strategies, and that we minimise 
the risk as much as possible through responsible use of pharmaceuticals and through 
effective wastewater and sludge treatment technology.   
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Wastewater and sludge treatment processes have been developed primarily for the 
removal of biological organic material, nutrients and pathogens, with the removal of 
micropollutants such as pharmaceuticals being a secondary consideration.  Recent 
advances in analytical techniques have facilitated monitoring at environmental 
concentrations within both the aquatic and terrestrial environment, providing the tools 
to measure removal rates within all sewage treatment plant processes.  Practically this is 
only possible for a limited number of pharmaceuticals because of interferences from 
matrix components, however the measurement of more compounds is likely in the 
future due to increasing use of more selective sample preparation techniques.  
  
Monitoring within STPs gives the most realistic information about the removal of 
pharmaceuticals during wastewater and sludge treatment processes.  However, this is 
not always feasible and laboratory simulations are commonly used to evaluate the 
removal of pharmaceuticals under controlled laboratory conditions.  There are 
numerous ways that this can be performed to evaluate behaviour under a range of 
environmental conditions and during various STP and sludge processing treatments.  
The behaviour of pharmaceuticals during sludge treatment processes is of particular 
interest because it offers a final opportunity for the removal of persistent compounds 
within the biosolids before disposal within the terrestrial environment.  Anaerobic 
digestion has become a popular choice for the treatment of sewage sludge prior to 
disposal because of the biogas produced during the process which may be used to 
generate electricity.  Available data suggests that it is a useful process for the removal of 
steroid oestrogens which may significantly reduce levels of endocrine disrupting 
chemicals within the environment.  However, further work is required to show effective 
removal of other compounds which may cause harm within the environment.  
 62 
 
1.4 Research strategy 
1.4.1 Research rationale 
Over the past three decades the presence of pharmaceuticals within the environment has 
been extensively monitored, and the impact upon both the aquatic and terrestrial 
environments investigated when exposed to biologically active substances.  Many 
substances have been demonstrated to have a significant effect upon wildlife species, 
and in response to these findings researchers within the field of wastewater engineering 
have sought to improve water quality and reduce environmental impact through 
improved processes for the treatment of both waste water and biosolids.  STP processes 
are known to effectively remove many micropollutants, however many others remain 
relatively intact and the exact fate of others particularly within the biosolids is still 
unknown.  Consequently more research is required within this area to increase 
knowledge and understanding, and to ensure accurate impact assessment.     
It is important that the tests used to evaluate chemicals during environmental risk 
assessment are relevant to the conditions encountered within their life cycle.  Anaerobic 
digestion is a treatment process which is showing a resurgence of interest for the 
treatment of biosolids and industrial waste due to the economic benefits of the biogas 
that may be used for the generation of electricity.  Two thirds of municipal biosolids 
within the UK are now treated using anaerobic digestion before final disposal.  Despite 
the fact that it is an extensively used treatment process, there is relatively little 
information regarding the efficacy of anaerobic digestion for the removal of 
micropollutants.  Currently it is assumed that any pharmaceutical residues adsorbed to 
the biosolids following aerobic treatment present a potential risk to the terrestrial 
environment.  However, this assumption may be inaccurate and for some 
pharmaceuticals the anaerobic digestion process may considerably reduce the 
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environmental risk.  It is therefore important to generate more information in order to 
identify whether current practice for environmental risk assessment takes full account of 
all processes that are commonly used for the treatment of waste water and biosolids.  
While many of the compounds previously identified within the biosolids are antibiotics, 
compounds within this therapy area were omitted from this thesis work since they were 
considered a special case due to their chemical diversity and the likelihood of exerting 
toxic effects upon the microbial population within the sludge. 
 
During the process of anaerobic digestion complex organic matter is degraded in the 
absence of oxygen by a symbiotic network of microorganisms through the processes of 
hydrolysis, acidogenesis, acetogenesis and methanogenesis to form the end products of 
methane and carbon dioxide.   The composition of sewage sludge is dynamic in nature, 
and changes in physical, chemical and biological properties occur over time.  One of the 
key variables within sewage sludge is redox potential which changes considerably 
throughout the various treatment processes.  It is considered that chemical speciation 
and bioavailability of redox-active elements are associated with the transformation of 
organic matter, and may therefore provide opportunities for the removal of various 
types of contaminants (Borch et al., 2010).  Biodegradation of organic compounds has 
so far been demonstrated in the presence of several electron acceptors including iron 
(III), manganese (IV), sulfate and carbon dioxide, and bioremediation studies simulating 
sediment layers have demonstrated variation in the removal of environmental pollutants 
following amendment of the redox environment (Barbieri et al., 2011; Sutton-Grier et 
al., 2011).  These electron acceptors predominate within an anaerobic environment and 
similar amendment to simulate different redox potentials within anaerobic sludge could 
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aid understanding of the microbial groups involved in the removal of pharmaceuticals 
during sludge treatment processes.  
 
1.4.2 Aims 
It is assumed under the current environmental risk assessment performed by industry for 
regulatory submission that all pharmaceuticals present within the biosolids persist 
during sludge stabilisation, and present a potential risk to the terrestrial environment 
following sludge disposal.  The overall aim of this study is to identify whether this 
‘worst-case-scenario’ assumption by industry for regulatory submission is correct, or 
whether pharmaceuticals are removed to any appreciable extent during the commonly 
used treatment process of anaerobic digestion.  Two hypotheses were investigated 
during this study: Hypothesis 1: anaerobic digestion offers potential for the removal of 
pharmaceuticals found within the biosolids, thus reducing the risk to the terrestrial 
environment; Hypothesis 2: pharmaceuticals present within the biosolids will be 
removed at varying rates following redox amendment.  The first hypothesis was tested 
using standard tests under anaerobic conditions with both respirometric and specific 
analysis; the second hypothesis was tested using an experimental system designed for 
the study of test substances under redox amended conditions.  The findings of these 
investigations were put into context with environmental risk assessment, with 
recommendations as to how/if current procedures may be amended to take into account 
all processes responsible for the removal of test substances within the environment. 
 
1.4.3 Objectives 
The study was subdivided into the following objectives: 
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1. To identify a number of pharmaceuticals and screen their anaerobic 
biodegradability using OECD standard guideline methodology, as presented in 
Chapter 3. 
2. To investigate methodology to study the behaviour of pharmaceuticals in 
sewage sludge under redox-controlled conditions, as presented in Chapter 4.  
3. To study the behaviour of the pharmaceuticals selected in Chapter 3 using the 
redox-controlled system investigated in Chapter 4.  The results of this 
investigation are presented in Chapter 5. 
4. To make recommendations on anaerobic biodegradability testing within 
Environmental Risk Assessment based upon the findings of experimental work, 
as presented in Chapters 6 and 7. 
 
1.4.4 Selection and screening of pharmaceuticals for further study 
A literature-based exercise was performed in order to select a range of pharmaceuticals 
for further study.  A number of pharmaceuticals were selected for use primarily based 
upon detection level within the biosolids and predicted biodegradability under anaerobic 
conditions using BIOWIN7 within EPISuite™ (U.S. EPA, 2012). 
 
Toxicity of the test substances to the microorganisms within the anaerobic sludge was 
investigated at relevant concentrations prescribed by the OECD standard guideline prior 
to performing biodegradability experiments.  Initial respirometric tests were performed 
using standard OECD guideline test methods to give information about the 
mineralisation of the test substances under anaerobic conditions.  Although not 
specified as a requirement of the OECD standard guideline, specific analysis was also 
performed to provide additional information about total removal.  Where it was 
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indicated from initial experiments that significant removal due to adsorption had taken 
place, adsorption experiments were performed to quantify partitioning to the sludge 
phase in gamma irradiated sludge used to eliminate any biotic effects. 
 
1.4.5 Amendment of redox potential within anaerobic digester sludge 
Amendment of test vessels containing anaerobic digester sludge to produce a range of 
conditions representative of the environments populated by carbonate-, nitrate- and 
sulfate-reducing microorganisms was investigated over a period of several months.  
Initially test vessels were amended by adjusting the ratio of air and nitrogen used to 
flush the headspace of test vessels.  Subsequently redox adjustment of test vessels was 
made by chemical amendment with Na2CO3, NaNO3 and Na2SO4.  Further to 
investigating the influence of amendment on redox potential, the influence of redox 
amendment on the removal of dissolved organic carbon following the addition of 
PEG 400 was investigated.   
  
1.4.6 Behaviour of selected pharmaceuticals under redox-controlled conditions 
The fates of selected pharmaceuticals were studied in sewage sludge under redox-
controlled conditions to identify if the rate and extent of removal varied due to the redox 
conditions and therefore the microbial populations present.  The removal of dissolved 
organic carbon, redox potential, and the utilisation of terminal electron acceptors were 
monitored at regular intervals throughout this investigation, in addition to specific 
analysis for the measurement of analyte removal.  Where removal was considered to be 
due to adsorption, sludge extraction procedures were used to identify if there was 
removal of the pharmaceuticals from the sludge phase.  Where removal was considered 
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to be due to biodegradation, LC-MS analysis was performed to identify any significant 
transformation products that were formed. 
 
1.4.7 Anaerobic biodegradability testing within environmental risk assessment  
Data generated in anaerobic biodegradability tests was assessed to identify if significant 
removal through anaerobic treatment was observed or if any patterns of removal were 
identified in relation to substance-specific properties.  This information was then put 
into context with the current procedure for pharmaceutical environmental risk 
assessment within the EU, and where appropriate the experimental data was used to 
support future recommendations about the inclusion of anaerobic digestion during 
environmental risk assessment of pharmaceuticals. 
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CHAPTER 2  
 
MATERIALS AND METHODS 
 
2.1 Sludge collection and storage 
Secondary and anaerobic digester sludges were collected in 10 L Nalgene® containers 
from the pipes entering and leaving the mesophilic anaerobic digester at Totnes Sewage 
Treatment Works (Newton Road, Totnes, Devon, TQ9 6LS) or Exeter Countess Wear 
Sewage Treatment Works (Rydon Lane, Exeter, Devon, EX2 7HR), which are both 
operated by South West Water.   
 
Totnes (OS 807613) is an activated sludge plant with a population equivalent of 
approximately 6,000, which treats an average of 7,000 m
3 
day
-1
.  The composition of the 
wastewater is 85% domestic versus 15% industrial.  Exeter Countess Wear (OS 9489) is 
an activated sludge plant with a population equivalent of 130,000, which treats an 
average of 41,000 m
3
 day
-1
.  The composition is 93% domestic versus 7% industrial.   
 
Following collection all sludges were transported directly to the laboratory within 2 h 
where further measurements were performed as described.  Sludge pH was measured 
and recorded, the headspace of the collection vessels flushed with nitrogen gas to 
maintain an anaerobic environment, and the sludge filtered through a 1 mm mesh sieve 
to remove large particulates and prevent blockages during experimental set-up.  
Secondary sludge was refrigerated at 4 ± 2 °C in a cold room.  Anaerobic digester 
sludge was stored at 35 ± 0.2 °C in a Gallenkamp Plus incubator (Sanyo, Watford, 
U.K.). 
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2.2 Test chemicals 
Polyethylene glycol (PEG 400) was purchased from Fisher Scientific Ltd., Bishop 
Meadow Road, Loughbourough, Leicestershire LE11 5RG.  Fluoxetine hydrochloride 
and paroxetine hydrochloride hemihydrate were purchased from LGC Standards, 
Queens Road, Teddington Middlesex TW11 0LY.  3,5-dichlorophenol (3,5-DCP), 
caffeine, cimetidine, ibuprofen, metformin hydrochloride, naproxen sodium, 
propranolol hydrochloride and salicylic acid were purchased from Sigma-Aldrich, Old 
Brickyard, New Road, Gillingham, Dorset, SP8 4XT.   
 
PEG 400 was supplied as a colourless to pale yellow liquid.  Salicylic acid and 3,5-DCP 
were supplied as white crystalline solids.  All other substances were supplied as white 
powders. All samples were stored at ambient temperature in the dark.           
 
2.3 Physicochemical measurements 
2.3.1 Measurement of pH 
pH was measured using a Hanna H18424 pH meter fitted with a Hanna HI 1230 B pH 
probe calibrated before use by immersing the electrode in pH 7.01 and pH 4.01 buffer 
and stirring gently. 
 
2.3.1 Measurement of redox potential 
Redox was measured using a Hanna H18424 meter fitted with a Sentek O14/NS/A/400 
redox probe.  The redox probe was calibrated before use by immersing into Zobell 
solution freshly prepared by mixing equal quantities of 0.2 M K4Fe(CN)6.3H2O and 
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0.1 M (K3Fe(CN)6).  Redox values were normalised to a hydrogen electrode for 
reporting by adding an offset voltage which is shown in Table 2.1. 
 
Table 2.1 Temperature dependent Eh correction values 
Temperature (°C) Correction (mV) 
0 226 
5 223 
10 220 
15 216 
20 213 
25 209 
30 205 
35 201 
 
 
2.3.2 Determination of mixed liquor total solids 
The MLTS method was used to determine the solids content in primary and digested 
sludges due to the high solids content.  Triplicate glass vials were dried in an oven 
(Gallenkamp) at 105°C for 60 min, before cooling in a desiccator.  Dried vials were 
numbered and weighed to the nearest mg (Weight A).  Approximately 10 g of wet 
solids were added to weighed vials, before reweighing to the nearest mg (Weight B).  
Wet solids were then placed in an oven at 105°C.  After a minimum of 16 h, vials were 
removed from the oven and cooled in a desiccator before reweighing to the nearest mg 
(Weight C).  The MLTS was determined using the following calculation:   
 
Weight C Weight A
Wet Sludge Weight B
 100   M  S  ( w w ) 
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2.4 Inhibition and mineralisation in anaerobic digester sludge by 
measurement of gas production  
While there were specific differences in the test conditions and the way in which the 
data was interpreted, the experimental design and methodology used to evaluate the 
inhibition of microbial activity and biodegradability under anaerobic conditions were 
very similar.  Both tests were performed for all prioritised test substances at 25 and 
50 mg C L
-1
 due to the concentration required for the measurement of gas above the 
background gas released by the sludge (OECD, 2006).   
 
Serum bottles with a total volume of 160 mL were dosed with aqueous stock solutions 
of the test substances being evaluated, and aliquots of sludge were added to give the 
required concentrations.  To ensure minimal exposure to oxygen, sludge was transferred 
to test vessels using a peristaltic pump (Watson Marlow, 503U) calibrated to transfer 
the required volume of prepared medium.  Test vessels contained a working volume of 
100 mL, and were prepared in triplicate at each concentration.  The headspace of each 
bottle was flushed with nitrogen before sealing with gas-tight silicone septa and 
crimping with aluminium rings.   
 
Figure 2.1 Measurement of gas pressure using hand held meter. 
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Sealed bottles were incubated at 35 ± 0.2°C in a Gallenkamp Plus incubator (Sanyo, 
Watford, U.K.).  Test vessels were placed in the incubator for 1 h to allow equilibration 
of temperature and equalisation to atmospheric pressure, before vessels were shaken and 
pressure measurements were made using a hand-held meter connected to a syringe 
needle with a three way gas-tight valve as shown in Figure 2.1.  
 
2.4.1 Determination of inhibition in anaerobic digester sludge  
The test system used was as described in OECD Test Guideline 224 (OECD, 2007).  
Anaerobic digester sludge was collected one day before use to allow for the 
determination of MLTS as described in Section 2.1.3.  Sludge was used in the study 
without any prior washing or dilution in mineral medium to ensure a high level of 
microbial activity.  Test vessels contained a total volume of 100 mL (93 mL sludge, 
2.0 mL substrate (Section 2.2.2.1), 5.0 mL test substance stock solution).   
 
2.4.1.1 Determination of inhibition (substrate solution) 
The substrate solution used for inhibition studies contained the following constituents 
per litre of reverse osmosis (RO) water:  100 g of D-glucose, 100 g of nutrient broth, 
100 g of yeast extract.  The medium was autoclaved at 121.15°C for 15 mins at 
1017 mbar (Ballast cycle) using a Touchclave R autoclave (LTE Scientific, Greenfield, 
Oldham, UK).  After cooling, solutions were stored overnight at 4.0 °C before use.  
 
2.4.1.2 Determination of inhibition (stock preparation) 
Stocks of caffeine, cimetidine, fluoxetine hydrochloride, ibuprofen, metformin 
hydrochloride, naproxen sodium, paroxetine hydrochloride hemihydrate, propranolol 
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hydrochloride and salicylic acid were prepared in RO water at 1,000 mg C L
-1
.  Where 
the stock concentration required for dosing was above the maximum aqueous solubility, 
test substances were prepared in acetone.  Stock solutions were serially diluted in RO 
water to give the following concentrations 500, 200, 50 and 20 mg C L
-1
.   The 
reference substance 3,5-DCP was dissolved in RO water at 3,000 mg L
-1
. 
 
2.4.1.3 Determination of inhibition (test vessel dosing) 
For test substances prepared in acetone, the stock solutions were added to the test 
vessels and the acetone evaporated off under a stream of nitrogen.  A 5.0 mL aliquot of 
sterile water was added to each bottle to correct the volume of the solvent-dosed test 
vessels.  Solvent control vessels and test vessels containing directly weighed test 
substances were also prepared for comparison.  The nominal concentrations of each test 
substance in test vessels were 1.0, 2.5, 10, 25 and 50 mg C L
-1
, the nominal 
concentration of 3,5-DCP in reference vessels was 150 mg L
-1
. 
 
2.4.1.4 Determination of inhibition (calculation)  
Pressure measurements were made twice daily over a 72 h period for each set of 
replicate bottles, and the mean cumulative gross gas pressure calculated.  Curves of the 
mean cumulative gas production against time were then plotted for control, test and 
reference vessels.  At a time on the linear part of the curve (48 h) the percentage 
inhibition was calculated from the equation: 
                
where: 
I = percentage inhibition; 
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Pt = the gas pressure produced with test substance at selected time (bar); 
Pc = the gas pressure produced in the control at the same time (bar). 
 
2.4.2 Determination of mineralisation in anaerobic digester sludge 
The test system used was as described in OECD Test Guideline 311 (OECD, 2007).  
Anaerobic digester sludge was pre-digested for one week to reduce the background gas 
production, and the MLTS determined as described in Section 2.1.3.  Anaerobic dilution 
medium was prepared as described in Section 2.2.2.1 in a carboy that had been flushed 
with N2 for a minimum of 20 mins before use.  The carboy was transferred to a water 
bath where it was stirred under nitrogen until the medium reached 35°C.  Sludge was 
washed before use to further reduce background gas production.  Aliquots of sludge 
were centrifuged in 250 mL Nalgene
®
 bottles at 3000 g for 5 mins at ambient 
temperature, before discarding the supernatant and washing the solids twice with 
anaerobic dilution medium.  An appropriate amount of washed anaerobic digester 
sludge was then determined using a measuring cylinder before adding to the medium to 
give a total suspended solids concentration of 3.0 g L
-1
.  Care was taken throughout to 
minimise exposure of the sludge to oxygen.  Test vessels contained a total volume of 
100 mL (95 mL stirred anaerobic sludge inoculum, 5.0 mL stock solution).     
           
2.4.2.1  Determination of mineralisation (mineral medium) 
The following mineral salts medium was used for biodegradation studies and for 
investigating modified terminal electron acceptors (TEA) conditions (ISO 1995; OECD 
2006).  This medium contained the following constituents per litre of RO water: 0.27 g 
KH2PO4, 0.564 g Na2HPO4.2H2O, 1.06 g NH4Cl, 0.075 g CaCl2.2H2O, 0.10 g 
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MgCl2.6H2O, 0.020 g FeCl2.4H2O, 0.001 g resazurin, 0.10 g Na2S.9H2O (added 
immediately before use to reduce the mixture).  To each litre of dilution medium 10 mL 
of trace element solution were added to give the following quantities of trace minerals 
per litre of dilution medium: 0.50 mg MnCl2.4H20, 0.050 mg H3BO3, 0.050 mg ZnCl2, 
0.030 mg CuCl2, 0.010 mg Na2MoO4.2H2O, 1.0 mg CoCl2.6H2O, 0.10 mg NiCl2.6H2O, 
0.050 mg Na2SeO3. 
 
2.4.2.2 Determination of mineralisation (stock preparation) 
Stock solutions of caffeine, cimetidine, fluoxetine hydrochloride, ibuprofen, metformin 
hydrochloride, naproxen sodium, paroxetine hydrochloride hemihydrate, propranolol 
hydrochloride and salicylic acid were prepared in RO water at 1,000 mg C L
-1
.  Where 
the stock concentration required for dosing was above the maximum aqueous solubility 
test substances were prepared in acetone.  Stock solutions were diluted in RO water to 
give 500 mg C L
-1
.   The reference substance PEG 400 was dissolved in RO water at 
1,000 mg C L
-1
. 
 
2.4.2.3 Determination of mineralisation (test vessel dosing) 
For test substances prepared in acetone, the stock solutions were added to the test 
vessels and the acetone evaporated off under a stream of nitrogen.  A 5.0 mL aliquot of 
sterile water was added to each bottle to correct the volume, and solvent control vessels 
were also prepared for comparison.  The nominal concentrations of each test substance 
in test vessels were 25 and 50 mg C L
-1
, the final concentration of PEG 400 in reference 
vessels was 50 mg C L
-1
. 
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2.4.2.4 Determination of mineralisation (calculation)  
Pressure measurements were made at weekly intervals over a 60-day period for each set 
of replicate bottles, and the mean cumulative gross gas pressure was calculated.   The 
extent of biodegradation was calculated from total inorganic carbon and methane carbon 
produced as a percentage of the measured or calculated amount of carbon added as test 
substance.  Since 1 mole of methane and 1 mole of carbon dioxide each contain 12 g of 
carbon, the number of moles of gas in a given volume was calculated from the equation: 
 
    
  
  
 
where: 
n = number of moles of gas 
p = pressure of the gas (Pa); 
V = volume of the gas (m
3
); 
R = molar gas constant [8.314 J/(mol K)]; 
T = incubation temperature (K). 
 
Values were corrected to allow for the production of gas in blank control vessels, and 
the mass of inorganic carbon in the liquid of the test vessels calculated to give the total 
amount of gasified carbon in the test vessels.  The percentage biodegradation from 
headspace gas was then determined by calculating the mass of carbon in the test vessels 
derived from the test substance added.  
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2.5 Removal of selected pharmaceuticals in anaerobic digester 
sludge with measurement by specific analysis 
Initial results suggested that abiotic mechanisms accounted for much of the removal of 
the test substances investigated.  Abiotic removal mechanisms include processes such as 
adsorption and hydrolysis in non-aquatic media.  In separate experiments, specific 
analysis was used to investigate both sorption and primary biodegradation in anaerobic 
digester sludge. 
 
For the investigation of primary anaerobic biodegradability and to evaluate the rate at 
which sorption equilibrium was achieved, a test system using serum bottles with a total 
volume of 160 mL as described in Section 2.4.2 was used.  For the investigation of 
adsorption to anaerobic digester sludge under modified concentrations of suspended 
solids, a batch test was conducted in glass tubes using lyophilised anaerobic digester 
sludge sterilised using gamma irradiation (Isotron, Swindon, UK).  All experiments 
were performed at mesophilic anaerobic digestion temperature (35 ± 1°C). 
 
2.5.1 Removal of pharmaceuticals in anaerobic digester sludge at 25 and 
50 mg C L
-1
 
In addition to the triplicate vessels prepared for manometric analyses to determine 
mineralisation in Section 2.4.2.3, one additional test vessel per treatment was prepared 
for specific analysis on days 0, 7, 14, 28 and 60.  A 21 gauge needle and syringe 
(Terumo, U.K.) was used for the removal of 2.0 mL samples through the septum of test 
vessels before transferring to Eppendorf tubes containing 20 μ  of 25 mg  -1 NaN3 to 
sterilise the sample.  Samples were centrifuged at 15000 g (Eppendorf 5417C) before 
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transferring the supernatant to fresh Eppendorf tubes for storage at -20 °C.  Samples 
were analysed in the aqueous phase using the methods described in Section 2.9.3.          
 
2.5.2 Removal of pharmaceuticals in anaerobic digester sludge at 1.0 and 
5.0 mg L
-1
 
The test set up used was as described in Section 2.4.2, however manometric analysis 
was not performed due to the concentration of test substance used.  Samples (2.0 mL) 
were removed from triplicate vessels for specific analysis at weekly intervals 
throughout the 60-day study as described in Section 2.5.1.  Samples were analysed in 
the aqueous phase only with minimal sample preparation using the analytical methods 
described in Section 2.9.3-2.9.9.  This test was performed for all selected test substances 
except metformin and salicylic acid, which were both shown to degrade rapidly under 
anaerobic conditions at 25 and 50 mg C L
-1
.     
      
2.5.2.1 Removal at 1.0 and 5.0 mg L-1 (stock preparation) 
Caffeine, cimetidine, fluoxetine hydrochloride, ibuprofen, naproxen sodium, paroxetine 
hydrochloride hemihydrate and propranolol hydrochloride (100 mg) were weighed into 
100 mL glass volumetric flasks, and dissolved in MeOH in to prepare 1,000 mg L
-1
 
stock solutions.  Solutions were further diluted in RO water to prepare stocks at a 
concentration of 100 and 20 mg L
-1
.   
    
2.5.2.2  Removal at 1.0 and 5.0 mg L-1 (test vessel dosing) 
All test vessels were dosed with stock solutions prepared in RO water.  The nominal 
concentrations of each test substance in test vessels were 1.0 and 5.0 mg L
-1
. 
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2.5.3 Adsorption to anaerobic digester sludge over time 
This test was performed over 24 h as recommended in OPPTS 835.1110 (OPPTS, 1998) 
in order to determine the time to equilibrium for the partitioning of test compound 
between the sludge and aqueous layer.  For comparison with previous experimental 
work the test was set up as described in Section 2.4.2, and was performed at 35 ± 1°C in 
160 mL glass serum bottles with a working volume of 100 mL (95 mL stirred inoculum, 
5.0 mL stock solution).  The concentration of each test substance used was 1.0 mg L
-1
.  
Samples (2.0 mL) were removed for analysis 0, 1, 2, 4, 8, 16 and 24 h as described in 
2.5.1.  Samples were analysed using the methods described in Section 2.9.7–2.9.9. 
 
2.5.3.1 Adsorption to anaerobic digester sludge over time (stock preparation) 
Propranolol hydrochloride, fluoxetine hydrochloride and paroxetine hydrochloride 
hemihydrate (10 mg) were weighed into 100 mL glass volumetric flasks, and dissolved 
in MeOH to prepare 100 mg L
-1
 stock solutions.  Solutions were further diluted in RO 
water to prepare the required 20 mg L
-1
 stock for dosing. 
 
2.5.3.2 Adsorption to anaerobic digester sludge over time (test vessel dosing) 
Test vessels containing a final volume of 100 mL were dosed with 5.0 ml of a 20 mg L
-1
 
stock solution, resulting in a nominal concentration of 1.0 mg L
-1
.  
 
2.5.4 Adsorption to anaerobic digester sludge with varying concentration of 
sludge solids 
This test was performed with varying concentrations of sludge solids as recommended 
by OPPTS (1998) in order to determine the degree of adsorption in relation to the 
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concentration of sludge used.  The test was conducted in 45 mL glass centrifuge tubes 
fitted with ground glass stoppers, with a working volume of 20 mL.  The total 
suspended solids concentrations that were used in the experiment were 0, 100, 300 and 
3,000 mg L
-1
.  This was achieved by weighing 2.0, 6.0 and 60 mg of lyophilised sludge 
prepared as described in Section 2.5.4.1 into test vessels and adding 20 mL of prepared 
mineral medium prepared as described in Section 2.4.2.1.  Control tubes contained 
mineral medium only.  Test vessels were equilibrated at 35 ± 1°C for 16 h on a roller at 
60-120 rpm, before centrifuging at 2,700 g for 15 mins.  Test vessels were dosed with 
test substance using a gas-tight syringe, and were rolled at 60-120 rpm for 24 h at 35 ± 
1°C.  After 24 h, tubes were centrifuged at 2,700 g for 15 mins and the supernatant 
sampled for specific analysis using the methods described in Sections 2.9.7 – 2.9.9.   
 
2.5.4.1 Preparation of freeze dried sludge 
Anaerobic digester sludge was collected as previously described and was decanted into 
Nalgene
®
 bottles in 250 mL aliquots.  The sludge was then centrifuged for 5 mins at 
5,000 g and the supernatants discarded.  The sludge pellets were washed by filling the 
bottles with RO water and shaking before centrifuging for 5 mins at 5,000 g and 
discarding the supernatants.  The washing process was repeated and the sludge 
centrifuged for a further 5 mins before discarding the final supernatant and transferring 
to Petri dishes for freezing at -20°C.  Frozen Petri dishes were transferred to the freeze-
drying apparatus (ModulyoD, ThermoFisher UK) which had been chilled in preparation 
for the addition of samples.  Removal of all water took approximately 48-72 h per 
batch, at which point dry sludge was disaggregated and transferred to a crystallising 
dish before placed in an oven at 105°C for at least 3 h and sieved when cool through a 
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500 μm sieve.  After preparation, free e dried sludge was stored refrigerated in sealed 
glass vials.  
 
2.5.4.2 Adsorption to anaerobic digester sludge with varying concentration of sludge 
solids (stock preparation) 
Propranolol hydrochloride, fluoxetine hydrochloride and paroxetine hydrochloride 
hemihydrate (5.0 mg) were weighed into 5.0 mL volumetric flasks, and dissolved in RO 
water to prepare 1,000 mg L
-1
 stock solutions. 
 
2.5.4.3 Adsorption to anaerobic digester sludge with varying concentration of sludge 
solids (test vessel dosing) 
 est vessels containing a final volume of 20 m  were dosed with 20 μ  of a 
1,000 mg L
-1 
stock solution, resulting in a nominal concentration of 1.0 mg L
-1
. 
 
 
2.6 Behaviour of pharmaceuticals in sewage sludge under redox-
controlled conditions 
To investigate behaviour under amended redox conditions, a batch test system was used 
that facilitated redox conditions to be monitored and adjusted throughout.  The removal 
of test substances was evaluated twice weekly using specific analyses.  Where removal 
due to adsorption was significant, analytes were measured in both the aqueous phase 
and in lyophilised biosolids following extraction.  Tests were performed at a 
concentration of 2.5 mg L
-1
, which was considered to be a concentration easily 
quantifiable using existing HPLC methodology coupled with UV or fluorescence 
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detection at one hundredth of the nominal dose (0.025 mg L
-1
).  The removal of 
naproxen, propranolol and fluoxetine were evaluated individually under these 
experimental conditions, in addition to measuring the removal of DOC following dosing 
with PEG 400.  A schematic of the experimental set-up used is shown in Figure 2.2.  
 
Figure 2.2 Redox amended batch test. 
 
Anaerobic digester and secondary sludges were blended together in a ratio of 4:1 (v/v) 
and diluted in reduced anaerobic dilution medium before being transferred to Quickfit 
flasks with a capacity of 1.0 L.  As with closed bottle experiments, stirred sludge 
inoculum was transferred to test vessels using a peristaltic pump (Watson Marlow, 
503U) in order to minimise exposure to oxygen.  Test vessels were prepared in triplicate 
for each redox amendment.  A redox probe (Sentek O14/NS/A/400) was placed in one 
vessel for each triplicate, and remained in situ for the duration of the experiment.  Size 
13 rubber bungs were drilled to allow 300 mm of 3.0 mm internal diameter silicone 
tubing to fit inside tightly, thus creating ‘sampling ports’ that were closed off with si e 
Vacuum
Control Amended Amended Amended
Redox probe
Test vessel
35ºC
Magnetic stirrer
Sampling
port
Control Control
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3 rubber bungs.  Stirrer bars were added to each test vessel before flushing the 
headspace with nitrogen and sealing with the rubber bungs described.  Test vessels were 
transferred to glass tanks containing RO water to a working volume of 45 L, maintained 
at 35 ± 1°C using 2 × 200 W heaters per tank (Interpet, UK).  Test vessels were stirred 
at a vortex depth of approximately 3.0 cm using multi-plate stirrers (IKAMAG EOA 5) 
placed under each tank (Figure 2.2).   
 
Following the addition of stirred sludge inoculum, test vessels were amended with 
carbonate, nitrate or sulfate through the addition of Na2CO3, NaNO3 or Na2SO4.  Test 
vessels were left to acclimatise for seven days before dosing with pharmaceuticals.  The 
removal of dissolved organic carbon (DOC) from all test vessels was evaluated 
throughout, and the redox potential and consumption of terminal electron acceptors by 
the system was monitored.  Where falling concentrations of terminal electron acceptors 
was observed, further amendments were made to maintain the desired conditions. 
       
2.6.1 Behaviour of pharmaceuticals in sewage sludge under redox-controlled 
conditions (set up) 
Anaerobic digester and secondary sludges were collected one day before use to allow 
for the determination of MLTS as described in Section 2.3.3.  The experiment was 
conducted in sealed 1.0 L volumetric flasks which were placed in a water bath 
maintained at 35 ± 1°C.  Anaerobic digester and primary sludges were blended together 
in a ratio of 4:1 (v/v), and were diluted to give total suspended solids concentration of 
3.0 g L
-1
 in reduced anaerobic dilution medium prepared as described in Section 2.4.2.1.  
Test vessels contained 995 mL of stirred sludge inoculum and 5.0 mL of a stock 
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solution of Na2CO3, NaNO3, Na2SO4 or RO water.  After seven days, acclimatised test 
vessels were dosed through the addition of 2.5 mL of test substance stock solutions.  
 
2.6.2 Behaviour of pharmaceuticals in sewage sludge under redox-controlled 
conditions (preparation of chemical reagent stocks) 
Na2CO3, NaNO3 and Na2SO4 (5.0 g) were weighed into 25 mL volumetric flasks and 
dissolved in RO water to prepare 200 g L
-1
 stock solutions. 
 
2.6.3 Behaviour of pharmaceuticals in sewage sludge under redox-controlled 
conditions (redox amendment of test vessels) 
Test vessels containing a final volume of 1,000 mL were dosed with 5.0 mL of a 
200 g L
-1
 stock solution, resulting in a nominal concentration of 1.0 g L
-1
 of each 
reagent.  The addition of Na2CO3, NaNO3 and Na2SO4 at a concentration of 1.0 g L
-1
 
resulted in the addition of CO2, NO3
-
 and SO4
2-
 at the following concentrations: 
 
CO2     415 mg L
-1
 
NO3
-
    729 mg L
-1
 
SO4
2-
     676 mg L
-1 
 
2.6.4 Behaviour of pharmaceuticals in sewage sludge under redox-controlled 
conditions (stock preparation) 
Fluoxetine hydrochloride, naproxen sodium and propranolol hydrochloride (100 mg) 
were weighed into 100 mL volumetric flasks and dissolved in RO water to prepare 
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1,000 mg L
-1
 stock solutions.  PEG 400 was dissolved in RO water at a concentration of 
10,000 mg C L
-1
. 
 
2.6.5 Behaviour of pharmaceuticals in sewage sludge under redox-controlled 
conditions (test vessel dosing) 
Test vessels containing a final volume of 1.0 L were dosed with 2.5 mL of a 
1,000 mg L
-1
 stock solution of fluoxetine hydrochloride, naproxen sodium or 
propranolol hydrochloride resulting in a nominal concentration of 2.5 mg L
-1
.  Test 
vessels containing a final volume of 0.50 L were dosed with 2.5 mL of a 
10,000 mg C L
-1
 stock solution of PEG 400, resulting in a nominal concentration of 
50 mg C L
-1
.       
 
2.7 Methods used for the analysis of organic and inorganic 
compounds 
2.7.1 Carbon analysis using the Hach Lange IL500 Carbon Analyser 
Total organic carbon (TOC), and total inorganic carbon (TIC) concentrations in aqueous 
samples were analysed using the Hach Lange IL500 carbon analyser.  The principle of 
operation involves the determination of the carbon content through the measurement of 
CO2 using a non-dispersive infrared sensor (NDIR).  Organic carbon substances are 
decomposed to CO2 in the UV reactor through the addition of acidified Na2S2O8 and 
exposure to UV radiation at 185 nm and 254 nm.  Inorganic carbon substances are 
released from solution through the addition of H3PO4 in the TIC reactor from another 
sample aliquot.  The CO2 formed is expelled by N2, and after drying is fed to the NDIR 
where the carbon content of the sample is determined.      
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Calibration functions for the measurement of TOC and TIC were selected before the 
start of each experiment.  New calibration standards were prepared for each experiment, 
and the calibration linked to the function and used for the quantification of samples 
throughout.  Standards for the measurement of TOC using the difference method 
(TOC = TC - TIC) were prepared by dissolving 1,000 mg C L
-1
 stock solutions of both 
potassium hydrogen phthalate (molecular formula C8H5KO4, molar mass 
204.22 g mol
-1
) and sodium carbonate (molecular formula Na2CO3, molar mass 
105.99 g mol
-1
) in RO water.  Serial dilutions were prepared by transferring appropriate 
volumes of stock solutions and sub-stocks to volumetric flasks using graduated pipette, 
and filling to the graduation level with RO water before mixing thoroughly by shaking.  
Standards for the measurement of TIC were prepared by serially diluting stock solutions 
of Na2CO3 at a concentration of 1,000 mg C L
-1
 in RO water.  
 
2.7.1 Chemical analyses using DR Lange cuvette tests 
Sample analyses were conducted on centrifuged samples using a spectrophotometer 
(DR2800 by Hach Lange) soon after collection.  Ammonium nitrogen was determined 
colorimetrically based upon the indophenol method (LCK 303, Hach Lange); nitrate 
was determined colorimetrically based upon the 2,6-dimethylphenol method (LCK 340, 
Hach Lange); and sulfate was measured turbidimetrically based upon the barium sulfate 
method (LCK 353, Hach Lange).  The accuracy of the test methods were checked using 
the corresponding Addista solutions (Hach Lange). 
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2.8 Methods used for extraction and clean-up of analytes from 
lyophilised sludge 
 
2.8.1 Preparation of spiked sludge for the verification of recovery from 
samples containing propranolol 
Two 6 mm glass-fibre filters (ThermoFisher, UK) were placed into the bases of three 
clean 1.0 mL ASE extraction cells (Thermofisher, UK), and were half-filled with 
Ottawa sand (VWR, UK).   Aliquots of lyophilised anaerobic digester sludge 
(25 ± 1 mg) were weighed into each cell.  The sludge aliquots were spiked using a 
gastight syringe with 50 μ  of 20 mg  -1 spiking stock prepared in MeOH, before being 
left to dry overnight in a fume cupboard.  Once dry the remaining volumes of the cells 
were filled with Ottawa sand, and were compressed tightly before sealing.  Spikes were 
then subjected to extraction and clean-up procedures as described in Sections 2.8.3 and 
2.8.4.  Spikes were prepared on each occasion that samples were extracted.   Sample 
concentrations were adjusted accordingly using an appropriate spike correction factor. 
 
2.8.2 Extraction of propranolol from using pressurised liquid extraction (PLE) 
The procedure followed is based upon the methods described by Scheurer et al. (2010).  
Aliquots of lyophilised sludge (25 ± 1 mg) were transferred to 1.0 mL ASE extraction 
cells (ThermoFisher, UK), each containing two 6 mm glass-fibre filters (ThermoFisher, 
UK) at each end to prevent leakage during extraction, which were filled with Ottawa 
sand (VWR, UK), and were compressed tightly before sealing. 
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Figure 2.3 Dionex ASE200 instrument used for PLE extraction. 
 
The PLE conditions used were: pre-fill method; solvents, MeOH: water: acetic acid 
(49/49/2); equilibration, 5 min; static time, 5 min; flush volume, 60%; purge time, 60 s; 
static cycles, two; temperature, 50°C.  Sample extracts were transferred to 100 mL 
volumetric flasks, filled to the level with RO water, and adjusted to pH 2.0 through the 
addition of 5 drops of 5 M H2SO4.   
 
2.8.3 Clean-up of propranolol extracts using solid phase extraction 
 SPE cartridges (6 mL volume) packed with 500 mg of Strata X-C (Phenomenex) were 
conditioned with 5.0 mL of MeOH, and rinsed with 10 mL of RO water before loading 
100 mL samples.  Cartridges were rinsed with 5.0 mL of 0.10 M HCl followed by 
5.0 mL of MeOH.  Once cartridges were dry, samples were eluted with 2 × 3.0 mL of a 
solution of 5% (v/v) NH4OH in MeOH.  Eluted samples were evaporated to dryness 
under vacuum before reconstitution in mobile phase for analysis.  Samples were then 
analysed using the method described in Section 2.9.7. 
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2.8.4 Preparation of spiked sludge for the verification of recovery from 
samples containing fluoxetine 
 Aliquots of lyophilised anaerobic digester sludge (25 ± 1 mg) were weighed into 45 mL 
glass centrifuge tubes fitted with ground glass stoppers.  The sludge aliquots were 
spiked using a gastight syringe with 25 μ  of 500 mg  -1 spiking stock prepared in 
MeOH, before being left to dry overnight in a fume cupboard.  Once dry the spikes were 
subjected to extraction and clean-up procedures as described in Sections 2.8.5 and 2.8.6.  
Spikes were prepared on each occasion that samples were extracted, and the recoveries 
determined against calibration standards.  Sample concentrations were adjusted 
accordingly using an appropriate spike correction factor.       
 
2.8.5 Extraction of fluoxetine using ultrasonic extraction 
The procedure followed is based upon the methods described by Wu et al. (2012).  
Aliquots of lyophilised sludge (25 ± 1 mg) were weighed into glass centrifuge tubes, 
mixed with 20 mL of acetone, and sonicated in an ultrasonic bath for 20 min.  Tubes 
were then removed from the ultrasonic bath and centrifuged at 2,000 g for 15 min.  The 
supernatant was decanted into a 40 mL vial, and the residue re-extracted with fresh 
solvent.  The combined supernatants were evaporated to dryness, and the dried extracts 
reconstituted in 1.0 mL of MeOH.  RO water (20 mL) was then added to the extracts, 
before adjusting to pH 3.0 through the addition of 2 drops of 5 M H2SO4.      
 
2.8.6 Clean-up of fluoxetine extracts using solid phase extraction 
 SPE cartridges (3mL volume) packed with 150 mg of Oasis MCX (Waters) were 
conditioned with 2.0 mL of MeOH, and rinsed with 4.0 mL of RO water before samples 
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were loaded.  Cartridges were rinsed with 2.0 mL of 2% (v/v) formic acid followed by 
4.0 mL of MeOH.  Once cartridges were dry, samples were eluted with 2 × 2.0 mL of a 
solution of 5% (v/v) NH4OH in MeOH.  Eluted samples were evaporated to dryness 
under vacuum before reconstitution in mobile phase for analysis.  Samples were then 
analysed using the method described in Section 2.9.8.  
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2.9 Methods used for specific analysis by HPLC with UV 
detection and fluorescence detection 
 
2.9.1 Preparation of calibration standards for sample quantification by 
specific analysis 
The stability of all test substances and the effects of sample matrix upon analyte 
detection was confirmed prior to the commencement of all experiments.  New 
calibration standards were prepared for each experiment, and all solutions were stored at 
4°C in the dark to minimise degradation.  Quantification was by external standard 
calibration throughout (n ≥ 6 data points), and matrix blank samples were analysed 
alongside all samples to account for chromatographic differences that may have occurred.   
 
For the preparation of stock solutions 10 mg of each test substance were weighed into 
100 mL glass volumetric flasks, and dissolved in MeOH to prepare 100 mg L
-1
 stock 
solutions.  For the analysis of samples in the aqueous phase stocks were serially diluted 
in RO water to prepare the required range of standards.  For the analysis of samples in 
the sludge phase stocks were serially diluted in mobile phase to matrix match samples.    
 
2.9.2 Determination of the limit of quantification by HPLC with detection 
using photodiode array/single wavelength UV detection/fluorescence detection 
The lowest concentration level at which measurement was considered to be 
quantitatively meaningful (LOQ) was calculated to be 10 times the signal/noise ratio.  
The maximum concentration level at which measurement was considered to be 
quantitatively meaningful was the point at which the calibration became non-linear.  
Both of these parameters were determined for each compound prior to the beginning of 
each study. 
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2.9.3 Analysis of seven pharmaceuticals by HPLC with detection using 
photodiode array 
High pressure liquid chromatography (HPLC) separation of caffeine, fluoxetine, 
ibuprofen, naproxen, paroxetine, propranolol, and salicylic acid was performed at 
ambient temperature using a Phenomenex Gemini NX C18 50 × 4.6 mm analytical 
column (3.0 μm particle size) at a flow rate of 0.8 mL min-1 and an injection volume of 
100 μ .  Gradient conditions were 85:15 100 mM ammonium acetate in H2O + 0.1% 
acetic acid v/v : 50:50 MeCN:MeOH held constant for 2 min, then MeCN:MeOH was 
raised to 100% over 6 min and held constant for 2 min.  Re-equilibration time was 2 min.    
Identification was performed by comparing UV spectra and chromatographic retention 
times of unknown peaks in the experimental samples with standard solutions.  All 
detection was performed using a Waters 996 PDA detector operating between 210 and 400 
nm.  All data was processed with the use of an Empower (Build 2154) chromatographic 
data system.   he retention time (R ) and λmax of each analyte were as follows: 
 
Table 2.2 Analytical parameters for specific analysis using HPLC-DAD 
Compound λmax Retention Time R
2
 
Caffeine 274 3.09 0.999 
Fluoxetine 225 8.81 0.998 
Ibuprofen 225 9.07 0.998 
Naproxen 232 8.35 0.998 
Paroxetine 229 9.06 0.998 
Propranolol 292 8.15 0.994 
Salicylic acid 304 2.12 0.999 
 
2.9.4 Analysis of caffeine by HPLC with single wavelength UV detection 
HPLC separation was performed using a Phenomenex Gemini NX C18 50 × 4.6 mm 
analytical column (3 μm particle si e) at a flow rate of 1.0 mL min-1 and an injection 
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volume of 10 μ .   he column was maintained at a constant temperature using a Jones 
Chromatography column heater set at 55°C.  Isocratic conditions were 15:85 100 mM 
ammonium acetate in H2O + 0.1% acetic acid v/v: 50:50 MeCN:MeOH.  Detection was 
performed using a Jasco UV-975 UV detector at a fixed wavelength of 275 nm. 
 
2.9.5 Analysis of ibuprofen by HPLC with single wavelength UV detection 
HPLC separation was performed using a Phenomenex Gemini NX C18 50 × 4.6 mm 
analytical column (3 μm particle si e) at a flow rate of 1.0 m  min-1 and an injection 
volume of 20 μ .   he column was maintained at a constant temperature using a Jones 
Chromatography column heater set at 55°C.  Isocratic conditions were (50:50 MeCN: 
H2O) + 0.1% formic acid.  Detection was performed using a Jasco UV-975 UV detector 
at a fixed wavelength of 225 nm.   
 
2.9.6 Analysis of cimetidine by HPLC with single wavelength UV detection 
HPLC separation of cimetidine was performed using a Phenomenex Luna Phenyl Hexyl 
150 × 4.6 mm analytical column (5.0 μm particle si e) at a flow rate of 1.0 m  min-1 and 
an injection volume of 200 μ .  The column was maintained at a constant temperature 
using a Jones Chromatography column heater set at 55°C.  Isocratic conditions were 
80:20 100 mM ammonium formate in H2O + 0.3% formic acid v/v: 50:50 MeCN:MeOH.  
Detection was performed using a Jasco UV-975 UV detector at a fixed wavelength of 
230 nm. 
 
 94 
 
2.9.7 Analysis of propranolol by HPLC with fluorescence detection  
HPLC separation was performed using a Phenomenex Gemini NX C18 50 × 4.6 mm 
analytical column (3 μm particle si e) at a flow rate of 1.0 m  min-1 and an injection 
volume of 5.0 μ .   he column was maintained at a constant temperature using a Jones 
Chromatography column heater set at 55°C.  Isocratic conditions were (65:35 MeOH: 
H2O) + 0.2% NH4OH.  Detection was performed using a Jasco FP-2020 fluorescence 
detector with the gain control setting at 10, at an excitation wavelength of 230 nm and 
an emission wavelength of 340 nm.  
 
2.9.8 Analysis of fluoxetine by HPLC with fluorescence detection 
HPLC separation was performed using a Phenomenex Gemini NX C18 50 × 4.6 mm 
analytical column (3 μm particle si e) at a flow rate of 1.0 m  min-1 and an injection 
volume of 20 μ .   he column was maintained at a constant temperature using a Jones 
Chromatography column heater set at 55°C.  Isocratic conditions were (75:25 MeOH: 
H2O) + 0.2% NH4OH.  Detection was performed using a Jasco FP-2020 fluorescence 
detector with the gain control setting at 100, at an excitation wavelength of 230 nm and 
an emission wavelength of 293 nm.    
 
2.9.9 Analysis of paroxetine by HPLC with fluorescence detection 
HPLC separation was performed using a Phenomenex Gemini NX C18 50 × 4.6 mm 
analytical column (3 μm particle si e) at a flow rate of 1.0 m  min-1 and an injection 
volume of 20 μ .   he column was maintained at a constant temperature using a Jones 
Chromatography column heater set at 55°C.  Isocratic conditions were (75:25 MeOH: 
H2O) + 0.2% NH4OH.  Detection was performed using a Jasco FP-2020 fluorescence 
 95 
 
detector with the gain control setting at 100, at an excitation wavelength of 295 nm and 
an emission wavelength of 350 nm.   
 
2.10  Methods used for statistical analysis of data 
Once data were generated using the methods described in this chapter, it was evaluated 
using Minitab 16 to create graphs for presentation and to show relationships between 
variables.  A number of statistical tools were used to assess data which are explained 
below. 
 
2.10.1 Mean 
The mean (arithmetic average) is the sum of all the observations divided by the number 
of observations, and is throughout used to describe sets of values.   
 
2.10.2 Standard deviation 
Standard deviation is the most common measure of dispersion, and is used to estimate 
the average distance of individual observations from the mean. 
 
2.10.3 Linear regression 
Linear regression uses an equation that describes a statistical relationship between a 
predictor and a response variable to predict new observations. 
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2.10.4 Analysis of Variance  
Analysis of variance (ANOVA) is a statistical hypothesis test used to determine 
significant relationships between variables (p < 0.05) through the comparison of the 
means of several groups.   
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CHAPTER 3  
 
SELECTION AND SCREENING OF PHARMACEUTICALS 
FOR EVALUATION 
 
This chapter firstly describes the selection of a number of pharmaceuticals for further 
study followed by the results of initial screening experiments performed to determine 
inhibition, biodegradability and total removal in anaerobic digester sludge. 
 
3.1  Criteria used to select pharmaceuticals for evaluation 
A wide range of compound types have been identified within the environment, however 
it is not feasible to assess the behaviour of each one due to resource limitations.  Those 
that are considered to be of the greatest importance must therefore be identified using a 
prioritisation system following the evaluation of numerous criteria (Boxall, 2004; Roos 
et al., 2012; Sui et al., 2012).  Selection criteria which are often taken into consideration 
when prioritising pharmaceuticals for environmental studies include consumption, 
occurrence, chemical properties and analytical capability (Kumar & Xagoraraki, 2010).  
Examples of prioritisation systems include QSARs, risk quotients which compare 
toxicity to environmental exposure, and the use of ranking systems whereby compounds 
are awarded scores for specific attributes which may be weighted in terms of 
importance and which are added together before being placed in a rank order (Besse & 
Garric, 2008; Kumar & Xagoraraki, 2010; Ottmar et al., 2012).   
 
Whichever system is used, it is important that the selection criteria reflect the primary 
aims of the research being performed.  To identify whether anaerobic digestion offers 
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potential to reduce the concentration of pharmaceuticals within the biosolids, as set out 
in the aims, it was important that the pharmaceuticals selected were likely to be found 
within the biosolids and that they have potential to degrade under anaerobic conditions.  
The potential to perform radiolabelled experiments could provide increased analytical 
flexibility, therefore the commercial availability of radiolabelled compounds was also 
included as a selection criterion. 
   
3.2 Selection of pharmaceuticals 
To identify which pharmaceuticals were most abundant within the biosolids a search 
was performed of literature detailing concentrations of pharmaceuticals measured 
within sewage sludge.   Several publications have reported concentrations of a large 
number of compounds as part of extensive monitoring campaigns.  These are 
summarised in Chapter 1 in Tables 1.5, 1.6 and 1.7.  Antimicrobial compounds were 
subsequently omitted, as the primary aim was to investigate the potential for 
biodegradation during anaerobic sludge treatment.  It is known that antimicrobial 
compounds inhibit microbial activity particularly in key groups such as methanogens 
which are known to be sensitive (Boxall, 2004).  The abundance of all remaining 
compounds listed in Tables 1.6 and 1.7 was scored in relation to the maximum 
concentration found within the biosolids and related environmental matrices.   
 
Pharmaceuticals detected at a concentration > 1,000 mg kg
-1
 were awarded a score of 3, 
pharmaceuticals detected at a concentration 100-1,000 mg kg
-1
 were awarded a score of 
2, and pharmaceuticals detected at a concentration < 100 mg kg
-1
 were awarded a score 
of 1.  These pharmaceuticals are listed in Table 3.1 in descending order of detection 
level within the biosolids with the score awarded shown alongside. 
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Table 3.1 Detection level of psychoactive, gastrointestinal, antidiabetes and 
respiratory compounds within the biosolids 
Compound 
 
Maximum Detected Concentration in 
Biosolids (mg kg
-1
) 
Score 
Salicylic acid 13,748 3 
Ibuprofen 11,900 3 
Cimetidine 9,780 3 
Diphenhydramine 7,000 3 
Carbamazepine 6,030 3 
Acetaminophen 4,535 3 
Fluoxetine 3,130 3 
Ranitidine 2,250 3 
Paroxetine  1,500 3 
Caffeine 1,200 3 
Metformin 1,160 3 
Naproxen 1,020 3 
Albuterol 380 2 
Ketoprofen 211 2 
Diclofenac 209 2 
Loratidine 53 1 
Codeine 22 1 
Famotidine 11 1 
Mefenamic Acid 3.5 1 
 
The predicted anarobic biodegradability of all psychoactive, gastrointestinal, 
antidiabetes and respiratory compounds listed in Tables 1.6 and 1.7 was determined 
using BIOWIN7 within EPISuite™ using SMI ES notation (simplified molecular-input 
line-entry system) as the structural entry format.  BIOWIN7 is used to predict the 
anaerobic biodegradability of organic chemicals, and describes compounds with a 
probability < 0.5 unlikely to degrade rapidly under anaerobic conditions.   The scores 
awarded to pharmaceuticals based upon this condition are shown in Table 3.2. 
Pharmaceuticals with a probability > 0.5 were considered likely to degrade rapidly 
under anaerobic conditions and were awarded a score of 3; pharmaceuticals with a 
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probability 0-0.5 were considered likely to degrade at a moderate rate under anaerobic 
conditions and were awarded a score of 2; pharmaceuticals with a probability < 0 were   
considered unlikely to degrade or likely to degrade very slowly under anaerobic 
conditions and were awarded a score of 1.   
 
Table 3.2 Predicted biodegradability of psychoactive, gastrointestinal, 
antidiabetes and respiratory compounds under anaerobic conditions 
 
Finally all psychoactive, gastrointestinal, antidiabetes and respiratory compounds listed 
in Tables 1.6 and 1.7 were given a score based upon the commercial availability of a 
radiolabel.  Pharmaceuticals that were available 
14
C or 
3
H labelled were awarded a score 
of 2, pharmaceuticals that were unavailable 
14
C or 
3
H labelled were awarded a score of 
1.  The scores awarded to pharmaceuticals based upon this condition are shown in Table 
3.3  
Compound 
Predicted Anaerobic Biodegradability 
Value BIOWIN7 
Score 
Salicylic acid 0.80 3 
Famotidine 0.79 3 
Metformin 0.68 3 
Fluoxetine 0.56 3 
Albuterol 0.55 3 
Caffeine 0.50 3 
Naproxen 0.39 2 
Paroxetine 0.38 2 
Cimetidine 0.33 2 
Ibuprofen 0.03 2 
Carbamazepine -0.07 1 
Acetaminophen -0.11 1 
Ketoprofen -0.17 1 
Loratidine -0.27 1 
Ranitidine -0.35 1 
Mefenamic Acid -0.59 1 
Codeine -0.79 1 
Diclofenac -0.85 1 
Diphenhydramine -1.09 1 
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Table 3.3 Commercial availability of psychoactive, gastrointestinal, 
antidiabetes and respiratory compounds as 
14
C or 
3
H radioisotopes. 
Compound Radiolabel Y/N Score 
Salicylic acid Y 2 
Metformin Y 2 
Fluoxetine Y 2 
Caffeine Y 2 
Naproxen Y 2 
Paroxetine Y 2 
Cimetidine Y 2 
Ibuprofen Y 2 
Carbamazepine Y 2 
Acetaminophen Y 2 
Ketoprofen Y 2 
Codeine Y 2 
Diclofenac Y 2 
Famotidine N 1 
Albuterol N 1 
Loratidine N 1 
Ranitidine N 1 
Mefenamic Acid N 1 
Diphenhydramine N 1 
 
The scores awarded to pharmaceuticals for detection level within biosolids, predicted 
biodegradability under anaerobic conditions and the commercial availability of 
radioisotopes were totalled.  Scores awarded for each criterion were given equal 
weighting.  Pharmaceuticals are listed in Table 3.4 in descending order of the total score 
for all three criteria.  The eight highest scoring pharmaceuticals were selected for further 
study
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Table 3.4 Total score awarded to psychoactive, gastrointestinal, antidiabetes 
and respiratory compounds for all three selection criteria  
Compound Total Score 
Salicylic acid 8 
Fluoxetine 8 
Paroxetine 8 
Caffeine 8 
Metformin 8 
Ibuprofen 7 
Cimetidine 7 
Naproxen 7 
Carbamazepine 6 
Acetaminophen 6 
Albuterol 6 
Diphenhydramine 5 
Ranitidine 5 
Ketoprofen 5 
Diclofenac 5 
Famotidine 5 
Codeine 4 
Loratidine 3 
Mefenamic Acid 3 
 
3.3 The selected pharmaceuticals 
Eight pharmaceuticals were selected for further study within commonly prescribed 
anatomical therapeutic chemical (ATC) groups: gastro-intestinal tract; cardiovascular 
system; central nervous system; endocrine system; anti-inflammatory.  In addition the 
β-blocker propranolol, was selected for use because its behaviour within the 
environment has been extensively researched, and previous investigations have 
indicated that it is incompletely removed during biological sewage treatment processes. 
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Table 3.5     Chemical formulae and structures of the selected pharmaceuticals 
Therapeutic Area, 
Compound & Class 
Chemical 
Structure 
CAS Number, Chemical Formula & IUPAC 
Name 
Cardiovascular 
β-blocker 
Propranolol  
CAS No: 525-66-6         Chemical Formula: C16H21NO2 
IUPAC name:1naphthen1yloxy-3-(propan-2-yl-
amino)propan-2-ol 
Gastrointestinal 
H2  antagonist 
Cimetidine  
CAS No: 51481-61-9   Chemical Formula: C10H16N6S 
IUPAC name:1-cyano-2-methyl-3[2[(5-methyl-1-
Himidazol-4-yl)-methylsufanyl]ethyl] guanidine 
Anti-diabetes 
Biguanide 
Metformin   
CAS No: 657-24-9          Chemical Formula: C4H11N5 
IUPAC name: 3-(diaminomethylidene)-1,1-
dimethylguanidinehydrochloride 
CNS 
NSAID 
Ibuprofen 
 
 
Naproxen 
 
 
Salicylic acid 
 
 
Stimulant 
Caffeine 
 
 
SSRI Antidepressant 
Fluoxetine  
 
 
Paroxetine   
 
 
 
 
 
 
     
 
 
 
     
      
 
CAS No: 15687-27-1     Chemical Formula: C13H18O2 
IUPAC name:α-Methyl-4(2methylpropyl)benzeneacetic 
acid 
 
CAS No: 22204-53-1     Chemical Formula: C14H14O2 
IUPAC name:(S)-6-Methoxyαmethyl-2-
naphthaleneacetic acid 
 
CAS No: 69-72-7           Chemical Formula: C7H6O3 
IUPAC name: 2-hydroxybenzoic acid 
 
CAS No: 58-08-2            Chemical Formula: C8H10N4O2 
IUPAC name: 1,3,7-trimethylpurine-2,6,-dione  
 
CAS No: 54910-89-3   Chemical Formula: C17H18F3NO 
IUPAC name: N-methyl-3-phenyl-3-[4-
(trifluoromethyl) phenoxy] propan-1-amine 
 
CAS No: 61869-08-7   Chemical Formula: C19H20FNO3 
IUPAC name: (3S, 4R)-3-(1,3benzodioxol5-
yloxymethyl)-4-(4-fluorophenyl) piperidine 
 
 he β-blocker propranolol hydrochloride is used for the treatment of hypertension and 
for the treatment of patients following heart attacks (Maurer et al., 2007).  Propranolol 
is a non-selective beta blocker which blocks the action of epinephrine and 
norepinephrine on both β1- and β2-adrenergic receptors.  It is a commonly prescribed 
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pharmaceutical frequently found within the environment, making it much-studied within 
environmental monitoring and ecotoxological studies. 
Cimetidine is a commonly prescribed drug used to relieve the symptoms of excessive 
stomach acid due to stomach ulcers, gastro oesophageal reflux and other disorders.  It is 
a H2 receptor antagonist which binds to the H2 receptors on the lining of the stomach 
preventing binding with histamine and the secretion of stomach acid (Ahmadi et al., 
2011). 
 
Metformin is one of the most widely used pharmaceuticals worldwide, used for the 
treatment of Type 2 diabetes (Scheurer et al., 2012).  Metformin is a biguanide which 
suppresses hepatic glucose production and increases the sensitivity of the body to 
glucose, in addition to increasing peripheral glucose uptake.  It is a first line medication 
for sufferers of Type 2 diabetes, and prescriptions of this and similar drugs are likely to 
increase further as obesity rates increase globally. 
 
The non-steroidal anti-inflammatory drugs naproxen and ibuprofen are widely 
prescribed and bought over-the-counter for the relief of mild to moderate pain and 
inflammation in rheumatic disease and in disorders of the joints.  Ibuprofen is also used 
for the treatment of flu-like symptoms.  Both drugs reduce the symptoms of pain by 
blocking cyclo-oxygenase (COX) which is produced in response to injury or disease 
(Boynton et al., 1988).  Salicylic acid is responsible for the anti-inflammatory properties 
of aspirin which is purchased in vast quantities worldwide, making it a commonly 
identified component in sewage effluent. 
 
Caffeine is a xanthine alkaloid which is a central nervous system stimulant which 
counteracts the action of the inhibitor neurotransmitter adenosine.  It is found in many 
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foods and beverages, and also in many prescription drugs due to the benefits associated 
with increased alertness.  It is considered to be the most commonly used psychoactive 
substance with average daily consumption of exceeding 200 mg per person (Miners & 
Birkett, 1996).  It is consequently found throughout the aquatic environment due to 
continual discharge, and may be used to indicate human faecal contamination of 
waterways (Martínez Bueno et al., 2011).  
 
Paroxetine and fluoxetine are selective serotonin reuptake inhibitors (SSRIs) used for 
the treatment of depression, anxiety and obsessive compulsive disorder (Cunningham et 
al., 2004; Oakes et al., 2010).  Fluoxetine and paroxetine both possess fluorine 
substituents which alter the chemical and physical properties of the molecule.  SSRIs 
inhibit a carrier protein for serotonin reuptake at the pre-synaptic membrane, producing 
an increase in serotonin at postsynaptic receptor sites.  Fluoxetine hydrochloride in 
particular has become one of the most prescribed drugs for the treatment of clinical 
depression due to its lower incidence of serious side effects in comparison with e.g. 
tricyclic antidepressants. 
 
3.3.1  Consumption of the selected pharmaceuticals 
Table 3.6 shows the numbers of items of the selected pharmaceuticals prescribed in 
England during 2009, 2010 and 2011 with the exception of caffeine (NHS Information 
Centre).  It is anticipated that the quantities of drugs dispensed such as ibuprofen, 
naproxen and salicylic acid are likely to be significantly lower than the actual amount 
consumed due to high levels purchased over the counter in pharmacies, supermarkets 
and other outlets (Clara et al., 2005; Fent et al., 2006). 
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Table 3.6 Quantities of selected pharmaceuticals dispensed in England (kg)  
Therapeutic Area, Compound and 
Class 
2009 (kg) 2010 (kg) 2011 (kg) 
Cardiovascular 
β-blocker 
Propranolol 
 
 
7,874 
 
 
8,174 
 
 
8,699 
Gastrointestinal 
H2  antagonist 
Cimetidine 
 
 
4,988 
 
 
4,127 
 
 
5,725 
Anti-diabetes 
Biguanide 
Metformin  
 
 
705,371 
 
 
771,489 
 
 
840,073 
CNS 
NSAID 
Ibuprofen 
Naproxen 
Salicylic acid 
SSRI Antidepressant 
Fluoxetine  
Paroxetine   
 
 
123,014 
57,192 
5,112 
 
4,640 
1,440 
 
 
123,257 
67,779 
6,968 
 
4,855 
1,393 
 
 
120,191 
93,036 
5,323 
 
5,025 
1,340 
References: NHS, 2009; NHS, 2010; NHS, 2011. 
 
3.3.2 Physicochemical properties of the selected pharmaceuticals 
Further to the evaluation of consumption data, the physicochemical properties of the 
selected pharmaceuticals including water solubility, acid dissociation constant, log Kow 
and solid-water partition coefficient were considered to understand how they interact 
with the physical environment.  These values for the selected pharmaceuticals are 
shown in Table 3.7.    
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Table 3.7 Physicochemical properties of the selected pharmaceuticals 
Compound and 
Class 
Water solubility 
(mg L
-1
) 
(a)
 
pKa 
(b-j) 
Log Kow
(b-j)
 Kd (L kg
-1
)
(b-j)
 
  Cardiovascular 
  β-blocker 
  Propranolol 
 
 
61.7 
 
 
9.5 
 
 
3.48 
 
 
331
Dig. sludge
 
  Gastrointestinal 
 H2 antagonist 
 Cimetidine 
 
 
9380 
 
 
7.1 
 
 
2.5 
 
 
11.0
Soil
 
  Anti-diabetes 
  Biguanide 
  Metformin 
 
 
1,000,000 
 
 
10.3& 12.3 
 
 
-1.43 
 
 
8.0 - 37.0
Soil
 
  CNS 
  NSAID 
  Ibuprofen 
  Naproxen 
  Salicylic acid 
  Stimulant 
  Caffeine 
  SSRI 
  Fluoxetine 
  Paroxetine 
 
 
21.0 
15.9 
2240 
 
21,000 
 
60.3 
35.3 
 
 
5.2 
4.1 
2.97 
 
10.4 
 
10.06 
9.6 
 
 
3.5 
3.2 
2.3 
 
-0.07 
 
4.26 
3.95 
 
 
21.0-38.0
Dig. sludge
 
36.0
Dig. sludge
 
23.0
Dig. sludge
 
 
14.0
Dig. sludge
 
 
992 – 12,546Soil 
355 – 6,386Soil 
References: 
a)
Barron et al., 2009; 
b)
Carballa et al., 2008; 
c)
Cleuvers, 2004; 
d)
Cunningham et al., 
2004; 
e)
Durán-Álvarez et al., 2012; 
f)
Garzon & Martinez, 2004; 
g)
Kwon & Armbrust, 2008; 
h)
Martínez Bueno et al., 2011; 
i)
SRC PhysProp Database 2011; 
j)
Wan et al., 2007. 
 
3.4 Inhibition by selected pharmaceuticals in anaerobic digester 
sludge by measurement of gas production  
The inhibitory activity of the selected pharmaceuticals was evaluated in closed bottles 
containing anaerobic digester sludge (OECD, 2007).  This was performed to verify that 
the selected pharmaceuticals were not inhibitory to the microorganisms present within 
anaerobic sludge at the concentrations used for the evaluation of biodegradability in 
section 3.1.5.  The maximum concentration used for each test substance was equivalent 
to 50 mg L
-1
 as carbon.  The pH within all test vessels at the end of the experiment was 
within the range pH 7.5 ± 1, and temperature throughout was maintained at 35 ± 1°C.  
The inhibition results for the selected pharmaceuticals are summarised in Table 3.8.  
Full results for these experiments are shown in Appendix B, Tables B-1 to B-4. 
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Table 3.8 Inhibition by selected pharmaceuticals in anaerobic digester sludge by 
measurement of gas production over 72 h  
Compound Concentration 
(mg L
-1
) 
Concentration 
(mg C L
-1
) 
48 h pressure 
(bar) 
Inhibition 
(%) 
Control - - 2.0-2.5 - 
MeOH Control - - 2.1-2.6 < 10 
3,5-DCP 15 6.5 0.8 63-69 
Salicylic acid 82 50 2.6 < 10 
Metformin 173 50 2.5 < 10 
Naproxen 69 50 2.6 < 10 
Caffeine 101 50 2.4 < 10 
Cimetidine  
(direct weight) 
105 50 2.5 < 10 
Cimetidine  
(MeOH) 
105 50 2.6 < 10 
Ibuprofen  
(direct weight) 
66 50 2.3 < 10 
Ibuprofen  
(MeOH) 
66 50 2.4 < 10 
Propranolol  
(direct weight) 
77 50 2.7 < 10 
Propranolol  
(MeOH) 
77 50 2.6 < 10 
Fluoxetine  
(MeOH) 
85 50 1.8 < 10 
Paroxetine  
(MeOH) 
82 50 1.9 < 10 
 
The use of the reference substance 3,5-DCP at a concentration of 15 mg L
-1
 was found 
to result in 63-69% inhibition which is within the expected range for this substance 
(OECD, 2007).  No inhibition was observed as a result of using methanol to dose 
compounds at concentrations above their maximum solubility in water.  None of the 
pharmaceuticals evaluated were found to result in inhibitory behaviour when compared 
with baseline activity at the concentrations evaluated.  There was, however, some 
indication that increased concentrations of fluoxetine and paroxetine may result in some 
degree of microbial inhibition (Appendix B, Table B-4). 
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Overall the results obtained suggest that the selected pharmaceuticals were not 
inhibitory to the microorganisms present within the sludge at the concentrations used, 
and the test substance concentrations were therefore considered to be tolerable for use in 
further biodegradability experiments.   It must, however, be noted that the biomass 
concentration used in this test was tenfold higher than the biomass concentration used in 
biodegradability experiments because there was no dilution in mineral medium.  This is 
because in biodegradability experiments which use respirometric determination a low 
level of background gas production is required for the determination of mineralisation.    
  
3.5 Mineralisation of selected pharmaceuticals in anaerobic 
digester sludge by measurement of gas production  
To evaluate biodegradability under anaerobic conditions, the mineralisation of the 
selected pharmaceuticals was evaluated in a closed bottle biodegradability experiment 
containing anaerobic digester sludge at concentrations equivalent to 25 and 50 mg L
-1
 as 
carbon (OECD, 2006).  The pH within all test vessels at the end of the experiment was 
within the range pH 7.5 ± 1, and the temperature throughout was maintained at 
35 ± 1°C.  The biodegradability results obtained for selected pharmaceuticals by 
measurement of gas production are summarised in Table 3.9.  Values are the mean of 
triplicate vessels, the standard deviation for each time point are shown in Appendix C. 
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Table 3.9 Mineralisation of selected pharmaceuticals in anaerobic digester sludge 
by measurement of gas production over 60 days 
Compound Concentration 
(mg C L
-1
) 
Mineralisation 
(%) 
Concentration 
(mg C L
-1
) 
Mineralisation 
(%) 
Control - - - - 
MeOH Control - - - - 
PEG 400 - - 50 28-64 
Salicylic acid 25 133 50 93 
Metformin 25 96 50 82 
Naproxen 25 32 50 40 
Caffeine 25 14 50 13 
Cimetidine  
(direct weigh) 
25 57 50 25.1 
Cimetidine  
(MeOH) 
25 < 10 50 20.1 
Ibuprofen  
(direct weigh) 
25 28 50 < 10 
Ibuprofen  
(MeOH) 
25 19 50 < 10 
Propranolol  
(direct weigh) 
25 < 10 50 < 10 
Propranolol  
(MeOH) 
25 < 10 50 < 10 
Fluoxetine  
(MeOH) 
25 < 10 50 < 10 
Paroxetine  
(MeOH) 
25 < 10 50 < 10 
 
The use of the reference substance, PEG 400, at a concentration of 50 mg L
-1
 as carbon 
resulted in 28-64% biodegradation, the upper value of which is within the expected 
range for this compound (OECD, 2006).   No effects were observed as a result of using 
solvent to dose compounds at concentrations above their maximum solubility in water.   
 
The loss due to mineralisation (α) was determined, and the half-life (t1/2) calculated 
from the slope (k) of log (100-α) against time.  Biodegradation in sewage sludge is 
assumed to follow a pseudo first-order rate law (Maurer et al., 2007).  Where first-order 
kinetics were observed over the full experimental period, all data points were included 
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in the plot of log (100-α) against time.  Where lag periods and tailing were observed, 
only the relevant areas were included where first-order kinetics were observed.  
Following the integrated first order rate law ln[A] = -kt + ln[A]0, t1/2 at 25 and 50 mg L
-1
 
as carbon was given by the equation: 
 
Over a test period of 60 days, a high degree of ultimate biodegradability was observed 
for salicylic acid and metformin in anaerobic digester sludge.  This is in agreement with 
predicted biodegradability values (Table 3.2), as both pharmaceuticals have a low 
molecular weight and were predicted to biodegrade rapidly under anaerobic conditions.  
These substances have also been shown to degrade rapidly during aerobic sewage 
treatment processes (Hashim et al., 2011; Scheurer et al., 2012).   
 
When dosed into test vessels in RO water at concentrations equivalent to 25 and 
50 mg L
-1 
as carbon, 133% (s.d. ± 1.88) and 93% (s.d. ± 0.43) mineralisation of salicylic 
acid, and 96% (s.d. ± 2.53) and 82% (s.d. ± 3.09) mineralisation of metformin was 
determined.  The mean rates of mineralisation in triplicate vessels for each of these 
pharmaceuticals after correction to background gas production are shown in Figure 3.1.  
Following the integrated first-order rate law, t½ at 25 mg C L
-1
 for salicylic acid and 
metformin were calculated to be 13 days and 11 days respectively.   At 50 mg C L
-1
, t½ 
for salicylic acid and metformin were calculated to be 30 days and 26 days respectively.  
Plots showing log (100-α) against time and t1/2 calculations are shown in Appendix C, 
Figures C-1, C-2, C-7 and C-8. 
t1/2 = ln (2)
             k
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Figure 3.1 Mineralisation of (a) salicylic acid, and (b) metformin in anaerobic 
digester sludge over 60 days. Values are the mean of triplicate vessels, error bars 
have been omitted for clarity.  Standard deviations for each time point are shown 
in Appendix C, Tables C-1, C-2, C-7 and C-8. 
 
Over a test period of 60 days, limited biodegradability was observed for cimetidine and 
naproxen in anaerobic digester sludge.  This is concurrent with predicted 
biodegradability values under anaerobic conditions (Table 3.2).  When weighed directly 
into test vessels at concentrations equivalent to 25 and 50 mg L
-1
 as carbon, 57% 
(s.d. ± 2.24) and 20% (s.d. ± 0.51) mineralisation of cimetidine was determined.  When 
dosed into test vessels in RO water at concentrations equivalent to 25 and 50 mg L
-1 
as 
carbon, 32% (s.d. ± 0.60) and 40% (s.d. ± 0.34) mineralisation of naproxen was 
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observed.   The mean rates of mineralisation in triplicate vessels after correction to 
background gas production are shown in figure 3.2.  Following the integrated first-order 
rate law, t½ at 25 mg C L
-1
 for cimetidine and naproxen were calculated to be 48 days 
and 102 days respectively.  At 50 mg C L
-1
, t½ for cimetidine and naproxen were 
calculated to be 169 days and 77 days respectively.  Plots showing log (100-α) against 
time and t1/2 calculations are described in Appendix C, Figures C-3, C-4, C-5 and C-6.    
 
Figure 3.2 Mineralisation of (a) cimetidine, and (b) naproxen in anaerobic digester 
sludge over 60 days.  Values are the mean of triplicate vessels, error bars have 
been omitted for clarity.  Standard deviations for each time point are shown in 
Appendix C, Tables C-3, C-4, C-5 and C-6. 
 
Over a test period of 60 days, a low level of ultimate biodegradability was observed for 
ibuprofen and caffeine in anaerobic digester sludge.  Caffeine was predicted to 
biodegrade rapidly under anaerobic conditions, while ibuprofen was predicted unlikely 
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to biodegrade rapidly (Table 3.2). When dosed into test vessels in RO water at 25 and 
50 mg C L
-1
, 14% (s.d. ± 0.36) and 13% (s.d. ± 0.46) mineralisation of caffeine was 
determined.  When weighed directly into test vessels at 25 and 50 mg C L
-1
, 25% (s.d. ± 
0.18) and 8% (s.d. ± 0.25) mineralisation of ibuprofen was determined.  The mean rates 
of mineralisation in triplicate vessels after correction to background gas production for 
each of these pharmaceuticals are shown in Figure 3.3.    
 
Figure 3.3 Mineralisation of (a) ibuprofen, and (b) caffeine in anaerobic digester 
sludge over 60 days.  Values are the mean of triplicate vessels, error bars have 
been omitted for clarity.  Standard deviations for each time point are shown in 
Appendix C, Tables C-9, C-10, C-11 and C-12. 
 
Following the integrated first-order rate law, t½ at 25 mg C L
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Plots showing log (100-α) against time and t1/2 calculations are described in Appendix 
C, Figures C-9, C-10, C-11 and C-12.   When dosed into test vessels in RO water at 
both 25 and 50 mg C L
-1
, < 10% mineralisation of fluoxetine, paroxetine and 
propranolol was observed over 60 days.     When blank corrected to control vessels, 
negative values were obtained for each of these three compounds and half-lives could 
not therefore be calculated (Appendix C, Tables C-13 to C-18).  While inhibition was 
not considered to be significant for these compounds in Section 3.4, it is considered that 
the reduced biomass concentration, absence of additional carbon source, and increased 
length of exposure in this experiment contribute to increased sensitivity of the 
microorganisms present.  This is in agreement with the findings of other investigators 
studying inhibitory and biodegradability behaviour (Gartiser et al., 2007). 
  
It is known that sensitivity is the main drawback of respirometric techniques which are 
based upon the measurement of gas production.  High test substance concentrations 
(25-50 mg L
-1
 as carbon) are required to overcome background gas production at the 
recommended biomass concentration.  This concentration range indicates rapidly 
biodegradable substances, but is not representative of conditions found within the 
environment where test substances are found at concentrations < 1.0 mg L
-1
, and more 
typically in the μg  -1 or even ng L-1 range.     
 
While there are recognised limitations of this methodology, the closed bottle screening 
method using respirometric determination is considered to be useful for the 
simultaneous evaluation of a number of compounds.  Several of the selected 
pharmaceuticals demonstrated no mineralisation at concentrations equivalent to 25 and 
50 mg L
-1 
as carbon, and further investigation using specific analysis was performed at 
lower test substance concentrations. 
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3.6 Removal of selected pharmaceuticals in anaerobic digester 
sludge with measurement by specific analysis 
The removal of the selected pharmaceuticals with measurement by specific analysis was 
evaluated in tandem with measurement of gas production in anaerobic digester sludge 
containing the selected pharmaceuticals at concentrations equivalent to 25 and 
50 mg L
-1
 as carbon.  This experiment measured removal due to mineralisation and 
abiotic factors such as hydrolysis, primary biodegradation and adsorption.  Where 
mineralisation was not observed at 25 or 50 mg C L
-1
, pharmaceuticals were further 
evaluated at 1.0 and 5.0 mg L
-1
 with measurement by specific analysis to identify if 
removal could be achieved at a concentration more representative to those found within 
the environment, but which could be easily quantified using UV detection.  Where 
measurement was made by specific analysis only, concentration is expressed as mg L
-1
 
as test substance.  The pH within all test vessels at the end of the experiment was within 
the range pH 7.5 ± 1, and the temperature throughout was maintained at 35 ±1°C.     
   
Table 3.10 Removal of selected pharmaceuticals in anaerobic digester sludge with 
measurement by specific analysis over 60 days. 
Compound Removal (%) 
50 mg C L
-1
 
Removal (%) 
25 mg C L
-1
 
Removal (%) 
5.0 mg L
-1
 
Removal (%) 
1.0 mg L
-1
 
Salicylic acid 100 100 - - 
Naproxen 100 100 - - 
Cimetidine 36 48 32 36 
Ibuprofen -18 24 2.1 15 
Caffeine -5.8 0.7 5.1 11 
Propranolol 60 71 55 67 
Fluoxetine 91 92 92 98 
Paroxetine 94 97 96 98 
 
When dosed into test vessels in RO water at concentrations equivalent to 25 and 
50 mg L
-1
 as carbon, 100% removal of both salicylic acid and naproxen in anaerobic 
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digester sludge was observed over a test period of 60 days.  Plots illustrating the 
measured removal for each of these pharmaceuticals over 60 days are shown in Figure  
3.4. 
 
 
Figure 3.4 Removal of (a) salicylic acid, and (b) naproxen in anaerobic digester 
sludge over 60 days with measurement by specific analysis.  Values are the mean of 
duplicate injections. 
 
High removal of propranolol, fluoxetine and paroxetine in anaerobic digester sludge 
was observed over a test period of 60 days when dosed into test vessels at 
concentrations of 1.0 and 5.0 mg L
-1
 as test substance.  Plots showing measured removal 
for each of these pharmaceuticals over 60 days are shown in Figure 3.5.   
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Figure 3.5 Removal of (a) propranolol, (b) fluoxetine, and (c) paroxetine in 
anaerobic digester sludge over 60 days with measurement by specific analysis.  
Values are the mean of triplicate vessels, error bars have been omitted for clarity.  
Standard deviations for each time point are shown in Appendix D, Figures D-3, D-
5 and D-6. 
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At 1.0 mg L
-1
 measured removals on Day 0 were 41.4% (s.d. ± 0.035), 96.8% 
(s.d. ± 0.035) and 96.8% (s.d. ± 0.001) for propranolol, fluoxetine and paroxetine 
respectively.  On Day 60 the measured removals for propranolol, fluoxetine and 
paroxetine at 1.0 mg L
-1
 were 66.7% (s.d. ± 0.058), 98.3% (s.d. ± 0.002) and 98.3% 
(s.d. ± 0.002), showing an increase in the removal of propranolol during the experiment 
but little change in the removal of fluoxetine and paroxetine.  At 5.0 mg L
-1
 measured 
removals on Day 0 were 24.5% (s.d. ± 0.912), 95.1% (s.d. ± 0.038) and 97.0% 
(s.d. ± 0.010) for propranolol, fluoxetine and paroxetine respectively.  On Day 60 the 
measured removals for propranolol, fluoxetine and paroxetine were 54.8% 
(s.d. ± 0.844), 92.1% (s.d. ± 0.093) and 96.2% (s.d. ± 0.026), showing a similar trend as 
observed at 1.0 mg L
-1
, with the removal of propranolol increasing during the 
experiment and the removal of fluoxetine and paroxetine remaining stable.  Overall, the 
removal of propranolol was higher at 1.0 mg L
-1
 than at 5.0 mg L
-1
, but concentration 
was not observed to influence the removal of fluoxetine and paroxetine.  It is likely that 
the removal of propranolol, fluoxetine and paroxetine was attributable to adsorption 
since removal was more rapid than would be expected for biological processes, with 
measurements for all three pharmaceuticals being considerably below dosed 
concentrations on Day 0, and also because Kd values reported in the literature indicate 
high affinity for organic matter (Table 3.7). 
 
Moderate removal of cimetidine was observed when dosed into test vessels at 1.0 and 
5.0 mg L
-1
 as test substance.  The measured removal over 60 days is shown in Figure 
3.6.  At 1.0 mg L
-1
 measured removal on Day 0 was 11.3% (s.d. ± 0.257), increasing to 
36.3% (s.d. ± 0.040) by Day 60.  At 5.0 mg L
-1
 measured removal was 3.8% 
(s.d. ± 1.154), and increased to 31.53% (s.d. ± 0.031) by Day 60.  When compared with 
manometric data (Table 3.9) these results suggest that removal was due to partial 
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mineralisation, and that there is little difference in the rate of removal with increasing 
concentration.   
 
Figure 3.6 Removal of cimetidine in anaerobic digester sludge over 60 days with 
measurement by specific analysis.  Values are the mean of triplicate vessels, error 
bars have been omitted for clarity.  Standard deviations for each time point are 
shown in Appendix D, Figure D-4. 
 
Low to moderate removal of ibuprofen, and caffeine in anaerobic digester sludge was 
observed over a test period of 60 days when dosed into test vessels at concentrations of 
1.0 and 5.0 mg L
-1
 as test substance.  Plots showing the measured removal for each of 
these pharmaceuticals over 60 days are shown in Figure 3.7.   
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removal, however, no distinct pattern of removal can be identified from the results 
obtained.    
 
Figure 3.7 Removal of (a) ibuprofen, and (b) caffeine in anaerobic digester sludge 
over 60 days with measurement by specific analysis.  Values are the mean of 
triplicate vessels, error bars have been omitted for clarity.  Standard deviations for 
each time point are shown in Appendix D, Figures D-1 and D-2. 
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of caffeine at the start of the experiment was higher than nominal suggesting inaccuracy 
during dosing or solubilisation of caffeine within the biomass.  Caffeine is likely to be 
present within the biomass due to its ubiquitous presence within the environment 
(Martínez Bueno et al., 2011). 
 
3.7 Adsorption of selected pharmaceuticals over time 
Following evaluation of the results generated by closed bottle biodegradability 
experiments, further investigation was required to measure adsorption for several of the 
selected pharmaceuticals.  As described in Section 2.3.3 the adsorption of propranolol, 
fluoxetine and paroxetine was evaluated over time with measurement by specific 
analysis.  In order that results were comparable with the results obtained from 
biodegradability experiments (Section 2.4), tests were performed at a test substance 
concentration of 1.0 mg L
-1 
in mineral medium in 160 mL glass serum bottles.  The 
sludge solids concentration used was 3.0 g L
-1
.  The pH of all solutions at the start of the 
experiment was within the range pH 7.5 ± 1, and experimental conditions were 
maintained at 35 ± 1°C.  Plots showing measured concentrations of fluoxetine, 
paroxetine and propranolol over time with and without anaerobic digester sludge are 
shown in Figure 3.8.  All three pharmaceuticals showed rapid adsorption behaviour, 
with reduced concentrations being observed immediately in test vessels containing 
sludge solids.   Removal of fluoxetine and paroxetine at the initial sampling point 
measured 85 and 92% respectively in the presence of sludge solids, while removal of 
propranolol at the initial sampling point measured 64% in the presence of sludge solids.  
Measured concentrations in test vessels containing mineral medium were within 20% of 
the 1.0 mg L
-1
 dosing concentration for each of the three pharmaceuticals.  Samples 
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were diluted ×2 for analysis, thus increasing experimental error and potentially 
accounting for increased deviation between nominal and measured concentrations.     
 
 
 
Figure 3.8 Measured concentration in the aqueous phase of (a) fluoxetine, (b) 
paroxetine and (c) propranolol over time. 
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3.8 Adsorption of selected pharmaceuticals with varying 
concentration of sludge solids 
Following evaluation of the results generated in biodegradability experiments, 
investigation was required to measure the adsorption of propranolol, fluoxetine and 
paroxetine with varying concentrations of sludge solids.  Experiments were performed 
in mineral medium at a test substance concentration of 1.0 mg L
-1
 in 50 mL glass 
centrifuge tubes fitted with ground glass stoppers.   
 
The sludge solids concentrations used were 100, 300 and 3,000 mg L
-1
.   The pH of all 
solutions at the start of the experiment was within the range pH 7.5 ± 1, and 
experimental conditions were maintained at 35 ± 1°C.  Measured concentrations of all 
three pharmaceuticals were close to nominal in the absence of sludge solids, and 
showed a decrease in the level of recovery with increasing sludge solids concentration.  
Recovery of fluoxetine, paroxetine and propranolol from the aqueous phase in the 
presence of 3000 mg L
-1
 sludge solids, equivalent to the sludge solids concentration 
used in biodegradability experiments, was 16%, 40% and 40% respectively. 
 
Using the Linear model, the concentration measured within the aqueous phase following 
subtraction from sludgeless controls was plotted for all three pharmaceuticals against 
the concentration calculated to be adsorbed within the sludge phase, assuming no 
adsorption to glass test vessels.  This model was found to provide a good fit for 
propranolol giving a Kd value of 33.62, but was found to be unsuitable for fluoxetine 
and paroxetine.  Using the Freundlich model, the log10 of the concentration measured 
within the aqueous phase following subtraction from sludgeless controls was plotted for 
all three pharmaceuticals against the log10 of the concentration calculated to be adsorbed 
within the sludge phase.  This model was also found to provide a good fit for 
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propranolol giving a log Kd value of 1.61, but was found to be unsuitable for fluoxetine 
and paroxetine.  The use of the Langmuir isotherm model was considered, however, this 
was not possible because no desorption data was collected to allow the calculation of 
the equilibrium constant.  Linear and Freundlich isotherms for fluoxetine, paroxetine 
and propranolol are shown in Figure 3.9.  
 
Figure 3.9  Measured aqueous concentrations of fluoxetine, paroxetine and 
propranolol plotted against calculated concentrations within the sludge phase 
using (a) linear isotherm parameters, and (b) Freundlich isotherm parameters. 
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experiment were within an acceptable range, therefore the results obtained for 
paroxetine may have been due to errors in sample dilution or because less of the test 
substance had opportunity to adsorb to the biosolids during the short exposure period.  It 
is also considerd that there may have been some problems during the phase separation, 
and that dissolution of material adsorbed to the biosolids may have occurred.  This was 
not further investigated, however, the use of CaCl2 may assist with similar problems in 
the future. 
 
Overall the results presented in Sections 3.8 and 3.9 confirm the removal of fluoxetine, 
paroxetine and propranolol during closed bottle experiments is due to adsorption.  
Results shown in Figure 3.8 showed removal to be rapid, with adsorption of all three 
pharmaceuticals taking place immediately following addition to equilibrated test vessels 
containing sludge solids.  In contrast, recoveries of pharmaceuticals from test vessels 
containing mineral medium were good.  The removal of fluoxetine, paroxetine and 
propranolol due to adsorption was further confirmed by the results shown in Figure 3.9, 
with the measured concentrations of all three pharmaceuticals within the aqueous phase 
decreasing in relation to increasing sludge solids concentration. 
 
3.9 Discussion 
The objective of this chapter was to identify a number of pharmaceuticals and screen 
under anaerobic conditions using standard guideline methodology to investigate the 
hypothesis that anaerobic digestion offers potential for the removal of pharmaceuticals 
found within the biosolids.  Test substances were selected using a scoring system based 
upon detection within the biosolids, predicted biodegradability, and commercial 
availability of radioisotopes.   
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Evaluation of the selected test substances under anaerobic conditions showed varying 
degrees of removal through biodegradation and adsorption.  At 50 mg C L
-1
, salicylic 
acid and metformin were removed by 93 and 82%, respectively due to mineralisation.  
At 50 mg C L
-1
, naproxen was completely removed due to primary biodegradation.  At 
50 mg C L
-1
, propranolol, fluoxetine and paroxetine were removed by 55, 92 and 96%, 
respectively due to adsorption.  Less extensive removal of caffeine, cimetidine and 
ibuprofen was observed. 
 
The high water solubility and low solid-water partition coefficient for salicylic acid and 
metformin (Table 3.7) means that they are not strongly associated with the solids and 
are freely available for consumption by microorganisms.  Salicylic acid (molar mass 
138.1 g mol
-1
) is a monocyclic aromatic compound, while metformin (molar mass 
129.16 g mol
-1
) is a branched chain molecule rich in nitrogen.  Generally, short chain 
compounds are known to be more degradable than monocyclic or polycyclic molecules, 
and the presence and positioning of substituted groups also has important effects upon 
biodegradability (Samiullah, 1990).  Mineralisation of the salicylic acid molecule has 
been shown to follow initial decarboxylation or β-oxidation of the constituent groups 
which releases points for hydroxylation of the aromatic ring (Musson et al., 2010; 
Wackett & Ellis, 1999). 
 
In contrast, the selective serotonin reuptake inhibitor fluoxetine has a much higher 
solid-water partition coefficient (Table 3.7), resulting in a much stronger association 
with the biosolids, and less availability to pelagic microorganisms for consumption.  
This is due to the presence of a trifluoromethyl group within the fluoxetine molecule 
(molar mass 309.33 g mol
-1
).  Fluorinated groups are commonly found within modern 
psychoactive drugs, but the strong C-F bonds have been shown to result in recalcitrance, 
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resistance to degradation, and toxicity within the aquatic environment (Kosjek & Heath, 
2010; Park et al., 2001).   
 
Information about the metabolic pathways used by microbes to degrade organic 
compounds is used for the compilation of databases and predictive tools such as 
BIOWIN7 and the University of Minnesota Biocatalysis/Biodegradation database (Gao 
et al., 2010; Wackett & Ellis, 1998).   BIOWIN7 within EPISuite™ was used to predict 
the anaerobic biodegradability of the selected pharmaceuticals.  Salicylic acid, 
metformin and fluoxetine were predicted to biodegrade rapidly under anaerobic 
conditions.  However, anaerobic biodegradation of fluoxetine was not demonstrated.  
This shows that when multiple removal mechanisms exist within a system, predictive 
tools based upon reaction pathways only have limited capabilities, whereas 
compartment models such as SIMPLETREAT, depict the transfer between aqueous and 
solid sytems and assign a first-order removal constant based upon cumulative factors 
including biodegradability, adsorption and volatiliation (van de Meent et al., 1995).   
 
Overall, the pharmaceuticals evaluated were removed very little through anaerobic 
biodegradation.  A number of test substances were shown to adsorb to the biosolids, 
however, this mechanism does not remove the risk to the environment.  It is recognised 
that the removal of contaminants may be optimised by altering environmental 
conditions to promote the activity of specific microbial groups.  The contribution of 
redox processes to the removal of contaminants within sediments and aquifers has 
previously been demonstrated (McMahon & Chapelle, 2008; Borch et al., 2010).  
Chapter 4 describes the evaluation of suitable methodology to poise redox potential 
within distinct regions of the Eh scale in order to investigate the impact of redox 
amendment on the behaviour of pharmaceuticals in anaerobic sewage sludge. 
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CHAPTER 4  
 
EVALUATION OF METHODOLOGY FOR THE CONTROL 
OF REDOX CONDITIONS 
 
Just as redox conditions are important in transforming organic compounds within 
natural aquatic systems, they are also important in the transformation of organic 
compounds during sewage treatment processes (Brezonik & Arnold, 2011).  The 
biodegradability of test substances has been shown to vary considerably under different 
redox conditions (Crawford et al., 2000; Lahti & Oikari, 2011).  Typically redox can 
vary from +700 mV to -300 mV.  During anaerobic respiration, a range of different 
compounds including nitrate, manganese (IV), iron (III), sulfate, and carbon dioxide 
accept the electrons lost during the oxidation of organic compounds.  Each operates 
within a distinct region of the Eh scale, and impacts upon microbial activity within the 
environment and the biodegradation of contaminants such as pharmaceuticals (Yu & 
Rinklebe, 2011; Husson, 2013).  To better understand the removal of organic 
compounds under specific redox conditions and how elimination may be optimised, this 
environment may be broken up and behaviour evaluated within these distinct regions.    
 
As set out in the Research Strategy in Section 1.4, it is hypothesised that 
pharmaceuticals present within the biosolids will be removed at varying rates and to 
varying extents under different redox conditions.  To test this hypothesis, this Chapter 
describes the evaluation of suitable methodology to poise redox potential within distinct 
regions of the Eh scale with relative stability, and provide conditions favourable for the 
removal of DOC.  DOC consists of a high number of different compounds, which if 
removed, indicates the presence of specialised bacteria capable of using trace organics 
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as an energy source, therefore removal of DOC was used to indicate the capacity of the 
system for biodegradation (Wiese et al., 2011).   
   
4.1 Characterisation of redox conditions found within secondary 
and anaerobic digester sludges 
Before evaluating a system for the control of redox conditions it was first necessary to 
understand the intrinsic conditions present within the sludge used.  A number of 
measurements were made including pH, Eh, DOC and the concentrations of terminal 
electron acceptors from across the Eh scale (Table 4.1) which are indicative of the redox 
status of the sludge.  Measurements of pH made within secondary and anaerobic 
digester sludges following collection as described in Section 2.3.1 were determined to 
be 5.80 and 7.30, respectively.  Measurements of Eh made within secondary and 
anaerobic digester sludges following collection as described in Section 2.3.2 were 
determined to be -338.2 mV and -380.3 mV, respectively.  Measurements of DOC made 
within secondary and anaerobic digester sludges as described in Section 2.7.1 were 
determined to be 1.83 and 3.17 g L
-1
, respectively.   
Table 4.1 Terminal electron acceptors present in secondary and anaerobic digester 
sludges 
Terminal Electron 
Acceptor 
Concentration in 
Secondary Sludge (mg L
-1
) 
Concentration in Anaerobic 
Digester Sludge (mg L
-1
) 
Mn
2+
 7.8 33.9 
Fe(II) 15.6 39.4 
Fe(III) <6.0 <6.0 
SO4
2-
 171 252 
S
2-
 0.96 3.39 
NH4
+
 34.7 60.6 
NO3
-
 <35.0 <35.0 
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4.2 Evaluation of test systems for the control of redox conditions 
This Section describes two methods for the control of redox conditions: the use of 
different mixtures of air and nitrogen at a total gas flow rate of 2.0 L min
-1
 to flush the 
headspace of test vessels; and chemical amendment of test vessels with carbonate 
through the addition of Na2CO3 at a concentration of 1.0 g L
-1
 (415 mg L
-1
 carbonate). 
 
4.2.1  Control of redox conditions through altering the gas used to flush the 
headspace of test vessels 
The test system used is illustrated in Figure 4.1.  Test vessels contained 2.0 L of a 
mixture of anaerobic digester and secondary sludge blended together in a ratio of 4:1 
(v/v) and diluted to give a total sludge solids concentration of 3.0 g L
-1
 in reduced 
anaerobic dilution medium prepared as described in Section 2.4.2.1.  Test vessels were 
maintained at 35 ± 1°C in a water bath for a period of 28 days and were stirred 
throughout. 
 
Figure 4.1 Test set-up used for control of redox potential through altering the 
gas used to flush the headspace of test vessels. 
 
Gas out
Redox probe
Test vessel
(2 L)
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Magnetic stirrer
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Rotameter
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Regular measurements of Eh, DOC and total solids were made over time to understand 
the impact of treatment, and are summarised in Figure 4.2.  
               
Figure 4.2  Influence of gas used to flush the headspace of test vessels on (a) Eh, 
(b) total solids, and (c) DOC over time.  Measurements shown are the mean of 
duplicate vessels. 
 
Initial Eh measurements for test vessels flushed with 100% air, 70% N2, and 100% N2 
were -27.85, 76.35 and -24.15 mV, respectively.  On Day 12 Eh measurements in 100% 
air, 70% N2, and 100% N2 amended vessels were 304, -81 and -148 mV, respectively.  
After this period values continued to change over time, but distinction in redox 
conditions between treatments could be observed.  On Day 28 Eh measurements in 
100% air, 70% N2, and 100% N2 amended vessels were 369, 234 and -196 mV.  
Overall, it was considered that Eh measurements within test vessels flushed with 100% 
N2 stabilised quickly, Eh measurements within test vessels flushed with 100% air 
became stable after approximately 12 days, and fluctuations in Eh were observed 
throughout within test vessels flushed with 70% N2.  This may have been due to 
inaccuracies with the measurement of individual gas flows, which may be overcome 
through the use of more accurate rotameters, or through the use of pre-blended gas 
mixtures purchased in cylinders.   
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Sludge solids were most effectively removed through aerobic treatment, with sludge 
solids declining steadily from 3,000 to 1,503 mg L
-1
 in test vessels flushed with 100% 
air during the 28-day experiment.  The removal of sludge solids was observed to a lesser 
degree in test vessels flushed with 70% N2 and 100% N2, with overall decreases from 
3,000 to 2,198 mg L
-1
 and from 3,000 to 1,958 mg L
-1
 respectively.  Some 
measurements showed increased sludge solids concentrations during the experiment, 
which may have been due to evaporative loss from test vessels, sampling of lumps, or 
gravimetric errors.       
 
DOC was most effectively removed through aerobic treatment, with concentrations 
falling from 272 to 130 mg L
-1
 in test vessels flushed with 100% air between days 4 and 
9, before tailing off to 90 mg L
-1
 during the remainder of the experiment.  In test vessels 
flushed with 70% N2 an increase in DOC from 285 to 331 mg L
-1
 was observed between 
days 4 and 9, which coincided with a decrease in sludge solids concentration through 
the solubilisation of complex polymers.  This was followed by a considerable decrease 
in DOC from 331 to 118 mg L
-1
 between days 9 and 13, when Eh was observed to 
increase from the anaerobic to anoxic region.  On Day 28 DOC concentration in test 
vessels flushed with 70% N2 was 113 mg L
-1
.  In test vessels flushed with 100% N2 an 
increase in DOC from 402 to 476 mg L
-1
 was observed between days 4 and 9, which 
also coincided with a decrease in sludge solids concentration.  However, no change in 
Eh or increase in the rate of removal was observed.  On Day 28 DOC concentration in 
test vessels flushed with 100% N2 was 429 mg L
-1
.  
 
The adjustment of redox potential was observed by altering the gas used to flush the 
headspace of test vessels.  However, the removal of DOC was used to indicate the 
capacity of the system for the breakdown of organic substances.  Flushing the headspace 
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of test vessels was considered to offer potential for the breakdown of organic substances 
under aerobic and anoxic, but not anaerobic conditions.  Alternative methods were 
therefore investigated for redox amendment which would facilitate the removal of DOC 
across the full Eh scale. 
 
4.2.2  Control of redox conditions over 21 days through chemically amending 
test vessels with carbonate 
The test system used is shown in Figure 4.3.  Test vessels contained 2.0 L of a mixture 
of anaerobic digester and secondary sludge blended together in a ratio of 4:1 v/v and 
diluted to give a total sludge solids concentration of 3.0 g L
-1
 in reduced anaerobic 
dilution medium prepared as described in Section 2.4.2.1.  Test vessels were maintained 
at 35 ± 1°C in a water bath for a period of 21 days and were stirred throughout. 
 
Figure 4.3 Test set-up used for control of redox potential through chemically 
amending test vessels with carbonate. 
 
Regular measurements of Eh, DOC and total solids were made over time to understand 
the impact of treatment, and are summarised in Figure 4.4. 
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Figure 4.4  Influence of chemical amendment with carbonate on (a) Eh, (b) total 
solids, and (c) DOC over time.  Measurements shown are the mean of duplicate 
vessels. 
 
 
Initial Eh measurements for test vessels flushed with N2, amended with carbonate, and 
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13 and -203 mV, respectively.  Conditions stabilised quickly within all test vessels to a 
region within the Eh scale within which carbonate was utilised as a terminal electron 
acceptor (< -200 mV; Brezonik & Arnold, 2011), with no notable differences in Eh 
between treatments.  On  ay 2, Eh measurements in ‘N2’, ‘Carbonate only’, and ‘N2 
and carbonate’ test vessels were -252, -223 and -329 mV, respectively.  Eh 
measurements remained stable throughout the experiment for all treatments, with the 
only observed fluctuation in Eh being a rise in carbonate amended test vessels after Day 
18.  On  ay 21, Eh measurements in ‘N2’, ‘Carbonate only’, and ‘N2 and carbonate’ test 
vessels were -171, -106 and -253 mV, respectively.   
 
Removal of sludge solids was observed in ‘N2’ and ‘N2 and carbonate’ test vessels, but 
not in ‘Carbonate only’ test vessels.  Initial sludge solids measurements in ‘N2’, 
‘Carbonate only’, and ‘N2 and carbonate’ test vessels were 2,245, 2,735 and 2,397 mg 
L
-1
, respectively.  On Day 21, sludge solids measurements in ‘N2’, ‘Carbonate only’, 
and ‘N2 and carbonate’ test vessels were 1,572, 2,385 and 1,445 mg L
-1
, respectively.  
The observed decreases in sludge solids measurements are potentially due to cell lysis 
and the release of DOC.  Removal of  OC was observed in ‘Carbonate only’ test 
vessels, but not in ‘N2’ or ‘N2 and carbonate’ test vessels.  Initial DOC measurements in 
‘N2’, ‘Carbonate only’, and ‘N2 and carbonate’ test vessels were 357, 391 and 385 mg 
L
-1
 respectively.  On Day 21 DOC measurements in ‘N2’, ‘Carbonate only’, and ‘N2 and 
carbonate’ test vessels were 330, 99 and 442 mg  -1 respectively.   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
The observed increase in DOC in ‘N2 and carbonate’ test vessels may have been due to 
evaporative loss, or the fixation of inorganic carbon by autotrophs.  To further 
understand the processes involved, the concentrations of carbonate within test vessels 
were measured over time.  The results of these measurements are shown in Figure 4.5.     
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Figure 4.5  Influence of chemical amendment with carbonate on specific TEA 
over time.  Measurements shown are the mean of duplicate vessels. 
 
Removal of carbonate was observed from ‘N2 and carbonate’ test vessels, however, 
concentrations were shown to be considerably raised in ‘Carbonate only’ test vessels.  
On Day 0, measurements in ‘Carbonate only’ and ‘N2 and carbonate’ test vessels were 
518 and 409 mg L
-1
 respectively.  On  ay 21, measurements in ‘Carbonate only’ and 
‘N2 and carbonate’ test vessels were 1,062 and 67 mg L
-1
 respectively.  These 
measurements indicate that the use of N2 resulted in the removal of a large proportion of 
carbonate from the system through diffusion, while carbonate addition without N2 
flushing resulted in the formation of additional carbonate following the removal of DOC 
through anaerobic processes.   
 
Overall, the results of this experiment suggest that chemical amendment is an effective 
strategy.  Adjustment of redox potential was observed through chemical amendment of 
test vessels with carbonate, and DOC was successfully removed.  However, in order to 
investigate the fate of the selected pharmaceuticals within a range of redox conditions, 
chemical amendment with different terminal electron acceptors was investigated. 
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4.3 Evaluation of different chemical amendments for the control 
of redox conditions  
The control of redox potential through chemically amending test vessels was shown to 
be more effective for the removal of DOC than altering the gas used to flush the 
headspace of test vessels.  However, methodology was required which resulted in 
poised redox potential across the Eh scale.  The use of different terminal electron 
acceptors in microbial metabolism are representative of different redox conditions 
(Figure 1.4).  To demonstrate differences between the behaviour of pharmaceuticals that 
may occur under these different redox conditions, chemical amendment of test vessels 
with terminal electron acceptors used within different regions of the Eh scale is 
required.  In addition to carbonate, nitrate and sulfate were selected for evaluation.  
These electron acceptors operate within opposite regions of the Eh scale, and 
denitrification and sulfate-reducing conditions are known to be easily achieved and 
maintained (Barbieri et al., 2011).  Eh, DOC and the concentration of specific terminal 
electron acceptors within test vessels were first evaluated over short periods of time 
(240 min), before evaluating the influence of nitrate and sulfate amendment in longer 
experiments (21 days). 
  
Test vessels used were as shown in Figure 4.3.  Test vessels contained 2.0 L of a 
mixture of anaerobic digester and secondary sludge blended together in a ratio of 4:1 
v/v and diluted to give a total sludge solids concentration of 3.0 g L
-1
 in reduced 
anaerobic dilution medium prepared as described in Section 2.4.2.1.  Test vessels were 
maintained at 35 ± 1°C in a water bath and were stirred throughout.  Comparison with 
nitrogen flushing was performed for each terminal electron acceptor. 
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4.3.1 Control of redox conditions over 240 min through chemically amending 
test vessels with carbonate, nitrate and sulfate 
To evaluate how chemical amendment with carbonate, nitrate or sulfate influenced 
redox conditions within a 3.0 g L
-1
 anaerobic digester sludge, Eh was monitored over a 
short period of time following the addition of Na2CO3, NaNO3 or Na2SO4 at an initial 
concentration of 1.0 g L
-1
.  Redox measurements were made at 15 min intervals, and the 
concentration of specific terminal electron acceptors measured at the start and at the end 
of the experiment.  Results obtained from redox measurements over 240 min are shown 
in Figure 4.6.
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Figure 4.6 Distribution of redox measurements over 240 min in test vessels flushed 
with N2 and/or amended with (a) carbonate, (b) nitrate, and (c) sulfate.  
Measurements are the mean of triplicate vessels.  
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Figure 4.6a shows that the addition of Na2CO3 at an initial concentration of 1.0 g L
-1
 
(415 mg L
-1
 carbonate) alone and in combination with N2 flushing resulted in the 
adjustment of redox potential to a region within the Eh scale within which carbonate 
was utilised as a terminal electron acceptor (< -200 mV) (Brezonik & Arnold, 2011).  
Measured concentrations of carbonate were not observed to change by any considerable 
extent during the 240 min experimental period.  Initial concentrations of CO2  in 
‘Carbonate only’ and ‘N2 and carbonate’ amended test vessels were 604 mg L
-1
 (s.d. ± 
25.46) and 484 mg L
-1
 (s.d. ± 14.14), respectively.  After 240 min, CO2 concentrations 
in ‘Carbonate only’ and ‘N2 and carbonate’ amended test vessels were 709 mg L
-1
 
(s.d.± 91.92) and 505 mg L
-1
 (s.d. ± 19.09), respectively.  
   
Figure 4.6b shows that the addition of NaNO3 at an initial concentration of 1.0 g L
-1
 
(729 mg L
-1
 nitrate) alone and in combination with N2 flushing resulted in increased 
redox potential, however values observed were not within the nitrate-reducing region of 
the Eh scale (+100 to +300 mV) within the 240 min experimental period (Brezonik & 
Arnold, 2011).  Measured concentrations of nitrate were not observed to change by any 
considerable extent during the 240 min experimental period.  Initial concentrations of 
NO3
-
  in ‘Nitrate only’ and ‘N2 and nitrate’ amended test vessels were 600 mg L
-1
 (s.d. ± 
40.55) and 593 mg L
-1
 (s.d. ± 46.01), respectively.  After 240 min, NO3
-
 concentrations 
in ‘Nitrate only’ and ‘N2 and nitrate’ amended test vessels were 588 mg L
-1
 (s.d. ± 
51.31) and 563 mg L
-1
 (s.d. ± 78.59), respectively.  
 
 Figure 4.6c shows that the addition of Na2SO4 at an initial concentration of 1.0 g L
-1
 
(676 mg L
-1
 sulfate) alone and in combination with N2 flushing resulted in redox 
potential being maintained within the sulfate-reducing region of the Eh scale (-100 to 
-200 mV) (Brezonik & Arnold, 2011).  Measured concentrations of sulfate were not 
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observed to change by any considerable extent during the 240 min experimental period.  
Initial concentrations of SO4
2-
 in ‘Sulfate only’ and ‘N2 and sulfate’ amended test 
vessels  were 507 mg L
-1
 (s.d. ± 54.50) and 470 mg L
-1
 (s.d. ± 71.02), respectively.  
After 240 min, SO4
2-
 concentrations in ‘Sulfate only’ and ‘N2 and sulfate’ amended test 
vessels were 471 mg L
-1
 (s.d. ± 73.23) and 432 mg L
-1
 (s.d. ± 50.51), respectively. 
 
Overall the Eh measurements for all treatments replicated well and were found to be 
stable throughout the experiment.  However, it was considered that anaerobic 
degradation was likely to occur over a longer time period, therefore a longer-term 
experiment was performed. 
 
4.3.2 Control of redox conditions over 21 days through chemically amending 
test vessels with nitrate and sulfate 
Chemical amendment of a 3.0 g L
-1
 anaerobic digester sludge was shown to maintain 
the redox conditions over a 240 min period.  However, for the purpose of evaluating the 
anaerobic biodegradation of substances such as pharmaceuticals, redox conditions need 
to be stable over a longer period of time.  To evaluate stability following chemical 
amendment with nitrate or sulfate, the test system was monitored for 21 days with 
regular measurements of redox, DOC and specific TEA.  Due to space and equipment 
limitations, only one replicate only per treatment could be set up. 
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Figure 4.7 Measurement of (a) redox measurements, and (b) specific TEA over 21 
days in test vessels flushed with N2 and/or amended with nitrate.  Secondary 
additions of nitrate into chemically amended test vessels are indicated by ‘ l’. 
 
Figure 4.7a shows that the redox potential was adjusted to the region of nitrate 
utilisation within the Eh scale (+100 to +300 mV) (Brezonik & Arnold, 2011) in 
‘Nitrate only’ test vessels, while adjustment of redox potential below the region of 
nitrate utilisation was observed in ‘N2’ and ‘N2 and nitrate’ test vessels.  Some degree of 
spread was observed within measurements, particularly during the first 7 days of the 
experiment, which was reflected in the consumption of nitrate (Figure 4.7b).  This initial 
removal of nitrate accompanied by a rapid decline in Eh to -200 mV is in agreement 
with the findings of Graetz et al. (1973). 
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No nitrate was detected within ‘N2’ test vessels at any stage of the experiment, while the 
initial addition of nitrate was removed within 24 h in ‘Nitrate only’ test vessels.   
However, additions made on Days 5 and 16 were not readily removed and final nitrate 
concentrations on Day 21 measured 3272 mg L
-1 in ‘Nitrate only’ test vessels.  It is 
considered that limited availability of DOC or inhibitory nitrate concentrations may 
have limited the removal of these subsequent additions.  In ‘N2 & nitrate’ test vessels, 
all amendments to the system were removed soon after addition, with final 
concentrations on Day 21 measuring 181 mg L
-1
.   
 
Figure 4.8 Measurement of (a) redox measurements, and (b) specific TEA over 21 
days in test vessels flushed with N2 and/or amended with sulfate.  Secondary 
additions of sulfate into chemically amended test vessels are indicated by ‘ l’. 
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Figure 4.8a shows that the redox potential was adjusted to the region within the  
Eh scale where sulfate is utilised as a terminal electron acceptor (-100 to +200 mV) 
(Brezonik & Arnold, 2011) in the test vessel that received Na2SO4 at an initial 
concentration of 1.0 g L
-1.  In ‘N2’ and ‘N2 and sulfate’ test vessels, redox potential was 
adjusted slightly below this region to -300 mV.  All treatments were found to result in 
stable redox conditions across the 21-day period.  
 
No sulfate was detected within N2 flushed test vessels at any stage of the experiment.    
Measured SO4
2- 
concentrations on Day 0 through amendment with sulfate addition, and 
N2 flushing in combination with sulfate addition were 382 and 492 mg L
-1
, respectively.  
Figure 4.5c shows that sulfate added at the start of the experiment was gradually 
removed over 14 days.   Further additions of sulfate made on Day 16 were not removed 
during the 21-day experimental period.  Measured SO4
2- 
concentrations on Day 21 
through amendment with sulfate addition, and N2 flushing in combination with sulfate 
addition were 378 and 540 mg L
-1
, respectively. 
       
This gradual removal of sulfate may be explained by the process of dissimilatory sulfate 
reduction, whereby sulfate is used as a terminal electron acceptor and organic substrates 
are used as the electron donor (Peck, 1961).  Sulfate-reducing bacteria can use a variety 
of organic compounds as electron donors, including one-carbon compounds and long- 
and short-chain alkanes.  However, sulfate reducing-bacteria cannot directly utilise 
polymeric compounds, and the fermentation of complex molecules by other types of 
microorganisms is vital to provide available substrates for growth (Muyzer & Stams, 
2008).                     
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Figure 4.9 Removal of DOC over 21 days in test vessels amended with 
carbonate, nitrate, and sulfate.  
 
Figure 4.9 shows that DOC was effectively removed over 21 days through amendment 
with specific terminal electron acceptors, but not through the use of N2 flushing or 
amendment with specific terminal electron acceptors in combination with N2 flushing.   
 
Amendment with all specific terminal electron acceptors in combination with N2 
flushing was observed to result in increased DOC concentrations.  Measured 
concentrations of DOC on Day 0 for test vessels amended with carbonate, nitrate and 
sulfate in combination with nitrogen gas flushing were 391, 356 and 342 mg L
-1
, 
respectively.  Measured concentrations on Day 21 for test vessels amended with 
carbonate, nitrate and sulfate in combination with nitrogen gas flushing were 442, 470 
and 509 mg L
-1
, respectively. 
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Amendment with all specific terminal electron acceptors without N2 flushing was 
observed to result in effective removal of DOC, with the most rapid removal being 
observed in nitrate amended test vessels.  Measured concentrations of DOC on Day 0 
for test vessels amended with carbonate, nitrate and sulfate in combination with 
nitrogen gas flushing were 380, 285 and 331 mg L
-1
, respectively.  Measured 
concentrations on Day 21 for test vessels amended with carbonate, nitrate and sulfate in 
combination with nitrogen gas flushing were 99, 54 and 74 mg L
-1
, respectively. 
 
Following this evaluation, it was considered that chemical amendment with carbonate, 
nitrate and sulfate was effective for the control of redox conditions in sewage sludge 
inoculum.  Regular measurement of Eh and specific terminal electron acceptors was 
found to be important to maintain constant conditions, and a period of acclimatisation to 
redox conditions was considered necessary (7 days).  It was also considered that the use 
of N2 was ineffective for the promoting biodegradation under redox-controlled 
conditions.  N2 flushing was therefore omitted from all further experiments, and the 
experimental set-up shown in Figure 2.2 was used throughout. 
 
4.4 Evaluation of Eh, DOC and TEA removal in redox-controlled 
anaerobic sludge with added PEG 400 
As shown in Sections 4.2.2 and 4.3, evaluation of Eh and the removal of DOC, without 
the addition of organic chemicals, showed that chemical amendment with carbonate, 
nitrate and sulfate was an effective tool for controlling the redox conditions of 3.0 g L
-1
 
anaerobic digester sludge.  However, further evaluation of the redox-controlled system 
was required following the addition of a degradable organic compound before initiating 
biodegradability experiments with pharmaceuticals.  Polyethylene glycols (PEG) are 
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non-ionic water-soluble polymers widely used in the chemical industry, and they have 
been widely studied in biodegradation experiments (Huang et al., 2005).  Consequently, 
the low molecular weight PEG 400 is often used as a control in biodegradability 
experiments.   
 
Operational parameters were evaluated in 3.0 g L
-1
 sludge inoculum amended with 
Na2CO3, NaNO3 and Na2SO4 at an initial concentration of 1.0 g L
-1
.  No additional 
electron acceptors were added to the dilution medium within control test vessels.  
Following acclimatisation of test vessels to specific terminal electron acceptors over 7 
days, PEG 400 was added at a final concentration of concentration of 50 mg L
-1 
as 
carbon.  Test vessels used were as shown in Figure 2.2.  Test vessels contained 1.0 L of 
a mixture of anaerobic digester and secondary sludge blended together in a ratio of 4:1 
v/v and diluted to give a total sludge solids concentration of 3.0 g L
-1
 in reduced 
anaerobic dilution medium prepared as described in Section 2.4.2.1.  Test vessels were 
maintained at 35 ± 1°C in a water bath and were stirred throughout.  Regular 
measurements of Eh, DOC and specific terminal electron acceptors were made 
throughout.  The results obtained from these measurements are summarised in Figures 
4.10 and 4.11.  Eh measurements are represented using boxplot diagrams depicting the 
smallest, lower quartile, median, upper quartile and largest observations. 
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Figure 4.10 Distribution of Eh measurements in redox-controlled anaerobic sludge 
with added PEG 400. 
 
Redox conditions were adjusted to regions of carbonate, nitrate and sulfate utilisation as 
described by Brezonik & Arnold (2011) through the addition of 1.0 g L
-1
 Na2CO3, 
NaNO3 and Na2SO4, respectively.  Removal of DOC was observed for all treatments 
during the 21-day experimental period, with the greatest removal of DOC being 
measured in carbonate amended test vessels.  DOC measurements for secondary and 
anaerobic digester sludges made upon collection were 1.73 g L
-1
 and 3.02 g L
-1
 
respectively.  Measured concentrations of DOC on Day 0 and Day 21 for carbonate 
amended test vessels were 198 and 94 mg L
-1
, respectively.  Measured concentrations of 
DOC on Day 0 and Day 21 for nitrate amended test vessels were 117 and 52 mg L
-1
, 
respectively.  Measured concentrations of DOC on Day 0 and Day 21 for sulfate 
amended test vessels were 116 and 33 mg L
-1
, respectively.  
 
However, DOC remained highest within carbonate amended test vessels at the end of 
the experimental period.  It is considered that all of the inorganic carbon present within 
solution may not have been completely driven off resulting in falsely high readings and 
an apparently lower removal of DOC.   
sulfatenitratecarbonatecontrol
400
300
200
100
0
-100
-200
-300
-400
Redox amendment
E
h
 (
m
V
)
 150 
 
 
Figure 4.11 Measurements showing (a) DOC concentrations, and (b) TEA 
concentrations over time in redox-controlled sludge spiked with PEG 400.   
 
Carbonate, nitrate and sulfate were removed in the presence of PEG 400, but at a lower 
rate than previously measured in test vessels amended with Na2CO3, NaNO3 and 
Na2SO4.  As with previous experiments, it is considered that the limiting factor which 
prevented further removal of TEAs by dissimilatory nitrate and sulfate reduction was 
the availability of organic carbon as an electron donor. 
 
Overall the addition of Na2CO3, NaNO3 and Na2SO4 to sludge inoculum spiked with 
PEG 400 resulted in acceptable shifts in redox potential and in the effective removal of 
DOC and TEAs.  This method was therefore considered suitable for redox amendment 
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in further experiments.  The behaviour of selected pharmaceuticals within anaerobic 
digester sludge under redox-controlled conditions using Na2CO3, NaNO3 and Na2SO4 is 
presented in the next chapter.  
 
4.5 Discussion    
The objective of this chapter was to develop methodology for the study of 
pharmaceuticals under redox-controlled conditions to investigate the hypothesis that 
pharmaceuticals present within the biosolids will be removed at varying rates and to 
varying extents under different redox conditions.   
 
Differing pathways of microbial degradation have been recognised for organic 
compounds under different redox conditions (Foght, 2008).  Different methodologies 
have been proposed to compartmentalise the redox environment, and evaluate behaviour 
within distinct regions, particularly for the purpose of bioremediating soils and 
sediments contaminated with petrochemicals, explosives, and halogenated compounds 
such as organochlorines (McMahon & Chapelle, 2008; Borch et al., 2010).  
Comparatively fewer studies have been performed to evaluate the removal of 
pharmaceutical compounds under redox-controlled conditions (Barbieri et al., 2011).  
Methods previously described for the study of biodegradation using various terminal 
electron acceptors include direct supplementation of the terminal electron acceptor 
through the addition of chemical reagents, the use of inhibitors to eliminate activity by 
specific microbial groups, and the creation of aerobic, anoxic and anerobic zones 
through N2 flushing (Crawford et al., 2000; Lahti et al., 2011; Zhuang et al., 2012).  
 The use of gas to flush the headspace of test vessels resulted in poised redox values 
within different regions of the Eh scale.  However, the use of gas to flush the headspace 
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of test vessels resulted in the removal of DOC removal under aerobic conditions only.  
In Section 4.2.2, increased DOC was observed in test vessels flushed with N2 due to the 
removal of sludge solids from the system.  It is considered that the observed increase in 
DOC in test vessels amended with specific terminal electron acceptors in combination 
with N2 flushing may also be due to the removal of sludge solids from the system.  This 
cannot, however, be confirmed as sludge solids measurements were not made. 
   
Stimulation of carbonate-, nitrate-, and sulfate-reducing conditions through the addition 
of nitrate, sulfate and carbonate without the use of gas to flush the headspace resulted in 
poised Eh values in the region of +200, -200 and -200 mV, respectively.  Multiple 
additions of nitrate were considered necessary to maintain stable Eh within nitrate-
reducing conditions, particularly when carbon was most abundant.  These findings are 
in agreement with previous research (Graetz et al., 1973; Zhuang et al., 2012).  Eh 
measurements are in agreement with the regions of nitrate, sulfate and carbonate 
utilisation as described in Brezonik & Arnold (2011), although differing slightly from 
those described by Atlas & Bartha (1993).  This highlights that while the order of 
electron acceptor utilisation is consistent, differences in Eh values for their use exist 
within the literature, and a comparison of values from different sources may be useful to 
give an understanding of the expected range.  Factors such as pH are known to influence 
redox potential, and may result in differences in values (Husson, 2013).   
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CHAPTER 5  
 
 
BEHAVIOUR OF SELECTED PHARMACEUTICALS UNDER 
REDOX-CONTROLLED CONDITIONS 
 
The biodegradability of organic compounds has been shown to vary considerably under 
different redox conditions, and redox processes are considered to offer potential for the 
removal of various types of contaminants within the environment (Borch et al., 2010).  
Dehalogenation has been demonstrated under nitrate-, sulfide-reducing and 
methanogenic conditions as a first step in the complete reduction of chlorinated 
hydrocarbons and more recently perfluorinated compounds (Milligan & Häggblom, 
2001; Parsons et al., 2008).  Sulfide-reducing and methanogenic conditions prevail 
within anaerobic sludge, therefore this mechanism may offer potential for the removal 
of fluorinated pharmaceuticals such as fluoxetine.      
 
It was hypothesised that pharmaceuticals present within the biosolids would be removed 
at varying rates and to varying extents under different redox conditions.  In Chapter 4 
the use of chemical reagents was identified as the most suitable method for the control 
of redox conditions, because it was shown to result in an environment in which organic 
carbon could be utilised as a substrate for growth.  In this chapter the method was 
applied to study the behaviour of pharmaceuticals under redox-controlled conditions. 
 
Three test substances were investigated under redox-controlled conditions: naproxen; 
propranolol; and fluoxetine.  These test substances were selected for further 
investigation because they displayed removal through different mechanisms in closed 
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bottle experiments presented in Chapter 3, with biodegradation shown to be the main 
removal mechanism for naproxen, and adsorption shown to be the main removal 
mechanism for propranolol and fluoxetine.  It was considered that this would 
demonstrate whether redox amendment had any influence upon removal through both 
mechanisms. 
 
5.1 Behaviour of naproxen under redox-controlled conditions 
In order to determine whether removal of the non steroidal anti-inflammatory 
pharmaceutical naproxen was influenced by redox conditions, behaviour was evaluated 
in redox amended sludge.  Regular measurements of redox, DOC and specific terminal 
electron acceptors were made throughout, in addition to investigating the influence of 
adding a degradable carbon substrate (2.0 mL MeOH) on Day 21.  The results obtained 
from these measurements are shown in Figure 5.1. 
 
Redox conditions were adjusted to similar regions of the Eh scale for CO2, NO3
-
 and 
SO4
2-
 utilisation as described by Brezonik & Arnold (2011) following the addition of 
chemical reagents (Figure 5.1a).  Patterns of DOC and TEA removal showed similar 
initial trends in the presence of naproxen to those observed when no pharmaceuticals 
were present (Figures 5.1b and 5.1c).  However, the addition of a readily degradable 
carbon source (MeOH) on Day 21 resulted in a spike in DOC accompanied by an 
increase in nitrate and sulfate utilisation.  This demonstrated that the MeOH was utilised 
quickly, and provided an electron donor for use by nitrate and sulfate reducing bacteria.   
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Figure 5.1 Measurements of (a) Eh, (b) DOC and (c) specific terminal electron 
acceptors over time in sewage sludge containing naproxen under redox-controlled 
conditions following the addition of carbonate, nitrate and sulfate. 
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Regular measurements of naproxen were made throughout in the aqueous phase by 
HPLC with detection using photo diode array.  The results obtained from these 
measurements are shown in Figure 5.2.  One way ANOVA was performed to identify 
significant differences in measured parameters between treatments.  Significant 
differences were found in measured concentration of naproxen between treatments 
(p = 0.001).  Removal was found lowest in nitrate amended test vessels (26%) and 
highest in sulfate and control vessels 97.6% and 100% respectively. 
 
Figure 5.2 Naproxen removal over time in sewage sludge under redox-
controlled conditions following the addition of carbonate, nitrate and sulfate. 
 
To investigate subsequent impacts upon test substance removal due to acclimation and 
the carbon availability 2.0 mL of 1,000 mg L
-1
 naproxen was added to control vessels, 
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addition of test substance to control vessels the rate of test substance removal increased 
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the rate of test substance removal in carbon dioxide and nitrate amended test vessels 
was unaffected by the presence of an additional carbon source.    
 
 The formation of an unknown degradation product with a retention time of 6.3 mins 
was observed, while the retention time of the parent compound was observed to be 7.5 
mins throughout.  The formation of this degradation product over time was plotted by 
measuring the area under the peak, and is shown in Figure 5.3.  Increasing 
concentrations were observed in all control, carbon dioxide and sulfate amended test 
vessels from Day 4 onwards, and approximately doubled following the addition of a 
second dose of test compound to control vessels. The UV absorption of both 
compounds was shown to be very close indicating structural similarity, with the λmax for 
naproxen being 232 nm and the λmax for the unknown compound being 231 nm. 
 
Figure 5.3 Relative peak area (μV s-1) of transformation product formed 
through the degradation of naproxen in sewage sludge under redox-controlled 
conditions following the addition of carbonate, nitrate and sulfate. 
 
Available literature detailing the biotransformation of naproxen within the environment 
was obtained, and LC-MS analysis of selected samples was performed to determine 
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analytical column (3.5 μm particle size) at a flow rate of 500 μL min-1 and an injection 
volume of 2.0 μ .  Gradient conditions were 100%  H2O + 0.1% formic acid v/v , then 
MeOH was raised to 100% over 4 min and held constant for 1.5 min.  Re-equilibration 
time was 1.5 min.    Detection was performed using Thermo Finnigan LTQ ion trap mass 
spectrometer.  The MS was operated in the full-scan EI mode.  The mass range was 100-
1000 amu with 0.5 s scan time.  All data were processed with the use of an Excalibur 
data system.   
 
Figure 5.4   LC-MS chromatograms obtained in full-scan (-ve) ionisation 
showing (a) degradation product with m/z corresponding to 6-O-
desmethylnaproxen, and (b) naproxen.   
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The formation of the stable metabolite 6-O-desmethylnaproxen (m/z = 216.24) 
following the microbial transformation of naproxen under aerobic and anaerobic 
conditions has been reported previously (Quintana et al., 2005; Lahti & Oikari, 2011).  
In the current experiment, LC-MS analysis of samples identified a peak corresponding 
to this mass in control, carbonate and sulfate amended test vessels.  An example of this 
analysis is shown in Figure 5.4.  The results obtained from this experiment suggest that 
this biotransformation did not take place under nitrate-reducing conditions.  For further 
identification of this transformation product through characterisation of its 
fragmentation pattern in MS
n
 experiments, analytical standards were required.  These 
experiments were not performed in the current study.   
      
5.2 Behaviour of propranolol under redox-controlled conditions 
 he removal of the β-blocker propranolol was evaluated in sludge amended through the 
addition of Na2CO3, NaNO3 and Na2SO4 at an initial concentration of 1.0 g L
-1
.  Regular 
measurements of redox, and specific terminal electron acceptors (TEA) were made 
throughout the experiment.  Following the addition of chemical reagents, redox 
conditions were adjusted to similar regions of the Eh scale for CO2, NO3
-
 and SO4
2-
 
utilisation as described by Brezonik & Arnold (2011), and patterns of TEA removal 
were similar to those previously observed.  Regular measurements of total sludge solids 
and DOC were made throughout the experiment, and are shown in Figure 5.4.   
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Figure 5.5 Removal of (a) total sludge solids, and (b) DOC over time in sewage 
sludge containing propranolol under redox-controlled conditions following the 
additon of carbonate, nitrate and sulfate. 
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measured parameters between treatments.   Significant differences (p = 0.010) were 
identified in the concentration of sludge solids between treatments, with the mean 
sludge solids concentration being lowest overall in control test vessels (1,895 mg L
-1
) 
and highest in nitrate amended test vessels (2,400 mg L
-1
).   Regular measurements of 
propranolol made throughout the experiment within both the aqueous and sludge phases 
are shown below in Figure 5.6.     
 
Figure 5.6  Stacked barchart showing partitioning of propranolol between 
aqueous and sludge phases over time under redox-controlled conditions following 
the additon of carbonate, nitrate and sulfate. 
 
The removal of propranolol in redox-controlled sludge is in close agreement with the 
removal of propranolol in closed bottle and adsorption experiments, with approximately 
60% remaining within the sludge phase.  The partitioning coefficient (Kd) was 
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3.7.  Kd was found to be significantly different between redox conditions (p = 0.022), 
with mean Kd being lowest in nitrate amended test vessels and highest in carbonate 
amended test vessels.  As shown in Table 5.1, there was no removal of propranolol 
under redox-controlled conditions based on mass balance.  
 
Table 5.1 Removal of propranolol under redox-controlled conditions based upon 
mass balance 
Day Aqueous  
(mg L
-1
) 
Sludge  
(mg kg
-1
) 
Solids  
(mg L
-1
) 
(%) Removal  Kd  
(L kg 
-1
) 
0 
Control 
Carbonate 
Nitrate 
Sulfate 
 
1.26 
0.84 
1.35 
1.17 
 
1,160 
1,446 
927 
1,741 
 
1,900 
1,789 
2,360 
895 
 
-24 
-28 
-41 
-16 
 
925 
1,906 
741 
1,494 
7 
Control 
Carbonate 
Nitrate 
Sulfate 
 
1.28 
1.13 
1.49 
1.15 
 
649 
749 
648 
514 
 
1,816 
2,394 
2,613 
3,052 
 
-6 
-14 
-27 
-15 
 
509 
682 
432 
450 
14 
Control 
Carbonate 
Nitrate 
Sulfate 
 
1.29 
1.30 
1.78 
1.40 
 
1,181 
1,216 
1,035 
1,043 
 
1,949 
2,012 
2,401 
2,359 
 
-35 
-44 
-39 
-40 
 
673 
884 
393 
489 
20 
Control 
Carbonate 
Nitrate 
Sulfate 
 
1.37 
1.14 
1.39 
1.26 
 
1,164 
1,287 
1,403 
1,167 
 
1,900 
2,056 
2,047 
2,200 
 
-16 
1 
-13 
-8 
 
539 
618 
569 
457 
 
5.3 Behaviour of fluoxetine under redox-controlled conditions 
The removal of the selective serotonin reuptake inhibitor fluoxetine was evaluated in 
sludge amended through the addition of Na2CO3, NaNO3 and Na2SO4 at an initial 
concentration of 1.0 g L
-1
.  Regular measurements of redox, and specific terminal 
electron acceptors (TEA) were made throughout the experiment and resulted in poised 
redox conditions within the relevant areas of the Eh scale and patterns of TEA removal 
similar to those previously observed.   
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Regular measurements of DOC and total sludge solids were also made throughout and 
are shown in Figure 5.7.  DOC did not change considerably during the experimental 
period, except for in carbonate amended test vessels where a 50% reduction was 
observed during the second half of the experiment.  The total sludge solids 
concentration also did not change considerably during the experimental period.  One 
way ANOVA was performed to identify significant differences in measured parameters, 
however no significant differences between treatments were identified.  
 
 
Figure 5.7 Measurements of (a) total sludge solids, and (b) DOC over time in 
sewage sludge containing fluoxetine under redox-controlled conditions following 
the additon of carbonate, nitrate and sulfate. 
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Figure 5.8   Stacked bar chart showing partitioning of fluoxetine between 
aqueous and sludge phases in redox amended sludge inoculum. 
 
Table 5.2 Removal of fluoxetine under redox-controlled conditions based upon 
mass balance 
Day Aqueous  
(mg L
-1
) 
Sludge  
(mg kg
-1
) 
Solids  
(mg L
-1
) 
(%) Removal  
 
Kd  
(L kg
-1
) 
0 
Control 
Carbonate 
Nitrate 
Sulfate 
 
0.30 
0.21 
0.23 
0.25 
 
729 
949 
794 
720 
 
2,556 
2,515 
2,712 
2,389 
 
-6.8 
-19.2 
-6.8 
-16.8 
 
2,430 
4,519 
3,452 
2,880 
7 
Control 
Carbonate 
Nitrate 
Sulfate 
 
0.34 
0.37 
0.42 
0.39 
 
584 
734 
722 
828 
 
1,902 
2,339 
2,429 
2,167 
 
29.2 
27.2 
47.2 
8.4 
 
1,718 
1,984 
1,719 
2,070 
14 
Control 
Carbonate 
Nitrate 
Sulfate 
 
0.29 
0.33 
0.42 
0.39 
 
735 
741 
1,738 
697 
 
2,282 
2,372 
1,784 
2,494 
 
22.4 
28.0 
34.4 
15.2 
 
2,534 
2,245 
4,138 
2,112 
20 
Control 
Carbonate 
Nitrate 
Sulfate 
 
0.13 
0.12 
0.16 
0.36 
 
705 
629 
627 
337 
 
2,230 
2,147 
2,329 
2,260 
 
29.2 
32.0 
48.4 
26.4 
 
5,423 
5,242 
3,919 
936 
As shown in Table 5.2, there was some removal of fluoxetine under redox-controlled 
conditions based on mass balance, but this was not significantly different between 
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treatments.  This removal may have been due to biodegradation, however, it is 
considered that it may be largely accounted for by loss of analyte during extraction from 
the biosolids. 
 
The partitioning of fluoxetine under redox-controlled conditions is in close agreement 
with the removal of fluoxetine in closed bottle and adsorption experiments.  Analysis of 
variance showed no significant differences in the measured concentration of fluoxetine 
in the aqueous or sludge phases, or in the Kd values between treatments.  On Day 0, 
aqueous concentrations of fluoxetine in control, carbonate-, nitrate- and sulfate-
amended test vessels measured 0.30, 0.21, 0.23 and 0.25 mg L
-1
, respectively.  On Day 
21 aqueous concentrations of fluoxetine in control, carbonate-, nitrate and sulfate-
amended test vessels measured 0.13, 0.12, 0.16 and 0.36 mg L
-1
, respectively.  Analysis 
of variance showed no significant difference in aqueous concentrations between 
treatments.   
 
On Day 0, concentrations of fluoxetine within the sludge phase in control, carbonate-, 
nitrate- and sulfate-amended test vessels measured 917, 1.107, 906 and 1.103 mg kg
-1
, 
respectively.  Kd values were 3,057, 5.269, 3.937 and 4.412 L kg 
-1
, respectively.  On 
Day 21, concentrations of fluoxetine within the sludge phase in control, carbonate-, 
nitrate- and sulfate-amended test vessels measured 750, 719, 492 and 691 mg kg
-1
, 
respectively.  Kd values were 5,772, 5,993, 3,075 and 1,919 L kg 
-1
 respectively.  
Analysis of variance showed a significant difference (p = 0.010) in the overall 
concentration of fluoxetine within the biosolids over time.  This is indicative that either 
primary biodegradation or irreversible binding to the biosolids took place during the 
experiment resulting in incomplete recovery of the analyte, however, no further 
investigation was performed to determine removal mechanism within the sludge phase.    
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5.4 Behaviour of propranolol in closed bottles under redox-
controlled conditions 
In order to determine whether the redox shifts observed in batch experiments following 
the addition of Na2CO3, NaNO3 and Na2SO4 at an initial concentration of 1.0 g L
-1
 
could be replicated in closed bottle experiments, the behaviour of the β-blocker 
propranolol was evaluated in redox amended sludge inoculum in 160 mL serum bottles 
at a concentration of 50 mg L
-1 
as carbon.    Redox measurements and measurements of 
propranolol within the aqueous phase were performed at the end of the 60-day 
experimental period.  Redox measurements and total removal of propranolol following 
the addition of carbonate, nitrate and sulfate are shown in Table 5.3.  
Table 5.3 Eh and total removal of propranolol in closed bottles under redox-
controlled conditions 
Redox Amendment Eh (mV) after 60 Days Total Removal of Propranolol (%) 
Control -172 70.9 
Carbonate -257 68.3 
Nitrate 15.8 50.3 
Sulfate -235 63.2 
 
After 60 days, redox measurements in closed bottles adjusted through the addition of 
1.0 g L
-1
 Na2CO3, NaNO3 and Na2SO4 were in the regions of carbonate, nitrate and 
sulfate utilisation, respectively as described by Brezonik & Arnold (2011).  The removal 
of propranolol over 60-days in redox-controlled closed bottles was in close agreement 
with observed removal in all other experiments.  These results show that the redox-
controlled conditions observed in larger test vessels may be replicated in closed bottle 
experiments, providing a valuable tool for the investigation of multiple redox 
conditions. 
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5.5 Discussion 
The objective of this chapter was to study the behaviour of selected pharmaceuticals 
using the methodology developed in Chapter 4 to investigate the hypothesis that 
pharmaceuticals present within the biosolids will be removed at varying rates and to 
varying extents under redox-controlled conditions.  The behaviour of three 
pharmaceuticals were chosen for investigation under redox-controlled conditions: the 
non-steroidal anti-inflammatory drug naproxen; the β-blocker propranolol; and the 
selective serotonin reuptake inhibitor fluoxetine. 
 
In Chapter 3 naproxen was shown to be removed due to primary biodegradation under 
anaerobic conditions.  Changes in the availability of terminal electron acceptors has 
previously been reported to exert potent biological responses by causing shifts in 
substrate availability to the microbial population (Crawford et al., 2000; Barbieri et al., 
2011).  Evaluation of this pharmaceutical under redox-controlled conditions 
demonstrated that changes in the redox conditions resulted in a change in the extent of 
biotransformation.  Overall, removal was greatest in control test vessels with a lower 
rate of removal in test vessels receiving carbonate and sulfate, and no change being 
observed in nitrate amended test vessels.   These findings suggest that unamended 
sludge containing mineral medium with nutrients balanced for a mixed anaerobic 
consortium provides the more favourable conditions for the biotransformation of 
naproxen, than sludge amended to promote the activity of specific microbial groups.  
This observation is supported by Boopathy and Peters (2001), who reported removal of 
trichloroethylene under several different redox conditions, with optimal removal taking 
place under mixed electron acceptor conditions in the presence of a heterogeneous 
microbial population.  Increased removal was observed following acclimation to the test 
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substance, and also following the addition of readily degradable organic carbon to 
sulfate reducing test vessels which is indicative of cometabolism within the system 
(Horvath, 1972).   
 
The complete biotransformation of naproxen has previously been observed in aerobic 
and anaerobic environments, with 6-O-desmethylnaproxen being confirmed as a stable 
metabolite under both conditions (Quintana et al., 2005; Lahti & Oikari, 2011).  The 
current study demonstrated biotransformation of naproxen and showed the presence of 
an ion with a m/z which corresponded to the previously identified metabolite 
6-O-desmethylnaproxen under control, carbonate and sulfate amended conditions but 
not under nitrate amended conditions.   
 
Results from Chapter 3 have demonstrated that under anaerobic conditions the removal 
of propranolol and fluoxetine is mainly due to adsorption.  Redox amendment had 
virtually no effect upon the removal of fluoxetine, and only minor influences were 
observed on the removal of propranolol.  Measured Kd values for fluoxetine were in 
agreement with literature values shown in Table 3.7, with no significant differences 
found in Kd between treatments.  Kd values for propranolol were slightly higher than the 
values shown in Table 3.7, which may be due to the nature of the experiment.  Due to 
its lipophilicity, adsorption is a more significant removal mechanism for propranolol 
within batch systems than during wastewater treatment (Maurer et al., 2007).  
Significant differences (p = 0.022) were found in the measured Kd for propranolol 
between treatments, with the highest Kd being measured in carbonate-amended test 
vessels which contained higher concentrations of DOC than all other treatments.  
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CHAPTER 6  
GENERAL DISCUSSION 
 
6.1    Environmental risk assessment & removal of pharmaceuticals 
during wastewater and sludge treatment processes  
Due to an ageing global population and improvements in healthcare provisions, the 
increased discharge of pharmaceuticals into municipal sewerage systems is likely to 
continue (Jones et al., 2005).  From the literature it can be seen that an accurate 
evaluation of how pharmaceuticals behave once they have been excreted from the 
human body is critical for the wellbeing of the environment.  Behaviour during 
wastewater and sludge treatment processes forms a critical component of this evaluation 
because these processes not only help to remove accumulations of nutrients and 
pathogens, but also offer the potential to reduce the concentration of micropollutants 
such as pharmaceuticals which have been found to result in devastating effects upon the 
wildlife population.    
 
In order to minimise any potential environmental impact it is important to assess fate 
and removal within sewage treatment plants, which for many compounds results in 
concentration within the sludge solids that undergo stabilisation through anaerobic 
digestion before disposal.  Sludge treatment processes are of particular interest because 
they offer a final opportunity for the removal of persistent and adsorptive compounds 
before the disposal of treated biosolids, with anaerobic digestion being a popular choice 
due to the reduction in the volume of biosolids during the process and also because of 
the potential for the production of renewable energy.  A significant reduction of many 
pharmaceuticals and personal care products within the aqueous environment through 
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biodegradation has been reported, but it is considered that the biodegradation of 
adsorptive pharmaceuticals in sewage sludge during anaerobic digestion is unlikely 
(Ternes et al., 2004).  Consequently, anaerobic biodegradation within sewage sludge is 
not included within the current environmental risk assessment, with evaluation of 
anaerobic biodegradability being performed only in sediment.   
 
The current guidance followed in Europe for the assessment of environmental risk was 
driven by EC Directive 93/39/EEC which implemented ERA as part of the marketing 
authorization procedure for all new pharmaceuticals (European Union, 1993).  The 
original guideline issued in 1995 required broad information regarding any potential 
risks which a substance may present to the environment.  However, there have been 
several modifications to these requirements since the issue of this original document.  
Major changes include the introduction of fish bioaccumulation tests where Kow > 1000, 
and water-sediment studies to determine the distribution of a substance within the 
aquatic environment where Koc (sludge) > 10,000, followed by toxological studies on 
sediment dwelling organisms e.g., chironomid if significant migration is demonstrated 
to the sediment compartment (Laenge et al., 2006).   
 
Throughout this process the pharmaceutical industry has sought to work with regulatory 
bodies to develop tailored testing approaches that are substance-specific.  This ensures 
that resources are directed where they are most needed, and that testing is concentrated 
around pharmaceuticals that present a real risk to the environment in the areas where 
they are most likely to be found.  The principal aim of this work was to investigate the 
potential that anaerobic digestion offered for the removal of pharmaceuticals within the 
biosolids to identify if the current assumption within the environmental risk assessment 
regarding the behaviour of adsorptive pharmaceuticals is realistic.     
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6.2 Behaviour of selected pharmaceuticals in anaerobic digester 
sludge 
A number of pharmaceuticals were identified for study within anaerobic digester sludge.  
The pharmaceuticals selected were within the highly prescribed therapeutic areas of 
cardiovascular, gastrointestinal, anti-diabetes and central nervous system.   The test 
substances evaluated represented acidic and basic molecules from a number of 
therapeutic areas.  Although they represent a high proportion of the pharmaceuticals 
detected within the biosolids, antibiotics were not investigated during this project due to 
concerns over inhibitory effects on the microbial population within anaerobic sludge 
(Gartiser et al., 2007).  Environmental monitoring studies have, however, demonstrated 
the presence of high concentrations of antibiotics within the biosolids (Table 1.5), and 
there is significant evidence to confirm their effects within the environment (Kümmerer, 
2009a).  Further work into biodegradability and inhibition of antibiotics in anaerobic 
sewage sludge is therefore recommended.     
 
A considerable amount of information about the processes of adsorption and 
biodegradation in relation to organic compounds are known, which has been used to 
compile databases and predictive tools (Wackett & Ellis, 1999).  The test substances 
evaluated were selected based upon measured concentrations within the biosolids, and 
also their predicted biodegradability under anaerobic conditions using the BIOWIN7 
within EPISuite™.  BIOWIN7 calculates the probability of biodegradation based on 
structural fragments (U.S. EPA, 2012).  As discussed in Chapter 3, predictive tools 
based upon biotransformation rules provide a useful first-line screening tool when 
evaluating the behaviour of a large number of compounds.  However, predicted 
biodegradability values were shown to be more accurate for test substances within the 
aqueous phase than for test substances associated with the biosolids.  Substance 
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bioavailability is dependent upon the sorptive properties of the respective compound 
and the organic matter, and has previously been shown to limit the biodegradation of 
micropollutants in sewage sludge (Jjemba, 2002).  For a more accurate prediction of 
biodegradability for adsorptive compounds in sewage sludge, tools should be used that 
predict substance bioavailability by estimating the concentration of contaminants 
through the different separation steps encountered during sewage treatment (Barret et 
al., 2010a). 
 
The presence of hydrophilic pharmaceuticals within the biosolids, such as metformin, is 
largely owing to extremely high frequency of use.  For more adsorptive 
pharmaceuticals, such as fluoxetine, presence within the biosolids is due to chemical 
structure, and more specifically the presence of electronegative fluorine which causes 
strong interactions with surfaces, and also makes them less susceptible to substitution 
and oxidation (Samiullah, 1990).  At 50 mg C L
-1
, the hydrophilic substances salicylic 
acid and metformin were removed by 93 and 82%, respectively due to mineralisation, 
while propranolol, fluoxetine and paroxetine (Kd > 300 L kg 
-1
) were removed by 55, 92 
and 96%, respectively due to adsorption.  The other test substances evaluated were 
shown to be removed to varying extents through a combination of mineralisation and 
primary biodegradation.  These results demonstrate how the removal processes of 
biodegradation and adsorption depend upon the physicochemical properties of the 
substance being investigated (Ternes et al., 2004). 
 
The pharmaceuticals evaluated were removed to varying extents under anaerobic 
conditions.  It is recognised that increased removal of contaminants may be achieved by 
modifying environmental conditions such as redox potential to promote the activity of 
specific microbial groups.  The process of anaerobic respiration includes microbial 
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populations that utilise different terminal electron acceptors, and that operate under 
different redox conditions.  The influence of redox processes has been investigated with 
respect to a number of contaminants including petroleum hydrocarbons, and has more 
recently been identified to contribute to the removal of emerging contaminants such as 
pharmaceuticals (McMahon & Chapelle, 2008; Borch et al., 2010; Ivanov et al., 2010).     
 
6.3 Amendment of redox potential within anaerobic digester 
sludge 
A secondary aim which was to evaluate the behaviour of the selected  pharmaceuticals 
under redox-controlled conditions to investigate the hypothesis that pharmaceuticals 
present within the biosolids will be removed at varying rates and to varying extents 
under different redox conditions.  The wastewater environment varies from aerobic to 
anaerobic, providing a range of habitats for use by different groups of microorganisms.  
Some species may be specialized for the utilisation of particular substances, and through 
the provision of specific conditions these groups may flourish thus promoting substance 
depletion.   
 
Different methodologies have been proposed to compartmentalise the redox 
environment for the purpose of bioremediating soils and sediments contaminated with 
petrochemicals, explosives, and halogenated compounds such as organochlorines 
(McMahon & Chapelle, 2008; Borch et al., 2010).  The study of distinct redox 
environments allows the effects of discrete groups of microorganisms within anaerobic 
respiration to be studied.  This methodology can be modified in many ways to gain 
significant understanding of how these microorganisms function, and also offers many 
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possibilities to exploit the specific properties of these organisms for the removal of 
environmental pollutants (Barbieri et al., 2011).  
 
Chapter 4 describes several experiments that were performed to ensure the stability of 
the system under nitrate, sulfate and carbonate amended conditions over a period of 
time before beginning biodegradability experiments.  The addition of nitrate, sulfate and 
carbonate were found to result in poised Eh values in the region of +200, -200 and -
200 mV, respectively which are within accepted ranges.  The removal of DOC was 
evaluated to indicate the presence of bacteria capable of using trace organics as an 
energy source.  Under nitrate, sulfate and carbonate amended conditions, 81, 78 and 
74% removal of DOC was shown, respectively.  A number of different redox conditions 
may have to be promoted in order to identify specific conditions that are favourable for 
contaminant removal.  However, the addition of chemical reagents containing these 
specific terminal electron acceptors was found to be successful for controlling redox 
conditions in batch vessels and also closed bottle experiments, which offers potential for 
the simultaneous evaluation of several electron acceptors. 
 
While the current set of experiments demonstrated that chemical addition with nitrate, 
sulfate and carbonate resulted in poised Eh values in the desired regions of electron 
acceptor utilisation. It was noted that there was some disparity between Eh values 
quoted within the literature for terminal electron acceptor utilisation (Atlas & Bartha, 
1993; Brezonik & Arnold, 2011).  It is considered that literature values often relate to 
soils with respect to biogeochemical cycling, and Eh is known to vary due to factors 
such as water, pH and agricultural practices (Husson, 2013).  Values should not, 
therefore, be considered absolute, and a comparison of values from different sources to 
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give an understanding of the expected range for each terminal electron acceptor is 
recommended. 
 
6.4 Behaviour of selected pharmaceuticals within sewage sludge 
under redox-controlled conditions 
In Chapter 3 it was demonstrated that a set of selected pharmaceuticals were effectively 
removed to varying extent under anaerobic conditions in sewage sludge inoculum 
through either biodegradation or adsorption dependent on physicochemical properties.  
It is known that the nature of sewage sludge is dynamic, and changes in terms of ion 
concentration, redox conditions and organic carbon content throughout the sewage 
treatment.  When feed sludge is fed into a batch digester volatile fatty acid (VFA) 
production stimulates changes within redox potential and terminal electron acceptor 
availability.  This type of amendment has been shown to be useful for the removal of 
persistent endocrine-disrupting substances (Ivanov et al., 2010), and results presented in 
the current study demonstrated that redox amendment resulted in changes in the extent 
of pharmaceutical removal within sewage sludge.  However, the way in which redox 
amendment influenced removal was shown to be dependent on the principal removal 
mechanism of the substance being evaluated.   
 
The altered rate of naproxen biotransformation in relation to redox amendment is an 
example of how redox amendment influences biological processes through terminal 
electron acceptor availability.  The current study demonstrated biotransformation of 
naproxen and showed the presence of an ion with a m/z which corresponded to the 
previously identified metabolite 6-O-desmethylnaproxen under control, carbonate and 
sulfate amended conditions but not under nitrate amended conditions (Quintana et al., 
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2005; Lahti & Oikari, 2011).  More effective degradation was observed in the presence 
of mixed electron acceptors that support a diverse consortium of anaerobic 
microorganisms with diverse metabolic and physiological characteristics, rather than a 
specific terminal electron acceptor that favours a specific group of microorganisms.  
Effective removal in the presence of mixed electron acceptors has been similarly 
demonstrated for biotransformation in soil (Boopathy & Peters, 2001; Boopathy, 2002; 
Zhuang et al., 2012).   
 
Redox amendment was observed to have much less influence upon adsorption, with few 
diferences observed in the removal of propranolol and fluoxetine between treatments.  
Some differences were found in the Kd values measured for propranolol under redox-
amended conditions, which may be related with increased organic carbon content in 
carbonate amended test vessels.  However, it may also be related to redox conditions as 
test substances have been found to be more recalcitrant under low redox conditions in 
constructed wetland environments (Matamoros & Bayona, 2006).  There was some 
indication that removal of fluoxetine took place under redox-controlled conditions, 
which may have been attributable to biodegradation, but may also have been fully or 
partially attributable to losses during sludge extraction procedures.  Norfluoxetine has 
been identified following the treatment of sewage sludge containg fluoxetine under 
aerobic conditions, but not under anaerobic conditions (Vasskog et al., 2009; Bergersen 
et al., 2012).  This indicates that its formation may be influenced in similar studies 
through redox amendment.    Transformation products from the degradation of 
fluoxetine were not quantified in the current study.  Future work to identify key removal 
mechanisms for fluoxetine during sludge treatment processes may be assisted through 
the use of radioisotopes (Nuck & Federle, 1996).  
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6.5 Possible implications of this work for environmental risk 
assessment 
The fate and effects of human pharmaceuticals within the environment has been of 
growing concern for a number of years, however there has been a recent focus upon the 
impact of pharmaceuticals carried within the biosolids and the risks that they present to 
both the terrestrial environment and to the aquatic environment through leaching or 
surface runoff.  Pharmaceuticals that remain within the biosolids are often adsorptive 
substances that are particularly resistant to degradation, and can maintain residual 
activity for long periods of time (Jjemba, 2002).  Particularly since application onto land 
is one of the principal routes of biosolids disposal, it is of importance that the risks are 
fully understood.  
 
For pharmaceuticals that are not readily biodegradable and have a strong affinity to 
sewage sludge (Koc (sludge) > 10,000), environmental assessment of its behaviour within 
the terrestrial environment during Phase II Tier B testing is currently required because it 
is considered likely to be diposed of through spreading onto agricultural soil (de Roode, 
2010).  Tier B assessment is conducted when predicted-environmental-concentration 
and predicted-no-effect-concentration (PEC/PNEC) ratios are found to exceed trigger 
values (1 for surface water and ground water, and 0.1 for sewage treatment plant).  
Environmental fate tests performed during this phase of testing include bioconcentration 
and/or soil degradation studies, and effects tests include toxicity studies on terrestrial 
organisms such as earthworms.   
 
Unlike their veterinary counterparts, the outcome of environmental risk assessment 
should not preclude the therapeutic use of human pharmaceuticals, but may impact upon 
product labelling, storage, and disposal (de Roode, 2010).  It remains important for the 
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human pharmaceutical industry that tests performed during environmental risk 
assessment accurately evaluate the environmental fate of all new substances, taking into 
consideration all relevant processes where substances may be significantly removed.  
The exclusion of processes that may remove pharmaceuticals may lead to the 
overestimation of concentrations within the environment and unnecessary concern. 
The industrial implication of this project is that the omission of anaerobic digestion 
from environmental risk assessment may have contributed to the overestimation of 
predicted concentrations within the terrestrial environment, and unnecessary Phase II 
Tier B testing which is both time consuming and expensive.  From the limited number 
of pharmaceuticals evaluated within this project the test substances with the strongest 
affinity to sewage sludge such as fluoxetine did not degrade under anaerobic conditions, 
but were instead removed through adsorption, and in a full-scale digester would remain 
within the biosolids upon disposal.  Previous studies have shown that fluoxetine has a 
high potential for bioaccumulation in soils and sediments, causes chronic effects to 
aquatic organisms at low concentration, and has also been shown to be taken up into the 
leaves of brassic plants (Redshaw et al., 2008; Schultz et al., 2011; Silva et al., 2012).   
 
In order to minimise any potential risk to the environment, it would be wisest to follow 
the current approach used for environmental risk assessment and assume that anaerobic 
sludge treatment is not a significant treatment process for the removal of 
pharmaceuticals that remain within the biosolids following aerobic sewage treatment 
processes.  However, further research is required in this area to evaluate the behaviour 
of further groups of pharmaceuticals such as antibiotics during anaerobic sludge 
treatment.  
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CHAPTER 7  
CONCLUSIONS 
1. Nine pharmaceuticals were selected for study on the basis of detection within the 
biosolids, predicted anaerobic biodegradability and the commercial availability of 
14
C radioisotopes.  Using a predictive tool based upon biotransformation rules, 
expected biodegradability values under anaerobic conditions were more reliable for 
smaller molecules that were in solution than for more complex molecules with 
halogen sustituents that were associated with the biosolids with limited 
bioavailability for degradation by the microbial population.    
2.  Redox conditions are known to have important impacts for the fate of 
environmental contaminants, however, this has not been researched significantly 
with respect to wastewater treatment.  A batch test system was developed which 
resulted in poised Eh values in the regions of +200, -200 and -200 mV following the 
addition of nitrate, sulfate and carbonate, respectively.  This system was found to be 
successful for the removal of organic carbon, indicating the capacity of the system 
for biodegradation, and was used to further investigate the behaviour of three 
pharmaceuticals that were shown to be removed through different mechanisms. 
3. There were significant differences (p = 0.001) in removal due to biodegradation 
between different redox conditions.  The elimination of naproxen through primary 
biodegradation was lowest in nitrate amended test vessels (26%), and highest 
(100%) in control test vessels.  In addition, a degradation product with m/z matching 
6-O-desmethylnaproxen, was observed in control, carbonate- and sulfate-amended 
test vessels, but not in nitrate-amended test vessels.   
4. There were no significant differences in abiotic removal between different redox 
conditions.  The extent of propranolol and fluoxetine removal due to adsorption did 
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not differ between redox conditions.  A significant decrease (p = 0.001) was 
observed in the Kd of propranolol over time, and significant differences (p = 0.022) 
were also observed in the Kd between redox-controlled conditions, with the lowest 
values being observed in nitrate amended test vessels, and the highest in carbonate 
amended test vessels.  Concentrations of fluoxetine within the sludge phase 
decreased significantly (p = 0.010) over time under all Eh conditions, however the 
mechanism was not identified.   
5. Overall, the findings of these experiments suggest that the current industry 
assumption that pharmaceuticals do not degrade extensively under anaerobic 
conditions is correct, and that due to limited bioavailability anaerobic digestion is 
not a significant process for the removal of adsorptive pharmaceuticals from the 
biosolids. 
6. Future work that is recommended within this area of research includes the the study 
of further compound classes under additional redox-controlled conditions, using 
14
C 
radioisotopes to assist in confirming the removal mechanisms of adsorptive 
compounds.  The quantification of known metabolites under anaerobic and redox-
amended conditions is also suggested.  
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Figure 8.1 Flow chart showing research strategy and major conclusions from the investigation of pharmaceutical behaviour in anaerobic 
and redox amended sewage sludge.
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Appendix A 
Table A-1 Human metabolism of selected pharmaceuticals 
Therapeutic Area, 
Compound & Class 
% Excretion 
of Parent Compound 
Metabolites Excreted in Urine & Faeces 
   
Cardiovascular 
β-blocker 
Propranolol  
 
 
0.5% 
 
 
32-50% naphthoxylactic acid  
27-59% glucoronic acid  
27-59% 4-hydroxypropranolol
 
sulfate  
10-25% propranolol glucoronide
a)
 
Gastrointestinal 
H2 antagonist 
Cimetidine  
 
 
70% 
 
 
19% sulphoxide
b)
  
Anti-diabetes 
Biguanide 
Metformin  
 
 
100% 
 
 
N/A 
c)
 
CNS 
NSAID 
Ibuprofen  
 
 
Naproxen  
 
Salicylic acid  
 
 
 
Stimulant 
Caffeine  
 
 
SSRI Antidepressant 
Fluoxetine  
 
Paroxetine  
 
 
0-15% 
 
 
5-6% 
 
1.3-31% 
 
 
 
 
0-5% 
 
 
 
0-10% 
 
1-2% 
 
 
73% 2-hydroxyibuprofen  
3-hydroxyibuprofen & conjugates 
14% ibuprofen glucoronide 
d)
  
28% demethylated naproxen 
66% naproxen glucoronide 
e)
 
19.8-65% salicyluric acid 
0.8-42% salicyl glucoronide 
1-3% gentisic acid  
1-3% salicyluric acid phenolic glucoronide 
f)
 
 
80% paraxanthine conjugates  
11% theobromine conjugates 
4% theophylline conjugates
g)
 
 
90% norfluoxetine glucoronide   
0-10% fluoxetine N-glucoronide
h)
  
64% paroxetine glucoronide & sulfate 
conjugates
i)
 
References: 
a)
Walle et al., 1985; 
b)
GlaxoSmithkline, 2008;  
c)
Campbell et al., 1996; 
d)
Rudy et 
al., 1991;
 e)
Runkel et al., 1972; 
f)
Hutt et al., 1986;
g)
Miners & Birkett, 1996; 
h)
Hiemke & Hartter, 
2000; 
i)
Kaye et al., 1989. 
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Table A-2 Removal of selected pharmaceuticals during biological sewage 
treatment processes 
Therapeutic Area, 
Compound & Class 
Removal (%) System Type 
Cardiovascular 
β-blocker 
Propranolol 
  
 
 
52-59 
59 
37-78 
                                                      
 
Conventional Activated Sludge
b) 
Biological Activated Sludge
c) 
Membrane Bioreactor
d) 
Gastrointestinal 
H2 antagonist 
Cimetidine 
  
24 
79 
Conventional Activated Sludge
b)
  
Biological Activated Sludge
b) 
Anti-diabetes 
Biguanide 
Metformin 90 Conventional Activated Sludgee)  
CNS 
NSAID 
Ibuprofen 
  
Naproxen 
  
  
Salicylic acid 
  
Stimulant 
Caffeine 
SSRI Antidepressant 
Fluoxetine 
 
Paroxetine 
 
 
85-99 
90-99 
50-85 
94 
61-91 
97 
100 
 
90 
 
33 
98 
90 
 
 
Conventional Activated Sludge
a),f),g) 
Membrane Bioreactor
a),c),f),h) 
Conventional Activated Sludge
a),b),f),g) 
Biological Activated Sludge
b) 
Membrane Bioreactor
a),c) 
Conventional Activated Sludge
h)
  
Biological Activated Sludge
h) 
 
Conventional Activated Sludge
i)
  
 
Conventional Activated Sludge
b)
  
Membrane Bioreactor
b) 
Membrane Bioreactor
f) 
References: 
b)
Maurer et al., 2007; 
a)
Lahti & Oikari, 2011; 
c)
Kasprzyk-Hordern et al., 2009; 
d)
Radjenovic et al., 2007; 
e)
Scheurer et al., 2012; 
f)
Joss et al., 2005; 
g)
Kimura et al., 2007; 
h)
Hashim et al., 2011;
 i)
Gómez et al., 2007. 
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Appendix B 
 
Table B-1 Inhibition by selected pharmaceuticals in anaerobic digester sludge 
by measurement of gas production (1) 
Treatment Test 
concentration 
pH 48 h cumulative gas 
pressure
 
Inhibition 
(%)
 
 (mg L
-1
) Start End (bar)  
Control - 7.8 7.4 2.5 - 
MeOH control - 8.0 7.5 2.6 <10 
3,5-DCP 15 8.1 7.1 0.8 69.1 
Propranolol 1.5 8.1 7.4 2.6 <10 
Propranolol 3.9 8.1 7.4 2.6 <10 
Propranolol 15 8.1 7.4 2.5 <10 
Propranolol 39 8.1 7.5 2.5 <10 
Propranolol (MeOH) 77 8.0 7.3 2.6 <10 
Propranolol(direct weigh) 77 7.8 7.3 2.7 <10 
Cimetidine 2.1 7.8 7.3 2.6 <10 
Cimetidine 5.3 7.8 7.3 2.6 <10 
Cimetidine 21 7.8 7.3 2.6 <10 
Cimetidine (MeOH) 53 7.9 7.3 2.6 <10 
Cimetidine (direct weigh) 53 7.9 7.3 2.6 <10 
Cimetidine (MeOH) 105 7.9 7.4 2.6 <10 
Cimetidine (direct weigh) 105 7.9 7.3 2.5 <10 
Table B-2 Inhibition by selected pharmaceuticals in anaerobic digester sludge 
by measurement of gas production (2) 
Treatment Test 
concentration 
pH 48 h cumulative gas 
pressure
 
Inhibition 
(%)
 
 (mg L
-1
) Start End (bar)  
Control - 8.3 7.4 2.5 - 
3,5-DCP 15 8.4 7.1 0.8 68.9 
Naproxen 1.4 8.4 7.4 2.6 <10 
Naproxen 3.4 8.4 7.5 2.6 <10 
Naproxen 14 8.4 7.4 2.6 <10 
Naproxen 34 8.3 7.4 2.6 <10 
Naproxen 69 8.4 7.4 2.6 <10 
Salicylic acid 1.6 8.2 7.4 2.6 <10 
Salicylic acid 4.1 8.2 7.4 2.6 <10 
Salicylic acid 16 8.2 7.4 2.7 <10 
Salicylic acid 41 8.1 7.4 2.7 <10 
Salicylic acid 82 8.0 7.4 2.6 <10 
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Table B-3 Inhibition by selected pharmaceuticals in anaerobic digester sludge 
by measurement of gas production (3) 
Treatment Test 
concentration 
pH 48 h cumulative gas 
pressure
 
Inhibition 
(%)
 
 (mg L
-1
) Start End (bar)  
Control - 8.3 7.3 2.4 - 
MeOH control - 8.2 7.3 2.5 <10 
3,5-DCP 15 8.2 6.9 0.8 67.8 
Metformin  3.5 8.2 7.2 2.5 <10 
Metformin  8.6 8.2 7.2 2.5 <10 
Metformin       35 8.1 7.2 2.5 <10 
Metformin  86 8.2 7.2 2.5 <10 
Metformin 173 8.2 7.2 2.5 <10 
Caffeine 2.0 8.2 7.2 2.4 <10 
Caffeine 5.1 8.3 7.2 2.4 <10 
Caffeine 20 8.2 7.1 2.4 <10 
Caffeine 51 8.2 7.1 2.4 <10 
Caffeine 101 8.2 7.1 2.4 <10 
Ibuprofen 1.3 8.2 7.1 2.5 <10 
Ibuprofen 3.3 8.3 7.1 2.4 <10 
Ibuprofen 13 8.2 7.1 2.4 <10 
Ibuprofen (MeOH) 33 8.2 7.2 2.4 <10 
Ibuprofen (direct weigh) 33 8.2 7.1 2.4 <10 
Ibuprofen (MeOH) 66 8.2 7.1 2.4 <10 
Ibuprofen (direct weigh) 66 8.2 7.1 2.3 <10 
Table B-4 Inhibition by selected pharmaceuticals in anaerobic digester sludge 
by measurement of gas production (4) 
Treatment Test 
concentration 
pH 48 h cumulative gas 
pressure
 
Inhibition 
(%)
 
 (mg L
-1
) Start End (bar)  
Control - 8.0 7.4 2.0 - 
MeOH  control - 8.0 7.3 2.1 <10 
3,5-DCP 15 8.0 7.0 0.8 62.5 
Fluoxetine  1.7 8.0 7.4 2.1 <10 
Fluoxetine  4.2 7.0 7.4 2.2 <10 
Fluoxetine  17 8.0 7.4 2.0 <10 
Fluoxetine  42 8.0 7.4 2.0 <10 
Fluoxetine (MeOH)  85 8.0 7.4 1.8 <10 
Paroxetine  1.6 8.0 7.5 2.1 <10 
Paroxetine  4.1 8.0 7.4 2.1 <10 
Paroxetine  16 8.0 7.4 2.1 <10 
Paroxetine  41 8.1 7.4 2.0 <10 
Paroxetine (MeOH)  82 8.1 7.3 1.9 <10 
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Appendix C  
Table C-1 Mineralisation of salicylic acid in anaerobic digester sludge at 25 mg C L
-1 
by measurement of gas production 
 
Salicylic acid           
25 mg C L
-1
Pressure 
(Bar)
Mean Pressure 
(Bar) 
Final carbon in 
Headspace
Liquid IC 
(mg L
-1
)
Total IC 
(mg)
Mineralisation (%) Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.006 * * * * 2.7 * *
Day 1 0.002 * * * * 0.9 * *
Day 1 0.003 0.004 * * * 1.4 1.7 0.94
Day 7 0.034 * * * * 15.4 * *
Day 7 0.027 * * * * 12.2 * *
Day 7 0.028 0.030 * * * 12.7 13.4 1.71
Day 14 0.090 * * * * 40.7 * *
Day 14 0.083 * * * * 37.5 * *
Day 14 0.084 0.086 * * * 38.0 38.7 1.71
Day 21 0.143 * * * * 64.6 * *
Day 21 0.134 * * * * 60.6 * *
Day 21 0.138 0.138 * * * 62.4 62.5 2.04
Day 28 0.178 * * * * 80.5 * *
Day 28 0.167 * * * * 75.5 * *
Day 28 0.172 0.172 * * * 77.8 77.9 2.49
Day 35 0.226 * * * * 102.2 * *
Day 35 0.208 * * * * 94.0 * *
Day 35 0.213 0.216 * * * 96.3 97.5 4.20
Day 42 0.252 * * * * 113.9 * *
Day 42 0.239 * * * * 108.0 * *
Day 42 0.243 0.245 * * * 109.9 110.6 3.01
Day 56 0.302 * * * * 136.5 * *
Day 56 0.292 * * * * 132.0 * *
Day 56 0.292 0.295 * * * 132.0 133.5 2.61
Day 60 0.300 * * * * 135.6 * *
Day 60 0.292 * * * * 132.0 * *
Day 60 0.294 0.295 0.00069 69.24 15.23 132.9 133.5 1.88
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**As shown, data from the time period which related to first-order kinetics was used for the 
determination of t1/2 (1-28 days).   This was performed in accordance with recommendations in 
Guideline OECD 309 (OECD, 2004).   
 
Integrated first order rate law: ln [A] = - kt + ln [A]0  
 
                                                           
 
 
 
 
 
Figure C-1    Calculation of t1/2 for salicylic acid 25 mg C L
-1
 
  
Time (days) Mineralisation (α) ln Mineralisation (100 α) ln (100 α)
0 0.0 0 100.0 4.61
1 1.7 0.51 98.3 4.59
7 13.4 2.60 86.6 4.46
14 38.7 3.66 61.3 4.12
21 62.5 4.14 37.5 3.62
28 77.9 4.36 22.1 3.10
35 97.5 4.58 2.5 0.92
42 110.6 4.71 -10.6 *
56 133.5 4.89 -33.5 *
60 133.5 4.89 -33.5 *
t1/2 = ln (2)
             k
      t1/2   =  ln (2)  =  10.5 days 
                0.0663 
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Table C-2 Mineralisation of salicylic acid in anaerobic digester sludge at 50 mg C L
-1 
by measurement of gas production 
 
Salicylic acid             
50 mg C L
-1
Pressure 
(Bar)
Mean Pressure 
(Bar) 
Final carbon in 
Headspace
Liquid IC 
(mg L
-1
)
Total IC 
(mg)
Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.007 * * * * 2.0 * *
Day 1 0.008 * * * * 2.3 * *
Day 1 0.009 0.008 * * * 2.6 2.3 0.28
Day 7 0.032 * * * * 9.1 * *
Day 7 0.034 * * * * 9.6 * *
Day 7 0.035 0.034 * * * 9.9 9.5 0.43
Day 14 0.086 * * * * 24.4 * *
Day 14 0.085 * * * * 24.1 * *
Day 14 0.086 0.086 * * * 24.4 24.3 0.16
Day 21 0.135 * * * * 38.3 * *
Day 21 0.134 * * * * 38.0 * *
Day 21 0.133 0.134 * * * 37.7 38.0 0.28
Day 28 0.162 * * * * 45.9 * *
Day 28 0.160 * * * * 45.3 * *
Day 28 0.160 0.161 * * * 45.3 45.5 0.33
Day 35 0.188 * * * * 53.3 * *
Day 35 0.187 * * * * 53.0 * *
Day 35 0.188 0.188 * * * 53.3 53.2 0.16
Day 42 0.223 * * * * 63.2 * *
Day 42 0.219 * * * * 62.1 * *
Day 42 0.219 0.220 * * * 62.1 62.4 0.65
Day 56 0.326 * * * * 92.4 * *
Day 56 0.327 * * * * 92.7 * *
Day 56 0.327 0.327 * * * 92.7 92.6 0.16
Day 60 0.327 * * * * 92.7 * *
Day 60 0.328 * * * * 93.0 * *
Day 60 0.325 0.327 0.00077 73.34 16.52 92.1 92.6 0.43
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**As shown, data from the time period which related to first-order kinetics was used for the 
determination of t1/2 (7-42 days).  This was performed in accordance with recommendations in 
Guideline OECD 309 (OECD, 2004).   
  
Integrated first order rate law: ln [A] = - kt + ln [A]0 
 
                                                         
 
 
 
 
Figure C-2 Calculation of t1/2 for salicylic acid 50 mg C L
-1
Time (days) Mineralisation (α) ln Mineralisation (100-α) ln (100-α)
0 0.0 0 100.0 4.61
1 2.3 0.82 97.7 4.58
7 9.5 2.26 90.5 4.50
14 24.3 3.19 75.7 4.33
21 38.0 3.64 62.0 4.13
28 45.5 3.82 54.5 4.00
35 53.2 3.97 46.8 3.85
42 62.4 4.13 37.6 3.63
56 92.6 4.53 7.4 2.00
60 92.6 4.53 7.4 2.00
t1/2 = ln (2)
             k
      t1/2   =  ln (2)  =  30.0 days 
                0.0231 
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Table C-3 Mineralisation of cimetidine in anaerobic digester sludge at 25 mg C L
-1 
by measurement of gas production 
Cimetidine        
25 mg C L
-1
Pressure 
(Bar)
Mean Pressure 
(Bar) 
Final carbon in 
Headspace
Liquid IC 
(mg L
-1
)
Total IC (mg) Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.011 * * * * 2.5 * *
Day 1 0.012 * * * * 2.7 * *
Day 1 0.011 0.011 * * * 2.5 2.5 0.13
Day 7 0.034 * * * * 7.6 * *
Day 7 0.035 * * * * 7.8 * *
Day 7 0.036 0.035 * * * 8.1 7.8 0.22
Day 14 0.083 * * * * 18.6 * *
Day 14 0.084 * * * * 18.8 * *
Day 14 0.088 0.085 * * * 19.7 19.0 0.59
Day 21 0.135 * * * * 30.2 * *
Day 21 0.133 * * * * 29.8 * *
Day 21 0.139 0.136 * * * 31.1 30.4 0.68
Day 28 0.165 * * * * 36.9 * *
Day 28 0.162 * * * * 36.2 * *
Day 28 0.168 0.165 * * * 37.6 36.9 0.67
Day 35 0.188 * * * * 42.1 * *
Day 35 0.185 * * * * 41.4 * *
Day 35 0.192 0.188 * * * 43.0 42.1 0.79
Day 42 0.211 * * * * 47.2 * *
Day 42 0.204 * * * * 45.6 * *
Day 42 0.212 0.209 * * * 47.4 46.8 0.98
Day 56 0.263 * * * * 58.8 * *
Day 56 0.243 * * * * 54.4 * *
Day 56 0.254 0.253 * * * 56.8 56.7 2.24
Day 60 0.263 * * * * 58.8 * *
Day 60 0.243 * * * * 54.4 * *
Day 60 0.254 0.253 0.00059 61.84 13.31 56.8 56.7 2.24
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Figure C-3 Calculation of t1/2 for cimetidine 25 mg C L
-1
 
Time (days) Mineralisation (α) ln Mineralisation (100-α) ln (100-α)
0 0.0 0 100.0 4.61
1 2.5 0.93 97.5 4.58
7 7.8 2.06 92.2 4.52
14 19.0 2.95 81.0 4.39
21 30.4 3.41 69.7 4.24
28 36.9 3.61 63.1 4.14
35 42.1 3.74 57.9 4.06
42 46.8 3.85 53.2 3.97
56 56.7 4.04 43.3 3.77
60 56.7 4.04 43.3 3.77
t1/2 = ln (2)
             k
      t1/2   =  ln (2)  =  47.8 days 
                0.0145 
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Table C-4 Mineralisation of cimetidine in anaerobic digester sludge at 50 mg C L
-1 
by measurement of gas production 
Cimetidine    
50 mg C L
-1
Pressure 
(Bar)
Mean 
Pressure 
(Bar) 
Final carbon in 
Headspace
Liquid IC  
(mg L
-1
)
Total IC 
(mg)
Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.014 * * * * 1.2 * *
Day 1 0.004 * * * * 0.3 * *
Day 1 0.009 0.009 * * * 0.8 0.8 0.42
Day 7 0.038 * * * * 3.2 * *
Day 7 0.029 * * * * 2.4 * *
Day 7 0.031 0.033 * * * 2.6 2.7 0.40
Day 14 0.088 * * * * 7.4 * *
Day 14 0.087 * * * * 7.3 * *
Day 14 0.082 0.086 * * * 6.9 7.2 0.27
Day 21 0.137 * * * * 11.5 * *
Day 21 0.139 * * * * 11.7 * *
Day 21 0.133 0.136 * * * 11.2 11.4 0.26
Day 28 0.162 * * * * 13.6 * *
Day 28 0.164 * * * * 13.8 * *
Day 28 0.155 0.160 * * * 13.0 13.5 0.40
Day 35 0.185 * * * * 15.5 * *
Day 35 0.190 * * * * 15.9 * *
Day 35 0.195 0.190 * * * 16.4 15.8 0.42
Day 42 0.203 * * * * 17.0 * *
Day 42 0.208 * * * * 17.4 * *
Day 42 0.211 0.207 * * * 17.7 17.4 0.34
Day 56 0.244 * * * * 20.5 * *
Day 56 0.251 * * * * 21.1 * *
Day 56 0.256 0.250 * * * 21.5 21.0 0.51
Day 60 0.244 * * * * 20.5 * *
Day 60 0.251 * * * * 21.1 * *
Day 60 0.256 0.250 0.00059 58.55 12.94 21.5 21.0 0.51
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Figure C-4 Calculation of t1/2 for cimetidine 50 mg C L
-1
 
Time (days) Mineralisation (α) ln Mineralisation (100-α) ln (100-α)
0 0.0 0 100.0 4.61
1 0.8 -0.29 99.3 4.60
7 2.7 1.01 97.3 4.58
14 7.2 1.97 92.8 4.53
21 11.4 2.44 88.6 4.48
28 13.5 2.60 86.6 4.46
35 15.8 2.76 84.3 4.43
42 17.4 2.86 82.6 4.41
56 21.0 3.04 79.0 4.37
60 21.0 3.04 79.0 4.37
t1/2 = ln (2)
             k
      t1/2   =  ln (2)  =  169.1 days 
                0.0041 
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Table C-5 Mineralisation of naproxen in anaerobic digester sludge at 25 mg C L
-1
 by measurement of gas production 
Naproxen 25 
mg C L
-1
Pressure (Bar) Mean Pressure 
(Bar) 
Final carbon in 
headspace (mg)
Liquid IC       
(mg L
-1
)
Total IC (mg) Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.006 * * * * 0.8 * *
Day 1 0.005 * * * * 0.7 * *
Day 1 0.005 0.005 * * * 0.7 0.7 0.08
Day 7 0.032 * * * * 4.3 * *
Day 7 0.031 * * * * 4.1 * *
Day 7 0.028 0.030 * * * 3.7 4.0 0.28
Day 14 0.083 * * * * 11.1 * *
Day 14 0.085 * * * * 11.3 * *
Day 14 0.082 0.083 * * * 10.9 11.1 0.20
Day 21 0.135 * * * * 18.0 * *
Day 21 0.138 * * * * 18.4 * *
Day 21 0.133 0.135 * * * 17.7 18.0 0.34
Day 28 0.155 * * * * 20.6 * *
Day 28 0.162 * * * * 21.6 * *
Day 28 0.166 0.161 * * * 22.1 21.4 0.74
Day 35 0.179 * * * * 23.8 * *
Day 35 0.177 * * * * 23.6 * *
Day 35 0.188 0.181 * * * 25.0 24.1 0.78
Day 42 0.197 * * * * 26.2 * *
Day 42 0.190 * * * * 25.3 * *
Day 42 0.198 0.195 * * * 26.4 26.0 0.58
Day 56 0.242 * * * * 32.2 * *
Day 56 0.240 * * * * 32.0 * *
Day 56 0.249 0.244 * * * 33.2 32.4 0.63
Day 60 0.242 * * * * 32.2 * *
Day 60 0.238 * * * * 31.7 * *
Day 60 0.247 0.242 0.00057 58.83 12.70 32.9 32.3 0.60
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Figure C-5 Calculation of t1/2 for naproxen 25 mg C L
-1
 
y = -0.0068x + 4.5876
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             k
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(day) 
Time (days) Mineralisation (α) ln Mineralisation (100-α) ln (100-α)
0 0.0 0 100.0 4.61
1 0.7 -0.34 99.3 4.60
7 4.0 1.40 96.0 4.56
14 11.1 2.41 88.9 4.49
21 18.0 2.89 82.0 4.41
28 21.4 3.07 78.6 4.36
35 24.2 3.18 75.9 4.33
42 26.0 3.26 74.0 4.30
56 32.5 3.48 67.6 4.21
60 32.3 3.47 67.7 4.22
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Table C-6 Mineralisation of naproxen in anaerobic digester sludge at 50 mg C L
-1 
by measurement of gas production 
 
 
 
Naproxen   
50  mg C L
-1
Pressure 
(Bar)
Mean 
Pressure (Bar) 
Final carbon in 
headspace (mg)
Liquid IC 
(mg L
-1
)
Total IC 
(mg)
Mineralisation (%) Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.006 * * * * 0.9 * *
Day 1 0.008 * * * * 1.2 * *
Day 1 0.007 0.007 * * * 1.0 1.0 0.15
Day 7 0.032 * * * * 4.7 * *
Day 7 0.034 * * * * 5.0 * *
Day 7 0.034 0.033 * * * 5.0 4.9 0.17
Day 14 0.089 * * * * 13.2 * *
Day 14 0.091 * * * * 13.5 * *
Day 14 0.091 0.090 * * * 13.5 13.4 0.17
Day 21 0.145 * * * * 21.5 * *
Day 21 0.147 * * * * 21.8 * *
Day 21 0.147 0.146 * * * 21.8 21.7 0.17
Day 28 0.178 * * * * 26.4 * *
Day 28 0.179 * * * * 26.5 * *
Day 28 0.176 0.178 * * * 26.1 26.3 0.23
Day 35 0.207 * * * * 30.7 * *
Day 35 0.207 * * * * 30.7 * *
Day 35 0.202 0.205 * * * 30.0 30.5 0.43
Day 42 0.222 * * * * 32.9 * *
Day 42 0.223 * * * * 33.1 * *
Day 42 0.221 0.222 * * * 32.8 32.9 0.15
Day 56 0.273 * * * * 40.5 * *
Day 56 0.274 * * * * 40.6 * *
Day 56 0.271 0.273 * * * 40.2 40.4 0.23
Day 60 0.273 * * * * 40.5 * *
Day 60 0.273 * * * * 40.5 * *
Day 60 0.269 0.272 0.00064 62.66 13.90 39.9 40.3 0.34
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Figure C-6 Calculation of t1/2 for naproxen 50 mg C L
-1
 
 
Time (days) Mineralisation (α) ln Mineralisation (100-α) ln (100-α)
0 0.0 0 100.0 4.61
1 1.0 0.04 99.0 4.59
7 4.9 1.60 95.1 4.55
14 13.4 2.60 86.6 4.46
21 21.7 3.08 78.3 4.36
28 26.4 3.27 73.7 4.30
35 30.5 3.42 69.6 4.24
42 32.9 3.49 67.1 4.21
56 40.4 3.70 59.6 4.09
60 40.3 3.70 59.7 4.09
t1/2 = ln (2)
             k
      t1/2   =  ln (2)  =  77.0 days 
                0.009 
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Table C-7 Mineralisation of metformin in anaerobic digester sludge at 25 mg C L
-1 
by measurement of gas production 
 
 
 
 
 
 Metformin 
25 mg C L
-1
Pressure 
(Bar)
Mean 
Pressure (Bar) 
Final carbon in 
Headspace (mg)
Liquid IC 
(mg L
-1
)
Total IC 
(mg)
Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.038 * * * * 21.0 * *
Day 1 0.035 * * * * 19.3 * *
Day 1 0.033 0.035 * * * 18.2 19.5 1.39
Day 7 0.053 * * * * 29.3 * *
Day 7 0.048 * * * * 26.5 * *
Day 7 0.045 0.049 * * * 24.9 26.9 2.23
Day 14 0.078 * * * * 43.1 * *
Day 14 0.074 * * * * 40.9 * *
Day 14 0.072 0.075 * * * 39.8 41.3 1.69
Day 28 0.096 * * * * 53.0 * *
Day 28 0.092 * * * * 50.8 * *
Day 28 0.090 0.093 * * * 49.7 51.2 1.69
Day 35 0.126 * * * * 69.6 * *
Day 35 0.122 * * * * 67.4 * *
Day 35 0.119 0.122 * * * 65.7 67.6 1.94
Day 42 0.159 * * * * 87.8 * *
Day 42 0.155 * * * * 85.6 * *
Day 42 0.151 0.155 * * * 83.4 85.6 2.21
Day 56 0.184 * * * * 101.7 * *
Day 56 0.180 * * * * 99.5 * *
Day 56 0.176 0.180 * * * 97.2 99.5 2.21
Day 60 0.179 * * * * 98.9 * *
Day 60 0.173 * * * * 95.6 * *
Day 60 0.170 0.174 0.00041 48.31 9.72 93.9 96.1 2.53
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**As shown, data from the time period which related to first-order kinetics was used for the 
determination of t1/2 (1-28 days).  This was performed in accordance with recommendations 
in Guideline OECD 309 (OECD, 2004).  
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Figure C-7 Calculation of t1/2 for metformin 25 mg C L
-1
 
 
t1/2 = ln (2)
             k
Time (days) Mineralisation (α) ln Mineralisation (100-α) ln (100-α)
0 0.0 0 100.0 4.61
1 19.6 2.98 80.4 4.39
7 26.9 3.29 73.1 4.29
14 41.3 3.72 58.8 4.07
28 51.2 3.94 48.8 3.89
35 67.6 4.21 32.4 3.48
42 85.6 4.45 14.4 2.66
56 99.5 4.60 0.5 -0.60
60 96.1 4.57 3.9 1.35
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Table C-8 Mineralisation of metformin in anaerobic digester sludge at 50 mg C L
-1 
by measurement of gas production 
 
 
 
 
 Metformin 
50 mg C L
-1
Pressure 
(Bar)
Mean 
Pressure (Bar)
Final carbon in 
Headspace (mg)
Liquid IC 
(mg L-1)
Total IC 
(mg)
Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.032 * * * * 14.1 * *
Day 1 0.033 * * * * 14.5 * *
Day 1 0.035 0.033 * * * 15.4 14.7 0.67
Day 7 0.046 * * * * 20.3 * *
Day 7 0.046 * * * * 20.3 * *
Day 7 0.049 0.047 * * * 21.6 20.7 0.76
Day 14 0.071 * * * * 31.3 * *
Day 14 0.073 * * * * 32.1 * *
Day 14 0.073 0.072 * * * 32.1 31.9 0.51
Day 28 0.089 * * * * 39.2 * *
Day 28 0.090 * * * * 39.6 * *
Day 28 0.088 0.089 * * * 38.8 39.2 0.44
Day 35 0.117 * * * * 51.5 * *
Day 35 0.117 * * * * 51.5 * *
Day 35 0.117 0.117 * * * 51.5 51.5 0.00
Day 42 0.151 * * * * 66.5 * *
Day 42 0.149 * * * * 65.6 * *
Day 42 0.148 0.149 * * * 65.2 65.8 0.67
Day 56 0.195 * * * * 85.9 * *
Day 56 0.183 * * * * 80.6 * *
Day 56 0.173 0.184 * * * 76.2 80.9 4.85
Day 60 0.192 * * * * 84.6 * *
Day 60 0.186 * * * * 81.9 * *
Day 60 0.178 0.185 0.00043 61.9 11.40 78.39 81.6 3.09
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**As shown, data from the time period which related to first-order kinetics was used for the 
determination of t1/2 (7-42 days).  This was performed in accordance with recommendations in 
Guideline OECD 309 (OECD, 2004).  
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Figure C-8 Calculation of t1/2 for metformin 50 mg C L
-1
 
 
t1/2 = ln (2)
             k
Time (days) Mineralisation (α) ln Mineralisation (100-α) ln (100-α)
0 0.0 0 100.0 4.61
1 14.7 2.69 85.3 4.45
7 20.7 3.03 79.3 4.37
14 31.9 3.46 68.1 4.22
28 39.2 3.67 60.8 4.11
35 51.5 3.94 48.5 3.88
42 65.8 4.19 34.2 3.53
56 80.9 4.39 19.1 2.95
60 81.6 4.40 18.4 2.91
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Table C-9`Mineralisation of caffeine in anaerobic digester sludge at 25 mg C L
-1 
by measurement of gas production 
 
 
 
 
Caffeine      
25 mg C L
-1
Pressure 
(Bar)
Mean 
Pressure (Bar) 
Final carbon in 
Headspace (mg)
Liquid IC 
(mg L
-1
)
Total IC 
(mg)
Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.00 * *
Day 0 0.000 0.000 * * * 0.00 0.00 0.00
Day 1 0.031 * * * * 2.97 * *
Day 1 0.035 * * * * 3.35 * *
Day 1 0.041 0.036 * * * 3.92 3.41 0.48
Day 7 0.043 * * * * 4.11 * *
Day 7 0.045 * * * * 4.30 * *
Day 7 0.054 0.047 * * * 5.17 4.53 0.56
Day 14 0.069 * * * * 6.60 * *
Day 14 0.072 * * * * 6.89 * *
Day 14 0.080 0.074 * * * 7.65 7.05 0.54
Day 28 0.085 * * * * 8.13 * *
Day 28 0.090 * * * * 8.61 * *
Day 28 0.092 0.089 * * * 8.80 8.51 0.34
Day 35 0.113 * * * * 10.81 * *
Day 35 0.118 * * * * 11.29 * *
Day 35 0.121 0.117 * * * 11.57 11.22 0.39
Day 42 0.144 * * * * 13.77 * *
Day 42 0.148 * * * * 14.16 * *
Day 42 0.151 0.148 * * * 14.44 14.12 0.34
Day 56 0.152 * * * * 14.54 * *
Day 56 0.157 * * * * 15.02 * *
Day 56 0.158 0.156 * * * 15.11 14.89 0.31
Day 60 0.144 * * * * 13.77 * *
Day 60 0.151 * * * * 14.44 * *
Day 60 0.150 0.148 0.00035 35.04 7.67 14.35 14.2 0.36
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Figure C-9 Calculation of t1/2 for caffeine 25 mg C L
-1
 
 
t1/2 = ln (2)
             k
      t1/2   =  ln (2)  =  288.8 days 
                0.0024 
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Time (days) Mineralisation (α) ln Mineralisation (100-α) ln (100-α)
0 0.0 0 100.0 4.61
1 3.4 1.23 96.6 4.57
7 4.5 1.51 95.5 4.56
14 7.0 1.95 93.0 4.53
28 8.5 2.14 91.5 4.52
35 11.2 2.42 88.8 4.49
42 14.1 2.65 85.9 4.45
56 14.9 2.70 85.1 4.44
60 14.2 2.65 85.8 4.45
(day) 
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Table C-10 Mineralisation of caffeine in anaerobic digester sludge at 50 mg C L
-1 
by measurement of gas production 
 
 
 
 
 Caffeine     
50 mg C L
-1
Pressure 
(Bar)
Mean 
Pressure (Bar)
Final carbon in 
Headspace (mg)
Liquid IC 
(mg L-1)
Total IC 
(mg)
Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.035 * * * * 2.9 * *
Day 1 0.034 * * * * 2.8 * *
Day 1 0.035 0.035 * * * 2.9 2.9 0.05
Day 7 0.049 * * * * 4.1 * *
Day 7 0.047 * * * * 3.9 * *
Day 7 0.049 0.048 * * * 4.1 4.0 0.10
Day 14 0.074 * * * * 6.2 * *
Day 14 0.071 * * * * 5.9 * *
Day 14 0.079 0.075 * * * 6.6 6.3 0.34
Day 28 0.094 * * * * 7.9 * *
Day 28 0.089 * * * * 7.5 * *
Day 28 0.096 0.093 * * * 8.0 7.8 0.30
Day 35 0.125 * * * * 10.5 * *
Day 35 0.118 * * * * 9.9 * *
Day 35 0.125 0.123 * * * 10.5 10.3 0.34
Day 42 0.156 * * * * 13.1 * *
Day 42 0.149 * * * * 12.5 * *
Day 42 0.157 0.154 * * * 13.1 12.9 0.37
Day 56 0.167 * * * * 14.0 * *
Day 56 0.159 * * * * 13.3 * *
Day 56 0.167 0.164 * * * 14.0 13.8 0.39
Day 60 0.161 * * * * 13.5 * *
Day 60 0.151 * * * * 12.6 * *
Day 60 0.160 0.157 0.00037 35.55 7.98 13.4 13.2 0.46
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Figure C-10 Calculation of t1/2 for caffeine 50 mg C L
-1 
 
Time (days) Mineralisation (α) ln Mineralisation (100-α) ln (100-α)
0 0.0 0 100.0 4.61
1 2.9 1.07 97.1 4.58
7 4.0 1.40 96.0 4.56
14 6.3 1.83 93.7 4.54
28 7.8 2.05 92.2 4.52
35 10.3 2.33 89.7 4.50
42 12.9 2.56 87.1 4.47
56 13.8 2.62 86.2 4.46
60 13.2 2.58 86.8 4.46
t1/2 = ln (2)
             k
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Table C-11 Mineralisation of ibuprofen in anaerobic digester sludge at 25 mg C L
-1 
by measurement of gas production 
 
 
 
 
Ibuprofen        
25 mg C L
-1
Pressure 
(Bar)
Mean 
Pressure 
(Bar) 
Final carbon in 
Headspace (mg)
Liquid IC 
(mg L
-1
)
Total IC 
(mg)
Mineralisation (%) Mean 
Mineralisation (%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0 * * * 0.0 0.0 0.00
Day 1 0.036 * * * * 5.6 * *
Day 1 0.034 * * * * 5.3 * *
Day 1 0.031 0.034 * * * 4.9 5.3 0.39
Day 7 0.047 * * * * 7.4 * *
Day 7 0.047 * * * * 7.4 * *
Day 7 0.053 0.049 * * * 8.3 7.7 0.54
Day 14 0.080 * * * * 12.5 * *
Day 14 0.078 * * * * 12.2 * *
Day 14 0.082 0.080 * * * 12.8 12.5 0.31
Day 28 0.096 * * * * 15.0 * *
Day 28 0.094 * * * * 14.7 * *
Day 28 0.098 0.096 * * * 15.3 15.0 0.31
Day 35 0.124 * * * * 19.4 * *
Day 35 0.123 * * * * 19.3 * *
Day 35 0.125 0.124 * * * 19.6 19.4 0.16
Day 42 0.156 * * * * 24.4 * *
Day 42 0.155 * * * * 24.3 * *
Day 42 0.154 0.155 * * * 24.1 24.3 0.16
Day 56 0.166 * * * * 26.0 * *
Day 56 0.166 * * * * 26.0 * *
Day 56 0.167 0.166 * * * 26.1 26.0 0.09
Day 60 0.157 * * * * 24.6 * *
Day 60 0.157 * * * * 24.6 * *
Day 60 0.159 0.158 0.00037 35.04 7.94 24.9 24.7 0.18
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Integrated first order rate law: ln [A] = - kt + ln [A]0 
   
                                                          
 
 
 
 
 
 
Figure C-11 Calculation of t1/2 for ibuprofen 25 mg C L
-1 
 
Time (days) Mineralisation (α) ln Mineralisation (100-α) ln (100-α)
0 0.00 0.00 100.0 4.61
1 5.27 1.66 94.7 4.55
7 7.67 2.04 92.3 4.53
14 12.53 2.53 87.5 4.47
28 15.03 2.71 85.0 4.44
35 19.41 2.97 80.6 4.39
42 24.27 3.19 75.7 4.33
56 26.04 3.26 74.0 4.30
60 24.69 3.21 75.3 4.32
t1/2 = ln (2)
             k
      t1/2   =  ln (2)  =  150.7 days 
                0.0046 
 
y = -0.0046x + 4.5624
R² = 0.9391
0.0
1.0
2.0
3.0
4.0
5.0
0 10 20 30 40 50 60
ln
 (
1
0
0
-α
)
Time (day)
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Table C-12 Mineralisation of ibuprofen in anaerobic digester sludge at 50 mg C L
-1 
by measurement of gas production 
 
 
 
 
 
 Ibuprofen    
50 mg C L
-1
Pressure 
(Bar)
Mean Pressure 
(Bar)
Final carbon in 
Headspace (mg)
Liquid IC (mg 
L-1)
Total IC 
(mg)
Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.00 0.00
Day 1 0.034 * * * * 1.9 * *
Day 1 0.029 * * * * 1.6 * *
Day 1 0.029 0.031 * * * 1.6 1.68 0.16
Day 7 0.047 * * * * 2.6 * *
Day 7 0.042 * * * * 2.3 * *
Day 7 0.049 0.046 * * * 2.7 2.52 0.20
Day 14 0.081 * * * * 4.4 * *
Day 14 0.075 * * * * 4.1 * *
Day 14 0.083 0.080 * * * 4.5 4.36 0.23
Day 28 0.092 * * * * 5.0 * *
Day 28 0.085 * * * * 4.6 * *
Day 28 0.094 0.090 * * * 5.1 4.94 0.26
Day 35 0.119 * * * * 6.5 * *
Day 35 0.112 * * * * 6.1 * *
Day 35 0.120 0.117 * * * 6.6 6.40 0.24
Day 42 0.150 * * * * 8.2 * *
Day 42 0.143 * * * * 7.8 * *
Day 42 0.152 0.148 * * * 8.3 8.11 0.26
Day 56 0.156 * * * * 8.5 * *
Day 56 0.152 * * * * 8.3 * *
Day 56 0.161 0.156 * * * 8.8 8.55 0.25
Day 60 0.148 * * * * 8.1 * *
Day 60 0.144 * * * * 7.9 * *
Day 60 0.153 0.148 0.00035 35.55 7.73 8.4 8.11 0.25
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Integrated first order rate law: ln [A] = - kt + ln [A]0 
   
                                                          
 
 
 
 
  
Figure C-12 Calculation of t1/2 for ibuprofen 50 mg C L
-1
 
 
y = -0.0014x + 4.5905
R² = 0.922
0.0
1.0
2.0
3.0
4.0
5.0
0 10 20 30 40 50 60
ln
 (
1
0
0
-α
)
Time (day)
t1/2 = ln (2)
             k
Time (days) Mineralisation (α) ln Mineralisation (100-α) ln (100-α)
0 0.00 0.00 100.0 4.61
1 1.68 0.52 98.3 4.59
7 2.52 0.92 97.5 4.58
14 4.36 1.47 95.6 4.56
28 4.94 1.60 95.1 4.55
35 6.40 1.86 93.6 4.54
42 8.11 2.09 91.9 4.52
56 8.55 2.15 91.4 4.52
60 8.11 2.09 91.9 4.52
      t1/2   =  ln (2)  =  495.1 days 
                0.0014 
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Table C-13 Mineralisation of propranolol in anaerobic digester sludge at 25 mg C L
-1 
with measurement by gas production 
 
 
 
Propranolol 
25 mg C L
-1
Pressure (Bar) Mean Pressure 
(Bar) 
Final carbon in 
headspace (mg)
Liquid IC       
(mg L
-1
)
Total IC (mg) Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.007 * * * * -5.4 * *
Day 1 0.000 * * * * 0.0 * *
Day 1 0.008 0.005 * * * -6.1 -3.8 3.33
Day 7 0.02 * * * * -15.3 * *
Day 7 0.015 * * * * -11.5 * *
Day 7 0.023 0.019 * * * -17.6 -14.8 3.09
Day 14 0.065 * * * * -49.7 * *
Day 14 0.059 * * * * -45.1 * *
Day 14 0.063 0.062 * * * -48.2 -47.7 2.34
Day 21 0.091 * * * * -69.6 * *
Day 21 0.09 * * * * -68.8 * *
Day 21 0.091 0.091 * * * -69.6 -69.3 0.44
Day 28 0.111 * * * * -84.9 * *
Day 28 0.111 * * * * -84.9 * *
Day 28 0.107 0.110 * * * -81.8 -83.9 1.77
Day 35 0.132 * * * * -100.9 * *
Day 35 0.133 * * * * -101.7 * *
Day 35 0.128 0.131 * * * -97.9 -100.2 2.02
Day 42 0.134 * * * * -102.5 * *
Day 42 0.136 * * * * -104.0 * *
Day 42 0.129 0.133 * * * -98.7 -101.7 2.76
Day 56 0.163 * * * * -124.7 * *
Day 56 0.164 * * * * -125.4 * *
Day 56 0.156 0.161 * * * -119.3 -123.1 3.33
Day 60 0.161 * * * * -123.1 * *
Day 60 0.162 * * * * -123.9 * *
Day 60 0.156 0.160 0.00037 43.48 8.84 -119.3 -122.1 2.46
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Table C-14 Mineralisation of propranolol in anaerobic digester sludge at 50 mg C L
-1 
with measurement by gas production 
 
 
 
Propranolol   
50  mg C L
-1
Pressure 
(Bar)
Mean 
Pressure (Bar) 
Final carbon in 
headspace (mg)
Liquid IC 
(mg L
-1
)
Total IC 
(mg)
Mineralisation (%) Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.011 * * * * -4.6 * *
Day 1 0.008 * * * * -3.4 * *
Day 1 0.006 0.008 * * * -2.5 -3.5 1.06
Day 7 0.026 * * * * -10.9 * *
Day 7 0.026 * * * * -10.9 * *
Day 7 0.024 0.025 * * * -10.1 -10.6 0.48
Day 14 0.067 * * * * -28.1 * *
Day 14 0.067 * * * * -28.1 * *
Day 14 0.057 0.064 * * * -23.9 -26.7 2.42
Day 21 0.092 * * * * -38.6 * *
Day 21 0.104 * * * * -43.6 * *
Day 21 0.096 0.097 * * * -40.3 -40.8 2.56
Day 28 0.113 * * * * -47.4 * *
Day 28 0.121 * * * * -50.7 * *
Day 28 0.114 0.116 * * * -47.8 -48.6 1.83
Day 35 0.124 * * * * -52.0 * *
Day 35 0.135 * * * * -56.6 * *
Day 35 0.132 0.130 * * * -55.4 -54.7 2.38
Day 42 0.126 * * * * -52.8 * *
Day 42 0.138 * * * * -57.9 * *
Day 42 0.132 0.132 * * * -55.4 -55.4 2.52
Day 56 0.157 * * * * -65.8 * *
Day 56 0.168 * * * * -70.5 * *
Day 56 0.152 0.159 * * * -63.7 -66.7 3.43
Day 60 0.155 * * * * -65.0 * *
Day 60 0.166 * * * * -69.6 * *
Day 60 0.160 0.160 0.00038 40.20 8.53 -67.1 -67.2 2.31
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Table C-15 Mineralisation of fluoxetine in anaerobic digester sludge at 25 mg C L
-1 
with measurement by gas production 
 
 
 
 
 
Fluoxetine     
25 mg C L
-1
Pressure (Bar) Mean Pressure 
(Bar) 
Final carbon in 
headspace (mg)
Liquid IC       
(mg L
-1
)
Total IC (mg) Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.003 * * * * -0.4 * *
Day 1 0.009 * * * * -1.1 * *
Day 1 0.012 0.008 * * * -1.5 -1.0 0.57
Day 7 0.012 * * * * -1.5 * *
Day 7 0.027 * * * * -3.4 * *
Day 7 0.024 0.021 * * * -3.0 -2.6 0.99
Day 14 0.030 * * * * -3.7 * *
Day 14 0.050 * * * * -6.2 * *
Day 14 0.047 0.042 * * * -5.8 -5.3 1.34
Day 28 0.042 * * * * -5.2 * *
Day 28 0.061 * * * * -7.6 * *
Day 28 0.059 0.054 * * * -7.3 -6.7 1.30
Day 35 0.064 * * * * -8.0 * *
Day 35 0.083 * * * * -10.3 * *
Day 35 0.080 0.076 * * * -9.9 -9.4 1.27
Day 42 0.089 * * * * -11.1 * *
Day 42 0.108 * * * * -13.4 * *
Day 42 0.107 0.101 * * * -13.3 -12.6 1.33
Day 56 0.088 * * * * -10.9 * *
Day 56 0.107 * * * * -13.3 * *
Day 56 0.106 0.100 * * * -13.2 -12.5 1.33
Day 60 0.084 * * * * -10.4 * *
Day 60 0.103 * * * * -12.8 * *
Day 60 0.102 0.096 0.00009 46.28 2.75 -12.7 -12.0 1.33
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Table C-16 Mineralisation of fluoxetine in anaerobic digester sludge at 50 mg C L
-1 
with measurement by gas production 
 
 
 
 
 
Fluoxetine       
50  mg C L
-1
Pressure 
(Bar)
Mean 
Pressure (Bar) 
Final carbon in 
headspace (mg)
Liquid IC 
(mg L
-1
)
Total IC 
(mg)
Mineralisation (%) Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.015 * * * * -1.9 * *
Day 1 0.012 * * * * -1.5 * *
Day 1 0.007 0.011 * * * -0.9 -19.2 0.50
Day 7 0.016 * * * * -2.0 * *
Day 7 0.013 * * * * -1.6 * *
Day 7 0.007 0.012 * * * -0.9 -20.4 0.57
Day 14 0.024 * * * * -3.0 * *
Day 14 0.021 * * * * -2.6 * *
Day 14 0.015 0.020 * * * -1.9 -34.0 0.57
Day 28 0.019 * * * * -2.4 * *
Day 28 0.016 * * * * -2.0 * *
Day 28 0.009 0.015 * * * -1.1 -24.9 0.64
Day 35 0.027 * * * * -3.4 * *
Day 35 0.025 * * * * -3.1 * *
Day 35 0.018 0.023 * * * -2.2 -39.6 0.59
Day 42 0.045 * * * * -5.6 * *
Day 42 0.044 * * * * -5.5 * *
Day 42 0.038 0.042 * * * -4.7 -71.9 0.47
Day 56 0.034 * * * * -4.2 * *
Day 56 0.033 * * * * -4.1 * *
Day 56 0.028 0.032 * * * -3.5 -53.8 0.40
Day 60 0.024 * * * * -3.0 * *
Day 60 0.023 * * * * -2.9 * *
Day 60 0.018 0.022 0.00002 26.4 1.21 -2.2 -36.8 0.40
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Table C-17 Mineralisation of paroxetine in anaerobic digester sludge at 25 mg C L
-1 
with measurement by gas production 
 
 
 
 
 
Paroxetine     
25 mg C L
-1
Pressure (Bar) Mean Pressure 
(Bar) 
Final carbon in 
headspace (mg)
Liquid IC       
(mg L
-1
)
Total IC (mg) Mineralisation 
(%)
Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.014 * * * * -1.4 * *
Day 1 0.012 * * * * -1.2 * *
Day 1 0.006 0.011 * * * -0.6 -1.1 0.42
Day 7 0.027 * * * * -2.7 * *
Day 7 0.025 * * * * -2.5 * *
Day 7 0.016 0.023 * * * -1.6 -2.3 0.59
Day 14 0.050 * * * * -5.0 * *
Day 14 0.049 * * * * -4.9 * *
Day 14 0.038 0.046 * * * -3.8 -4.6 0.67
Day 28 0.062 * * * * -6.2 * *
Day 28 0.062 * * * * -6.2 * *
Day 28 0.048 0.057 * * * -4.8 -5.8 0.81
Day 35 0.085 * * * * -8.5 * *
Day 35 0.085 * * * * -8.5 * *
Day 35 0.071 0.080 * * * -7.1 -8.1 0.81
Day 42 0.112 * * * * -11.3 * *
Day 42 0.112 * * * * -11.3 * *
Day 42 0.097 0.107 * * * -9.8 -10.8 0.87
Day 56 0.114 * * * * -11.5 * *
Day 56 0.115 * * * * -11.6 * *
Day 56 0.099 0.109 * * * -10.0 -11.0 0.90
Day 60 0.111 * * * * -11.2 * *
Day 60 0.112 * * * * -11.3 * *
Day 60 0.095 0.106 0.00010 44.35 2.78 -9.6 -10.7 0.96
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Table C-18 Mineralisation of paroxetine in anaerobic digester sludge at 50 mg C L
-1
 with measurement by gas production 
 
 
 
 
 
 
Paroxetine       
50  mg C L
-1
Pressure 
(Bar)
Mean 
Pressure (Bar) 
Final carbon in 
headspace (mg)
Liquid IC 
(mg L
-1
)
Total IC 
(mg)
Mineralisation (%) Mean 
Mineralisation 
(%)
Std Deviation
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 * * * * 0.0 * *
Day 0 0.000 0.000 * * * 0.0 0.0 0.00
Day 1 0.016 * * * * -1.6 * *
Day 1 0.013 * * * * -1.3 * *
Day 1 0.010 0.013 * * * -1.0 -0.9 0.30
Day 7 0.033 * * * * -3.3 * *
Day 7 0.031 * * * * -3.1 * *
Day 7 0.024 0.029 * * * -2.4 -2.0 0.48
Day 14 0.057 * * * * -5.7 * *
Day 14 0.052 * * * * -5.2 * *
Day 14 0.044 0.051 * * * -4.4 -3.5 0.66
Day 28 0.070 * * * * -7.0 * *
Day 28 0.064 * * * * -6.4 * *
Day 28 0.054 0.063 * * * -5.4 -4.2 0.81
Day 35 0.091 * * * * -9.2 * *
Day 35 0.086 * * * * -8.7 * *
Day 35 0.076 0.084 * * * -7.6 -5.7 0.77
Day 42 0.117 * * * * -11.8 * *
Day 42 0.111 * * * * -11.2 * *
Day 42 0.102 0.110 * * * -10.3 -7.5 0.76
Day 56 0.114 * * * * -11.5 * *
Day 56 0.109 * * * * -11.0 * *
Day 56 0.099 0.107 * * * -10.0 -7.3 0.77
Day 60 0.109 * * * * -11.0 * *
Day 60 0.105 * * * * -10.6 * *
Day 60 0.094 0.103 0.00009 43.12 2.70 -9.5 -7.0 0.78
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Appendix D 
 
 
 
Figure D-1 Removal of caffeine in anaerobic digester sludge at 1.0 and 5.0 
mg L 
-1
 with measurement by specific analysis. 
 
 
 
 
 
 
 
1.0 mg L
-1
 caffeine
Day 1 2 3 Mean Std. Dev.
0 1.47 1.49 1.38 1.45 0.059
7 1.39 1.29 0.92 1.20 0.248
14 0.91 1.17 1.23 1.10 0.170
21 1.00 0.87 1.06 0.98 0.097
35 0.81 0.86 0.84 0.84 0.025
60 0.83 1.04 0.80 0.89 0.131
5.0 mg L
-1
 caffeine
Day 1 2 3 Mean Std. Dev.
0 8.36 8.89 6.69 7.98 1.148
7 7.97 7.27 8.01 7.75 0.416
14 6.32 6.75 4.78 5.95 1.036
21 4.77 5.87 5.78 5.47 0.611
35 4.57 4.67 4.62 4.62 0.050
60 4.60 5.03 4.61 4.75 0.245
Stock Analysis
20 mgL
-1
 stock 20.54 102.70%
100 mgl
-1
 stock 103.73 103.70%
Spike Conc. (mgL
-1
) % recovery in 
PTFE filter vials
Spike 1 5.0 101
Spike 2 5.0 95
Spike 3 5.0 108
Samples not spike corrected
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Figure D-2 Removal of ibuprofen in anaerobic digester sludge at 1.0 and 5.0 
mg L
-1
 with measurement by specific analysis. 
 
 
 
 
 
1.0 mg L
-1
 ibuprofen
Day 1 2 3 Mean Std. Dev.
0 0.91 0.91 0.92 0.91 0.006
7 0.90 1.12 1.11 1.04 0.124
14 1.34 1.24 0.89 1.16 0.236
21 0.90 0.89 0.76 0.85 0.078
35 0.87 0.88 1.19 0.98 0.182
60 0.87 0.84 0.83 0.85 0.021
5.0 mg L
-1
 ibuprofen
Day 1 2 3 Mean Std. Dev.
0 4.48 4.47 4.56 4.50 0.049
7 5.60 5.79 5.60 5.66 0.110
14 4.48 4.47 4.58 4.51 0.061
21 4.49 4.49 4.50 4.49 0.006
35 4.39 4.50 4.55 4.48 0.082
60 4.42 5.75 4.51 4.89 0.743
Stock Analysis
20 mgL
-1
 stock 20.00 100%
100 mgl
-1
 stock 97.24 97.20%
Spike Conc. (mgL
-1
) % recovery in 
PVDF filter vials
Spike 1 5.0 97
Spike 2 5.0 96
Spike 3 5.0 95
Samples not spike corrected
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Figure D-3 Removal of propranolol in anaerobic digester sludge at 1.0 and 5.0 
mg L
-1
 with measurement by specific analysis. 
1.0 mg L
-1
 propranolol
Day 1 2 3 Mean Std. Dev.
0 0.62 0.55 0.59 0.59 0.035
7 0.56 0.50 0.52 0.53 0.031
14 0.58 0.60 0.75 0.64 0.093
21 0.53 0.51 0.50 0.51 0.015
35 0.34 0.30 0.32 0.32 0.020
60 0.30 0.30 0.40 0.33 0.058
5.0 mg L
-1
 propranolol
Day 1 2 3 Mean Std. Dev.
0 4.72 3.70 2.90 3.77 0.912
7 2.70 2.91 2.51 2.71 0.200
14 2.90 3.16 4.09 3.38 0.626
21 2.68 2.84 2.93 2.82 0.127
35 2.49 1.90 2.94 2.44 0.522
60 1.69 1.86 3.23 2.26 0.844
Stock Analysis
20 mgL
-1
 stock 19.13 95.65%
100 mgL
-1
 stock 100.03 100.03%
Spike Conc. (mgL
-1
) % recovery in 
PVDF filter vials
Spike 1 5.0 56
Spike 2 5.0 55
Spike 3 5.0 57
Fluorescence method (low inj. vol.) no filtration used
 236 
 
 
 
 
Figure D-4 Removal of cimetidine in anaerobic digester sludge at 1.0 and 5.0   
mg L
-1
 with measurement by specific analysis. 
 
 
 
 
1.0 mg L
-1
 cimetidine
Day 1 2 3 Mean Std. Dev.
0 0.70 1.18 0.78 0.89 0.257
7 0.43 0.49 0.67 0.53 0.125
14 0.53 0.56 0.48 0.52 0.040
21 0.55 0.51 0.54 0.53 0.021
35 0.68 0.56 0.57 0.60 0.067
60 0.68 0.63 0.60 0.64 0.040
5.0 mg L
-1
 cimetidine
Day 1 2 3 Mean Std. Dev.
0 4.07 6.14 4.22 4.81 1.154
7 2.96 2.96 2.93 2.95 0.017
14 2.78 2.83 3.79 3.13 0.569
21 2.58 2.87 2.87 2.77 0.167
35 4.26 5.03 3.28 4.19 0.877
60 3.45 3.39 3.43 3.42 0.031
Stock Analysis
20 mgL
-1
 stock 21.02 105.10%
100 mgL
-1
 stock 107.11 107.10%
Spike Conc. (mgL
-1
) % recovery in 
PTFE filter vials
Spike 1 5.0 89
Spike 2 5.0 89
Spike 3 5.0 88
Spike correction method used
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Figure D-5 Removal of fluoxetine in anaerobic digester sludge at 1.0 and 5.0    
mg L
-1
 with measurement by specific analysis. 
1.0 mg L
-1
 fluoxetine
Day 1 2 3 Mean Std. Dev.
0 0.012 0.012 0.073 0.032 0.035
7 0.015 0.021 0.023 0.020 0.004
14 0.018 0.031 0.022 0.024 0.007
21 0.027 0.035 0.031 0.031 0.004
60 0.016 0.016 0.020 0.017 0.002
5.0 mg L
-1
 fluoxetine
Day 1 2 3 Mean Std. Dev.
0 0.27 0.20 0.26 0.243 0.038
7 0.23 0.19 0.24 0.220 0.026
14 0.41 0.28 0.30 0.330 0.070
21 0.47 0.44 0.49 0.467 0.025
60 0.50 0.32 0.37 0.397 0.093
Stock Analysis
20 mgL
-1
 stock 20.24 101.20%
100 mgL
-1
 stock 101.02 101.02%
Spike Conc.  (mgL
-1
) % recovery after 
centrifugation
Spike 1 0.50 32
Spike 2 0.50 32
Spike 3 0.50 32
Fluorescence method (low inj. vol.) no filtration used
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Figure D-6 Removal of paroxetine in anaerobic digester sludge at 1.0 and 5.0 
 mg L
-1
 with measurement by specific analysis. 
1.0 mg L
-1
 paroxetine
Day 1 2 3 Mean Std. Dev.
0 0.015 0.016 0.017 0.016 0.001
7 0.017 0.017 0.018 0.017 0.001
14 0.017 0.017 0.018 0.017 0.001
21 0.030 0.024 0.025 0.026 0.003
60 0.015 0.018 0.019 0.017 0.002
5.0 mg L
-1
 paroxetine
Day 1 2 3 Mean Std. Dev.
0 0.15 0.14 0.16 0.150 0.010
7 0.16 0.15 0.15 0.153 0.006
14 0.17 0.20 0.23 0.200 0.030
21 0.25 0.21 0.29 0.250 0.040
60 0.20 0.16 0.21 0.190 0.026
Stock Analysis
20 mgL
-1
 stock 19.79 98.95%
100 mgl
-1
 stock 100.54 100.54%
Spike Conc.  (mgL
-1
) % recovery after 
centrifugation
Spike 1 1.0 28
Spike 2 1.0 28
Spike 3 1.0 28
Fluorescence method (low inj. vol.) no filtration used
